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 The aza-oxyallylic cation is a reactive intermediate that undergoes a [4+3] 
cycloaddition reaction with dienes to form seven-membered nitrogen heterocycles. Although 
the existence of this intermediate had been proposed for over 50 years, only recently has 
experimental evidence been established to support its existence. The intermediate was 
generated by base-mediated dehydrohalogenation of α-haloamide precursors synthesized from 
the corresponding acid halide in dichloromethane, respectively. From the analogous aza-
oxyallylic cation intermediates generated in situ, a series of bicyclic lactam scaffolds were 
easily prepared from a [4+3]-cycloaddition reaction of the corresponding α-haloamide and 
either furan or cyclopentadiene as the diene moiety. With the exception of one case, all 
monoaryl and monoalkyl haloamides provided selectively the endo diastereoisomer (≥19:1). 
Computational and experimental evidence suggest that an N-alkoxy substituent provides 
necessary stabilization to the aza-oxyallylic cation intermediate. 
 Balanol is a fungal metabolite first isolated from Verticillium balanoides and has been 
shown to be a potent protein kinase C (PKC) inhibitor. Starting from the α-chlorocycloadduct 
synthesized in Chapter 2, a concise synthesis of the hexahydroazepine-containing fragment was 
undertaken that was both scalable and stereoselective. Polyhydroxylated azepanes are a 
relatively new class of compounds with broad therapeutic potential in a variety of biological 
and pharmaceutical applications. A general synthesis of (±)-(4R, 5R, 6R)-4,5,6-trihydroxy-3,3-
dimethylazepane is achieved in only five short synthetic steps starting from the corresponding 
cycloadduct, allowing for rapid access to the seven-membered iminosugar class of compounds. 
The reaction sequence is efficient, diastereoselective, scalable, and has the capability of 
incorporating a wide variety of functional groups at the ring three-postion. 
Polyhydroxylated piperidines are a functionally rich class of biologically active 
compounds that also have broad therapeutic potential. Previously described aza-[4+3] 
 ii 
cycloadditions of putative aza-oxyallylic cations provide heterocyclic scaffolds that enabled a 
concise synthesis of polyhydroxylated piperidines. Chemoselective amide reduction and 
subsequent hemiaminal ether ring opening of four α-chlorocycloadducts by aluminum hydride 
provided in one pot four novel 3-chloroazepines. Aziridinium ion-mediated ring contraction 
and chloride displacement was triggered by silver acetate, followed by acetate hydrolysis under 
basic conditions to give the corresponding tetrahydropyridine diols. Alkene dihydroxylation 
catalyzed by osmium tetroxide installed the final hydroxyl groups, which yielded four novel 
polyhydroxylated N-alkoxypiperidine iminosugar analogs in good overall yield and high 
diastereoselectivity. 
Expanding on the originally reported methodology of dehyrohalogenation of α-
haloamides as a means to generate aza-oxyallylic cation intermediates, efforts were undertaken 
to explore alternative methods to generate the afformentioned intermediates that could 
incorporate heteroatoms at the α-position. 2-methoxy-N-(phenylmethoxy)acetamide and 2-
phthalyl-N-(phenylmethoxy)acetamide were synthesized to serve as model substrates and 
screened according to solvent, base, and oxidant in order to determine conditions that would 
allow for aza-oxyallylic cation formation. 
 All compounds were fully characterized by NMR, IR, and high-resolution mass 
spectrometry. Additionally, six compounds that were of exceptionally high crystallinity were 
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Chapter 1: Introduction 
 
1.1 Natural Products as a Template to Organic Synthesis 
 Natural products, also known as secondary metabolites, are organic compounds produced 
by plants that are not directly part of normal growth, development, or reproduction of the 
organism.1 Unlike primary metabolites, the absence of secondary metabolites does not result in 
immediate death, but rather may in the long term impair the organism’s survivability, fecundity, 
aesthetics, or could in contrast not result in any significant change at all. Plants utilize secondary 
metabolites for their defense characteristics against herbivorous predators and as interspecies 
defense strategies, whereas humans have found these compounds to have wide applications in 
medicinal drugs and food flavorings.2,3 Throughout history, organic chemists have continued to 
draw inspiration from natural products as motivation for total synthesis, or the development of 
new reaction methodology. In 1828 Friedrich Wöhler discovered that urea could be synthesized 
from the simple inorganic starting materials silver cyanate and ammonium chloride (Figure 
1.1.1).4 This significant finding represented a major milestone in chemistry because it was 
demonstrated that a substance previously thought to be only a biological product could be 
synthesized in the lab. The synthesis of acetic acid from elemental carbon by Kolbe in 1845 
marked the second major feat in the field of total synthesis, and additionally was the first time the 
word “synthesis” was used to describe the process of assembling a compound from other 














Figure 1.1.1. Selected examples of nineteenth century landmarks in total synthesis. 
2 
Fischer, not only for its structural complexity, which for the first time included stereogenic 
centers, but also for the exceptional degree of stereochemical control that accompanied his 
method.6 These compounds, although simple and primitive in form, piqued the curiosity of early 
synthetic chemists and represent the foundations from which the fields of total synthesis and 
organic reaction methodology were built. 
 Natural products of significant biological and pharmaceutical importance have been and 
continue to be a driving force for the development of new organic reaction methodologies to 
either aid in their total synthesis, or provide a general means to construct an important but 
challenging aspect of their architecture. For example, the spirocyclopentaneoxindole scaffold is a 
common structural motif found in a wide variety of biologically active natural products (1, 2, 3, 
Scheme 1.1.1), and motivated Kanger and co-workers to develop an organocatalytic cascade 
reaction of simple isatin derivatives 4 and nitroketones 5 to access the core skeleton 6.7 Inspired 
by the indolizine core being a common structural unit found in many bioactive natural alkaloids 
(7-11, Scheme 1.1.2), Barbas and co-workers utilized a pyrrole enolate intermediate 12 formed in 
situ as an electron donor for the general synthesis of 5,6-dihydroindolizine frameworks 14.8 As 
new natural products continue to emerge with pharmaceutical relevance, organic chemists will be 
challenged with the task of devising methods to aid in the synthesis of these complex compounds. 
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Scheme 1.1.1. Spirocyclopentaneoxindole natural products and organocatalytic cascade reaction.7 
	  
Scheme 1.1.2. Representative hydroindolizine-containing natural and biologically active products. Dual 
iminium-enolate activated catalytic strategy.8 
 
1.2 Heterocycle Synthesis Using Dipolar Aza-Electrophilic Intermediates: Toward New 
Dipoles for Cycloaddition Reactions 
 Nitrogen containing heterocycles are a common moiety found in many pharmaceuticals, 
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established as an invaluable method in the synthesis of heterocyclic natural products.9 Despite 
extensive research in this area, reactions of dipolar intermediates that feature an electrophilic 
nitrogen atom at one terminus of the dipole have not been comprehensively explored. Indeed, 
methods for forming C-N bonds that avoid the use of azides and hydrazine, as well as green 
souces of electrophilic nitrogen species remain a priority in pharmaceutical manufacturing.10 
Lactams are nitrogen-containing heterocycles that are an important functional group in organic 
chemistry, and have been widely used in the synthesis of complex molecules, with applications 
being found in medicinal chemistry and materials research. This structural unit can be found in 
many natural products and biologically active compounds such as the bengamides 15, vitronecin 
antagonist receptors 16, and tuberostemonone 17 (Figure 1.2.1). With the flexible and direct 
synthesis of lactams still posing a challenge, it was recognized that a modular and concise 
synthesis that afforded highly substituted and stereodefined nitrogen heterocycles was needed. 
We envisioned that the types of compounds in Figure 1.2.1 could be accessed by a hetero [4+3] 
cycloaddition of an aza-oxyallylic cation intermediate 18 with a diene 19 to give a seven-
membered lactam 20. 
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Figure 1.2.1. Representative lactam-containing natural products and proposed access via aza-[4+3] 
cycloaddition. 
 
 If lactam skeletons could be accessed from this intermediate, it would provide insight into 
novel reactivity as well as entry into several classes of biologically active target compounds. The 
use of oxyallylic cationic intermediates in [4+3] cycloaddition reactions with dienes has become a 
powerful method for the construction of seven-membered carbocycles.11 Our group considered 
that an analogous aza-oxyallylic cation intermediate could be employed for the synthesis of 
seven-membered azacycles. The aza-oxyallyic cation intermediate has previously been discussed 
in the context of α-lactams 21, namely their synthesis, reactions, and rearrangements (Scheme 
1.2.1). Sheehan and Lengyl suggested that these intermediates could possibly be relevant to the 
regioselectivity trends of the nucleophilic ring opening of α-lactams.12 Conversely, Stang and 
Anderson proposed an aza-oxyallylic cation intermediate to be involved in the conversion of an 
alkylidine oxazirine 22 to an α-lactam.13 However despite both theoretical and stereochemical 










































proposed intermediate have failed to provide any experimental and thus compelling evidence for 
its involvement in these types of processes.14,15 Base mediated dehydrohalogenation of α-
haloketones has been a commonly employed method of generating oxyallylic cation 
intermediates,11 therefore we considered that a similar dehydrohalogenation reaction of an α-
haloamide 23 could provide an aza-oxyallylic cation intermediate 18 in situ. Research efforts 
towards the exploration of aza-oxyallylic cations as intermediates for heterocycle synthesis are 
outlined in more detail in Chapter 2. 
 
	  
Scheme 1.2.1. Previously proposed methods to access aza-oxyallylic cation intermediate 18, proposal to 
trap intermediate with a diene to generate seven-membered heterocycles 20. 
	  
1.3 Balanol and Iminosugars: Target Directed Studies Utilizing Aza-[4+3] Cycloaddition 
Scaffolds 
 Recently, there has been a growing recognition of the importance of protein kinase 
inhibitors and their important role in an variety of cellular events.16 Although the number of 
known protein kinases continues to expand, the significance associated with protein kinase C 
(PKC) has remained incomparable.17 Phosphorylation of proteins by PKC is known to lead to a 
number of cell responses including cell proliferation and gene expression.18 Activated PKC has 
























cardiovascular disorders, inflammation, diabetes, and CNS disfunction.18 With regard to cancer, 
the observation that tumor-promoting phorbol esters cause PKC activation has led to the 
conclusion that PKC inhibitors could prove beneficial in cancer therapy applications. Balanol 24 
(Scheme 1.3.1) is a fungal metabolite produced by Verticillium balanoides and represents an 
significant new discovery in the ongoing search for effective PKC inhibitors.19 Balanol has been 
observed to inhibit the majority of PKC isozymes in nanomolar concentrations, and its unique 
novel structure has provided a guiding template in the advancement of new potent and selective 
PKC inhibitors.16 The assets of devising a concise and flexible synthesis of balanol and 
derivatives of balanol include providing understanding into single transduction pathways 
involving PKC, and also allowing for the discovery of new drug candidates with substantial 
therapeutic value.18 The structural features of balanol led us to consider the strategic bond 
disconnections shown in Scheme 1.3.1. The hexahydroazepine ring could be simplified by 
removal of the 4-hydroxybenzoic acid residue through the amide bond, and further dissection of 
the ester linkage would provide the necessary seven-membered heterocyclic core 25. We 
envisioned the hexahydroazepine ring 25 to be a reduced form of cycloadduct 27, with the amine 
functionality arising from nucleophilic displacement of a leaving group on 26 by nitrogen. 
Finally, 27 could be formed from the reaction of a simple functionalized α-haloamide 28 and 
furan 29. Progress in utilizing simple aza-[4+3] scaffolds toward the synthesis of balanol are 
described in Chapter 3. 
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Scheme 1.3.1. Balanol 24 and retrosynthetic analysis to lead back to simple starting materials. 
 
 
 Polyhydroxylated azepanes and piperidines, also referred to as iminosugars, are a class of 
small organic compounds where the endocyclic oxygen atom has been replaced with a nitrogen 
atom. Iminosugars have received considerable attention from researchers due to their glycosidase 
inhibitory properties, which make them good candidates for therapeutic applications in the 
treatment of HIV, cancer, and diabetes.20, 21 They occupy a region of space similar to traditional 
carbohydrates but on the same hand they remain different from other small heterocyclic 
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9 
complement compound libraries for pharmaceutical companies. As small polar molecules, they 
resemble carbohydrates enough to allow efficient cellular uptake, but remain chemically distinct 
enough from traditional sugars to avoid degredation by carbohydrate-modifying enzymes.23 This 
“dual personality” allows for iminosugars to serve as a special class of compounds in the ongoing 
search for new drug targets.24 Many types of iminosugars exist, both natural and synthetic, and 
can range from five to seven-membered ring sizes as well as bicyclic systems. Our curiosity was 
piqued towards the possibility of using aza-[4+3] cycloaddition skeletons to provide a concise 
and general synthesis of iminosugars (Scheme 1.3.2). We envisioned that polyhydroxylated 
azepanes 32 (seven-membered iminosugars) and polyhydroxylated piperidines 33 (six-membered 
iminosugars) could be accessed by simple synthetic manipulations of a richly functionalized 
cycloadduct 31. Chapters 3 and 4 provide a detailed description of our synthetic efforts to access 
the iminosugars class of compounds. 
	  




1.4 Alternative Methods for Generating Aza-Oxyallylic Cation Intermediates 
	   Our initial report of the first experimental evidence supporting the existence of aza-



























means of generating the desired intermediates.28,29 As part of our lab’s ongoing interest in 
electrophilic nitrogen species, we were eager to explore the viability of utilizing other starting 
materials and alternative methods to generate aza-oxyallylic cations. Chapter 5 details progress 
toward the alternative generation of aza-oxyallylic cation intermediates beyond our current 
methodology. 
The intriguing properties of aza-oxyallylic cations and the highly functionalized and 
stereodefined scaffolds they could potentially afford led us to further exploration of these 
intermediates and their application toward the synthesis of seven-membered heterocycles. This 
dissertation is divided into four major sections, with additional chapters including an introduction, 
conclusion, and appendix. Chapter 2 describes our studies on aza-oxyallylic cations and their 
application for the synthesis of 7-membered heterocycles, and includes computational and 
experimental results toward developing this new methodology. Chapter 3 highlights our target 
directed studies on utilizing the aforementioned scaffolds for the synthesis of balanol and 
polyhydroxylated azepanes. Chapter 4 involves utilizing an unexpected ring contraction to access 
polyhydroxylated N-alkoxypiperidines in good overall yield and high diastereoselectivity. 
Chapter 5 outlines our work on the exploration of using α-heteroatom substituted amides and 
alternative methods to generate aza-oxyallylic cations other than dehydrohalogenation of α-
haloamides. Finally, Chapter 6 concludes with a general summary and future directions based on 
the results of this dissertation. 
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Chapter 2: Generation and Reactivity of Aza-Oxyallylic Cations: Aza-[4+3] 
Cycloaddition Reactions for Heterocycle Synthesis 
 
2.1 Introduction 
 The aza-oxyallylic cation is a reactive intermediate that has eluded chemists for 
decades, with its existence only being hypothesized but never proven with experimental 
evidence. The Jeffrey lab’s interest in the generation of electrophilic nitrogen species piqued 
our curiosity towards exploring this intermediate and its potential use for the rapid synthesis 
of 7-membered aza-cycles. The proposal to intercept the aza-oxyallylic cation 45 was largely 
inspired by the comprehensive body of work related to oxyallylic cation intermediates (46, 
Scheme 2.1.1) and their reactivity in [4+3]-cycloaddition reactions with dienes to form 7-
Scheme 2.1.1. Established methods to access oxyallylic cation 
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membered rings.1 More specifically, we envisioned a base-mediated dehydrohalogenation 
event of an α-halo amide 42 as a way to generate the desired intermediate, much in the same 
way that the dehydrohalogenation process of α-halo ketones 47 to give oxy-allyl cations 46.1 
With the larger goal of developing new C-N bond forming reactions with broad applications 
in target directed syntheses, we envisioned that cycloadditions of aza-oxyallylic cations could 
be employed as a powerful method to prepare nitrogen-containing seven-membered 
heterocycles. 
 Trapping or even establishing the existence of the aza-oxyallylic cation has been a 
long road and was not a novel idea when we began experimenting with the intermediate. The 
aza-oxyallylic cation 45 was first proposed by Sheehan in the 1960s during his foray into the 
chemistry of α-lactams such as 43 (Scheme 2.1.1).2 The first α-lactam to be isolated and 
characterized was synthesized in 1962 by Baumgarten.3 Prior to this, α-lactams were believed 
to be intermediates in a variety of reactions, but it was still unknown if the 3-membered ring 
would encumber too much ring strain to permit isolation. Building on the work of 
Baumgarten, Sheehan and Lengyel observed that the stability of the α-lactams was enhanced 
by the presence of a tert-butyl group or other bulky substituent on the nitrogen atom.2 Despite 
this general trend however, attempted syntheses of α-lactams with bulky phenyl substituents 
on the nitrogen atom were surprisingly unsuccessful. Sheehan hypothesized that charge 
delocalization through the phenyl rings made possible a highly reactive acyclic intermediate 
45 (an aza-oxyallylic cation) that was more stable than the corresponding α-lactam 43 he was 
trying to synthesize, but was not isolable.2 Sheehan also suggested the involvement of this 
dipolar intermediate in the thermal decomposition of some α-lactams and their nucleophilic 
ring opening. Following the analogy of the oxyallylic cation in the Favorskii rearrangement 
previously described by House and Gilmore,4 Sheehan did not rule out the possibility of an 
analogous dipolar aza-oxyallylic cation intermediate in the nucleophilic substitution reaction 
of isolable α-lactams. Moreover, the proposed intermediate could explain the dichotomous C-
2 versus C-3 nucleophilic ring opening of this highly reactive aza-cycle (Scheme 2.1.2). 
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Scheme 2.1.2. The stereospecific nucleophilic ring opening of 
enantiopure α-lactams to give products 51 and 52. 
	  
 The proposal of Sheehan and Lengyel along with the ambivalent reactivity of α-
lactam electrophiles 50 stimulated numerous theoretical and mechanistic studies of their 
nucleophilic ring opening.5 While it remained difficult to predict whether nucleophilic attack 
would be favored at the C-2 or C-3 position of the lactam 50, an elegant set of experiments by 
Hoffman and co-workers using enantiopure α-lactams 50 established that attack at the C-2 
position consistently produced an amino acid derivative 51 with retention in stereochemistry, 
while attack at the C-3 position produced an amide 52 with inversion of stereochemistry 
(Scheme 2.1.2).5 The stereospecificity of the reaction at C-3 was inconsistent with the 
formation of a planar aza-oxyallylic cation intermediate, which instead would have resulted in 
product racemization. Several other research groups also suggested the role of the aza-
oxyallylic cation as an intermediate or transition state in transformations involving α-lactams 
α-haloamides, and related species. In 1955, Stang and Anderson proposed an aza-oxyallylic 
cation intermediate in their studies of the interactions of alkylidene carbenes with nitroso 
compounds.6 In 2004, Toscano and co-workers performed a computational study that 
illustrated an aza-oxyallylic cationic transition state in their isomerization studies of the 
conversion of an alkylidene oxazirine 44 to the α-lactam (Scheme 2.1.1).7 Despite all of these 
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Scheme 2.1.3. The solvolysis experiment of Kikugawa and co-workers that highlights the importance 
of a donor group in the possible strategy for stabilizing aza-oxyallylic cations. 
	  
 The most promising evidence of the viability of an aza-oxyallylic cation intermediate 
came from the Kikugawa group in 1993.8 A series of solvolysis experiments on α-haloamides 
53 and 55 demonstrated the importance of an alkoxy donor group on the nitrogen atom 
(Scheme 2.1.3). They observed that the 2-chloro-N-alkoxyphenylacetamide 53 underwent 
rapid solvolysis when treated with a base in ethanol to provide the amide 54; however, no 
reaction was observed when the N-methylamide 55 was subjected to the same conditions. 
This result implied that the alkoxy-substituent in 53 could stabilize a pathway through a 
highly electrophilic aza-oxyallylic cation, thereby accelerating the rate of solvolysis of the N-
methoxyphenylacetamide 53. Coupled with the previously described reports of an increase in 
the stability of oxyallylic cations and N-acyl nitrenium ions9 with the addition of an alkoxy 
donor group, the Kikugawa experiment led us to believe that an electron-donating substituent 
could potentially stabilize an aza-oxyallylic cation intermediate and give it enough of a 
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Scheme 2.1.4. Proposed aza-[4+3] cycloaddition reaction of a stabilized aza-oxyallylic cation with a 
diene. 
	  
 One of the primary methods of generating oxyallylic cations for [4+3]-cycloadditions 
is through the dehydrohalogenation of α-haloketones.1 The first example of such a reaction 
was reported by Fort in 1962.9 In this experiment, Fort reacted α-chlorodibenzylketone with 
furan in the presence of a base to yield a 7-membered carbocycle with a bridging oxygen 
atom. Hoffman continued work in this area, pioneering much of the chemistry surrounding 
the synthesis of 7-membered rings through the reaction of allyl cations with dienes.10 In 1965, 
Woodward and Hoffman published a Letter proposing that a concerted cycloaddition reaction 
of a diene and an allyl cation was thermally allowed by orbital symmetry.11 To support his 
theory, Hoffman published the first example of such a reaction in 1968.12 Following 
Hoffman’s work, numerous examples of [4+3]-cycloaddition reactions through oxyallylic 
cations have been reported.1 Strategic incorporation of electron-donating groups such as 
nitrogen,13 oxygen,14 or sulfur,15 on the dienophile have been shown to facilitate [4+3]-
cycloaddition reactions of oxyallylic cations through the extra stability afforded to the 
intermediate. It was this very simple but thus far overlooked observation that led us to the 
capture of the aza-oxyallylic cation. The difference between the aza-oxyallylic cation and the 





















Could a stabilized aza-oxyallylic cation be
generated and trapped in an
aza-[4+3] cycloaddition reaction?
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2.2 Preliminary Computational Studies of Stabilized Aza-Oxyallylic Cations 
 Initial studies of stabilized aza-oxyallylic cations began by computationally modeling 
our hypothesis.16 Two α-lactams, one N-substituted with an ethyl group 57, and one N-
substituted with a methoxy group 58 (Figure 2.2.1) were chosen as model systems. The 
relaxed potential energy plot for the heterolytic cleavage of the C(2)-N bond of each α-lactam 
to an aza-oxyallylic cation 59 in methanol was predicted using a B3LYP/6-31G* level of 
theory with a conductor polarized continuum model (CPCM)17 to simulate solvent effects.18,19 
As expected, the ethyl-substituted α-lactam 57 did not arrive at a second energy minimum 
corresponding to the aza-oxyallylic cation intermediate. However, the α-lactam with a 
strongly electron-donating methoxy substitutent 58 showed that the aza-oxyallylic cation 59 
was in a second energy minimum, consistent with our hypothesis and with Kikugawa’s 
solvolysis experiments. Comparison of isomerization in the gas phase and in methanol for the 
methoxy α-lactam demonstrated qualitative differences in the well depth for the intermediate 
Figure 2.2.1. Relaxed potential energy scans along the C(3)-N(1) coordinate of α-lactams 57 
and 58. Green line = 57 in methanol, red line = 58 in methanol, black line = 59 in the gas phase. 
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59. According to these calculations, the aza-oxyallylic cation intermediate was more stable in 
a polar solvent than in the gas phase, which was consistent with the proposed zwitterionic 
structure of an aza-oxyallylic cation intermediate. 
2.3 Preliminary Experimental Studies of the Reaction of Stabilized Aza-Oxyallylic 
Cations with Furan 
 Experimentally, our investigation began with synthesizing 2-bromo-N-
benzylbutyramide 60 from the corresponding acid bromide and benzylamine (Scheme 2.3.1). 
As expected for the reaction of an α-haloamide lacking a donor group, treatment of this 
substrate with a base in the presence of furan as the diene and trifluoroethanol (TFE) as the 
solvent only resulted in recovery of the starting material. To test our hypothesis of a donor 
group being crucial for stabilizing the desired intermediate, a 2-bromohydroxamate 62 was 
synthesized from again the corresponding acid bromide but this time O-
benzylhydroxylamine. Treatment of 62 to the Föhlisch conditions20 provided the desired 
cycloadduct 63 and trifluoroether 64, providing the first example of a reaction of an aza-
oxyallylic cation with a diene. 
 
	  
Scheme 2.3.1. First example of an aza-[4+3] reaction and a control experiment that demonstrates the 
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2.4 The Aza-[4+3] Cycloaddition Reaction as a New Method for the Synthesis of 
Caprolactams 
 Initial optimization studies were aimed at minimizing the solvolysis product 64 and 
thereby increase the yield of the cycloadduct. Switching to the bulkier hexafluoroisopropanol  
solvent was found to circumvent solvolysis and provide the desired product in 78% yield.21 
Carbonate bases were found to provide the desired cycloadduct in comparable yields to the 
reaction using triethylamine (entries 4-6, Table 2.4.1). The reaction could also be effected in 
ether by using triethylamine with lithium perchlorate as a Lewis acid additive,22 but under 
these reaction conditions a methacrylamide was isolated as the major product from 
elimination of the cationic intermediate or a transient α-lactam. 
 
Entry R Solvent Base Yielda % 
1 Bn TFE Et3N no reaction 
2 OBn TFE Et3N 38%b 
3 OBn HFIP Et3N 78% 
4 OBn HFIP Cs2CO3 58% 
5 OBn HFIP K2CO3 67% 
6 OBn HFIP Na2CO3 74% 
7 OBn TFE imidazole decomp. 
8 OBn TFE pyridine no reaction 
9 OBn Et2O Et3N, LiClO4 See text 




















60: R = Bn
62: R = OBn
61: R = Bn
63: R = OBn
64: R = OBn
CF3
Table 2.4.1. Solvent and Base Effects on the Yield of
the Aza-[4+3] Reaction of 62 with Furan
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The aza-[4+3] cycloaddition reaction was found to be general, providing the desired 
cycloadducts in good to excellent yields with a variety of alkyl and halo substrates substituted 
at the α-carbon (Table 2.4.2). Monoalkyl stubstituted bromo amides (entries b-f) provided the 
highest yields of the cycloadduct, and all monoaryl and monoalkyl haloamides selectively 
demonstrated a preference for the endo-diastereoisomer (> 19:1).23 In the case of entry f, it 
was observed that the ratio of diastereoisomers at about 40% conversion was > 19:1 
endo:exo, but upon complete consumption of the starting material equilibrated to a ratio of 
2:1 endo:exo. Monoalkyl bromoamides were found to react slower than aryl and dialkyl 
substituted haloamides, and α-chloroamides reacted slower than α-bromoamides (cf. b and e). 
α -Chloromethoxyacetamide proved difficult to handle and decomposed under the 
cycloaddition conditions, and the unsubstituted bromoacetamide (X = Br, R1 = R2 = H, entry 
a) was unreactive and resulted in recovery of the starting material. Dialkyl and aryl substrates 
provided the desired cycloadduct in moderate yields when run in HFIP (entries h, i, and l). 
Cyclopentadiene was also found to be a viable diene for the [4+3] cycloaddition, affording 
the cycloadducts in comparable yields to those of furan, albeit with less selectivity for the 
endo diastereoisomer (entries j-l). As mentioned previously for the case of the α,α-
dichloroamide substrate, the ratio of diastereoisomers at early conversion (> 19:1, endo:exo at 
ca. 40%) was greater than at complete conversion (2:1, endo:exo). In order to gain more 
insight on this observation, the purified endo cycloadduct was resubjected to the reaction 
conditions. After 24 hours, it was found that the endo cycloadduct had equilibrated to a 1:1 
mixture of diastereoisomers, suggesting that there is a kinetic preference for the endo-product. 
The exact nature of this selectivity is a project still under investigation. 
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aConditions: solvent was furan or cyclopentadiene (1:1 v/v, 0.25 M) at 0 to 25 °C with Et3N (2.0 
equiv.). Diastereoisomeric ratio (dr) was determined from crude 1H NMR analysis. b ≥ 19:1 dr indicates 






























R = H (0%)
R = Me (67%)
R = Et (86%)






























































































Table 2.4.2. Evaluation of the Substrate Scope of the Aza-[4+3] Reaction
A = O or CH2
65a-k 66a-n
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 The experimental and computaional data support a mechanism whereby 
dehydrohalogenation of an α-haloamide 67 under basic conditions generates an aza-oxyallylic 
cation intermediate 68 that reacts as a dienophile in an aza-[4+3] cycloaddition (Scheme 
2.4.1). An alkoxy electron donating group (OBn) is essential for allowing the cycloaddition to 
take place, and was computationally found to stabilize the proposed intermediate. Aryl 
substituents accellerate the overall rate of conversion. In conjunction with the all-carbon 
[4+3] cycloaddition with cyclic dienes, the aza-[4+3] cycloaddition demonstrates a preference 
for the formation of the endo diastereoisomer. The observation that the diastereoisomeric 
ratio of cycloadducts (entry f, Table 2.4.1) was high at early conversion and that the purified 
endo-adduct isomerized to a 1:1 ratio of diastereoisomers (69-endo to 69-exo, R = Cl, Scheme 
2.4.1) under the reaction conditions suggests that there is a kinetic preference for the endo-
cycloadduct. 
	  
Scheme 2.4.1. Proposed mechanism for the aza-[4+3] cycloaddition reaction with furan (A = O) and 
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2.5 Experimental 
 All reactions were carried out under an atmosphere of nitrogen in oven-dried 
glassware with magnetic stirring, unless otherwise specified. Dichloromethane was purified 
by passage through a bed of activated alumina. Cyclopentadiene was distilled from 
dicyclopentadiene immediately prior to use. All other reagents and solvents were purchased 
from Sigma-Aldrich Chemical Company and used without any further purification. TLC 
information was recorded on Silicycle glass 60 F254 plates and developed by staining with 
KMnO4 or ceric ammonium molybdate. Purification of reaction products was carried out by 
flash chromatography using Silicycle Siliaflash® P60 (230-400 mesh). 1H-NMR spectra were 
measured on Varian 400 (400 MHz), Varian MR400 (400 MHz), or Varian 500 (500 MHz) 
spectrometers and are reported in ppm (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad; integration; coupling constant(s) in Hz), using TMS as an internal 
standard (TMS at 0.00 ppm) in CDCl3 or the solvent peak (1.94 ppm) in CD3CN. 13C-NMR 
spectra were recorded on V400 or V500 spectrometer and reported in ppm using solvent as an 
internal standard (CDCl3 at 77.16 ppm) or (CD3CN at 118.26 ppm). Infrared (IR) spectra 
were recorded on a Nicolet 6700 FT-IR with a diamond ATR and data are reported as cm-1 (br 
= broad, st = strong). High-resolution mass spectra were obtained using an Agilent 6230 TOF 
LC/MS with an (atmospheric pressure photo- ionization (APPI) or electrospray (ESI) source 
with purine and HP-0921 as an internal calibrants. Haloamides HRMS were obtained with an 
inlet temperature of 200 °C. 
General Procedure A: For the synthesis of alpha-haloamides  
 To a suspension of the O-benzylhydroxylamine hydrochloride in dichloromethane 
(0.25 M) and triethylamine was added the alpha-haloacid halide dropwise at 0 °C. The 
reaction mixture was stirred at that same temperature until TLC analysis (3:1 hexanes:ethyl 
acetate) revealed complete consumption of the starting material. The mixture was then 
warmed to room temperature and quenched with water. The aqueous phase was extracted 3x 
with dichloromethane and the combined organic extracts were washed with water, brine, and 
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dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and 
the crude residue was purified by column chromatography (3:1 hexanes:ethyl acetate) to 
afford the pure haloamides in 45 – 90% yield as white crystalline solids. 
 
General Procedure B: For the cycloaddition reaction of furan or cyclopentadiene in 
trifluoroethanol or hexafluoroisopropanol. 
 To a solution of the haloamide (1 equiv.) in CF3CH2OH and furan [1:1 (v/v) 0.25 M] 
or (CF3)2CHOH was added triethylamine (2 equiv.) dropwise at 0 °C. The solution was then 
allowed to warm to room temperature and the reaction progress monitored by TLC (3:1 or 2:1 
hexanes:ethyl acetate) until complete consumption of the haloamide. The volatiles were 
removed under reduced pressure and the crude residue purified by flash column 
chromatography (4:1 to 3:1 hexanes:ethyl acetate) to afford the pure cycloadducts as oils (54 




 Prepared in 91% yield (0.42 mmol, 10.7 g) from the reaction of 2-bromo-2-
methylpropanoyl bromide (0.46 mmol, 10.6 g) with benzylamine (0.46 mmol, 5.1 mL) via 
general procedure A. Rf = 0.84 (3:1 hexanes:ethyl acetate); M.P. = 73.4 – 75.5 °C; 1H NMR 
(400 MHz, CDCl3): δ 7.41 – 7.23 (m, 5H), 7.03 (br s, 1H), 4.46 (d, J = 5.8 Hz, 2H), and 1.99 
(s, 6H); 13C NMR (125 MHz, CDCl3): δ 172.0, 137.8, 128.8, 127.6, 62.8, 44.4, and 32.6; IR 
(neat) 3291 (br), 3065, 3014, 3008, 2938, 2919, 1642 (st), and 1533 cm-1; HR-ESIMS 

















	   27 
 
2-bromo-2-methyl-N-(phenylmethoxy)propanamide (62, 65h): 
 
 Prepared in 87% yield (11.3 mmol, 3.53 g) from the reaction of 2-bromo-2-
methylpropanoyl bromide (13 mmol, 3.0 g) with O-benzylhydroxylamine hydrochloride (13 
mmol, 2.13 g) via general procedure A. Rf = 0.58 (3:1 hexanes:ethyl acetate); M.P. = 88.6 – 
91.1 °C; 1H NMR (500 MHz, CDCl3): δ 9.05 (br s, 1H), 7.45 – 7.34 (m, 5H), 4.94 (s, 2H), 
and 1.93 (s, 6H); 13C NMR (126 MHz, CDCl3): δ 169.7, 134.9, 129.6, 129.1, 128.8, 78.4, 
59.5, and 32.6; IR (neat) 3195 (br), 3034, 2954, 2890, 1652 (st), 1505, 1469, 1454, 1112, 
1032, and 1004 cm-1; HR-ESIMS requires for C11H18BrNO2 (M+NH4)+ 289.0546, found 
289.0543. 
 
 (±)-2-bromo-N-(phenylmethoxy)propanamide (65b): 
 
 Prepared in 53% yield (631 mg, 2.44 mmol) from the reaction of 2-bromo-2- 
methylpropanoyl bromide (1.0 g, 4.6 mmol) with O-benzylhydroxylamine hydrochloride (742 
mg, 4.6 mmol) via general procedure A. Rf = 0.28 (3:1 hexanes:ethyl acetate); M.P. = 75.3-
77.4 °C; 1H-NMR (500 MHz, CDCl3): δ 9.61 (br s, 1H), 7.44 – 7.26 (m, 5H), 4.90 (s, 2H), 
4.31 (q, J = 7.7 Hz, 1H), and 1.77 (d, J = 6.4 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 167.5, 
134.8, 129.45, 128.9, 128.7, 78.3, 40.5, and 22.2; IR (neat) 3110 (br), 2924, 2852, 1675 (st), 
1508, 1495, 1453, 1364, 1188, 1038, and 1023 cm-1; HR-ESIMS requires for C10H12BrNO2 





































 Prepared in 72% yield (4.71 g, 17.3 mmol) from the reaction of 2-bromobutyryl 
bromide (5.0 g, 24 mmol) with O-benzylhydroxylamine, hydrochloride via general procedure 
A. Rf = 0.49 (3:1 hexanes:ethyl acetate); M.P. = 99.3 - 101.6 °C; 1H-NMR (500 MHz, 
CDCl3): δ 8.92 (br s, 1H), 7.52 – 7.31 (m, 5H), 4.93 (s, 2H), 4.12 (app q, J = 7.2 Hz 1H), 2.02 
- 1.94 (m, 2H), and 1.00 (t, J = 7.0 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 166.6, 134.8, 
129.5, 129.0, 128.7, 78.4, 48.8, 28.8, and 11.8; IR (neat) 3112, 2963, 2933, 2874, 1695, 1668 
(s), 1528, 1496, 1454, 1364, 1177, 1089, 1023 cm-1; HR-ESIMS requires for C11H15BrNO2 




 Prepared in 61% yield (11.8 mmol, 3.5 g) from the reaction of 2-bromo-2,2- 
dimethylpropanoyl chloride (19.3 mmol, 4.98 g) with O-benzylhydroxylamine (19.3 mmol, 
3.12 g), hydrochloride via general procedure A. Rf = 0.33 (3:1 hexanes:ethyl acetate); 1H-
NMR (500 MHz, CDCl3): δ 8.73 (br s, 1H), 7.55 – 7.29 (m, 4H), 4.92 (s, 2H), 3.95 (s, 1H), 
1.11 (s, 9H); 13C-NMR (126 MHz, CDCl3): δ 166.1, 135.0, 129.6, 129.0, 128.8, 78.3, 59.4, 
35.2, and 27.4; IR (neat): 3179 (br), 3037, 2985, 2960, 2944, 2885, 1657 (st), 1511, 1479, 




































 Prepared in 48% yield (3.9 mmol, 0.97 g) from the reaction of 2-chloropropanoyl 
chloride (8.2 mmol, 1.03 g) with O-benzylhydroxylamine, hydrochloride (8.2 mmol, 1.03 g) 
via general procedure A. Rf = 0.43 (3:1 hexanes:ethyl acetate); M.P. = 70.1-72.8 °C; 1H-NMR 
(500 MHz, CDCl3): δ 9.09 (br s, 1H), 7.44 – 7.35 (m, 5H), 4.93 (s, 4H), 4.33 (q, J = 7.1 Hz, 
1H), and 1.69 (d, J = 6.8 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 167.1, 134.8, 129.5, 129.1, 
128.8, 78.5, 53.2, and 22.3.; IR (neat): 3112 (br), 2931, 1678 (st), 1494, 1454, 1364, 1222, 




 Prepared in 82% yield (11.1 mmol, 2.6 g) from the reaction of 2,2-dichloroacetyl 
chloride (13.6 mmol, 2.0 g) with O-benzylhydroxylamine, hydrochloride (13.6 mmol, 2.15 g) 
via general procedure A. Rf = 0.52 (3:1 hexanes:ethyl acetate); 1H NMR (400 MHz, CD3CN) 
δ 9.89 (br s, 1H), 7.63 – 7.17 (m, 4H), 6.02 (s, 1H), and 4.89 (s, 2H); 13C NMR (101 MHz, 
CD3CN) δ 162.2, 136.1, 130.4, 129.7, 129.4, 78.8, and 65.6; IR (film) 3135 (br), 2996, 2880, 
2860, 1700, 1677 (st), 1531, 1468, 1454, 1367, 1341, 1214, 1200, 1046, 1027 cm-1; HR-





































 A suspension of the epoxynitrile (1.2 mmol, 315 mg ~ 80 % pure) and O- 
benzylhydroxylamine hydrochloride (1.5 mmol, 240 mg) in acetonitrile (0.1 M, 15 mL) was 
heated to reflux overnight. The suspension was cooled and the mixture was concentrated to 5 
mL. The residue was partitioned between water and ethyl acetate and the aqueous phase was 
extracted with ethyl acetate (3 x 15 mL). The combined organic layers were washed with 
brine (15 mL), dried over Na2SO4, filtered, and evaporated under reduced pressure. The 
residue was recrystallized from hexanes and ethyl acetate to provide the product as a colorless 
solid (0.69 mmol, 215 mg, 58% yield). Rf = 0.20 (3:1 hexanes:ethyl acetate); 1H NMR (400 
MHz, CD3CN) δ 9.76 (s, 1H), 7.51 – 7.29 (m, 9H), 5.27 (s, 1H), and 4.84 (s, 2H). 13C NMR 
(101 MHz, CD3CN) δ 165.2, 136.6, 136.3, 135.5, 130.6, 130.4, 129.8, 129.6, 129.4, 78.6, and 
57.9; IR (neat): 3115.8 (br), 2942, 2842, 2662, and 1492 (st) cm-1; HR-ESIMS requires for 
C15H13Cl2NO2 (M+Na)+ 332.0216, found 332.0216. 
 
(±)-2-bromo-N-(phenylmethoxy)carboxamide (65i, 65l): 
 
 Prepared in 72% yield (14.5 mmol, 4.5 g) from the reaction of 2-bromocyclohexanoyl 
bromide (20.1 mmol, 4.53 g) with O-benzylhydroxylamine, hydrochloride (20.1 mmol, 3.21 
g) via general procedure A. Rf = 0.47 (3:1 hexanes:ethyl acetate); M.P. = 84.6-86.1 °C; 1H 
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14.6, 10.9, 4.0 Hz, 2H), 2.00 (dt, J = 14.0, 4.1 Hz, 2H), 1.80 – 1.57 (m, 5H), 1.42 – 1.23 (m, 
1H); 13C NMR (101 MHz, CDCl3) δ 169.6, 135.0, 129.6, 129.0, 128.7, 78.2, 38.1, 24.7, and 
22.6. IR (neat): 3235 (br), 3034, 2936, 2862, 1680, 1651 (st), 1470, 1459, 1270, 1249, 1210, 
1122, 1025, 1000 cm-1; HR-APPIMS requires for C14H16BrNO2 (M+H)+ 312.0594, found 
312.0206. 
 
(±)-(4S, 5R, 1S)-4-methyl-8-oxo-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one 
(66b): 
 
 Prepared in 67% yield (0.26 mmol, 63.3 mg) from the reaction of 2-bromo-N- 
(phenylmethoxy)propanamide (0.39 mmol, 100.7 mg) with furan via general procedure B. Rf 
= 0.3 (3:1 hexanes:ethyl acetate); 1H-NMR (500 MHz, CDCl3): δ 7.47 – 7.32 (m, 5H), 6.57 
(dd, J = 6.2, 1.0 Hz, 1H), 6.41 (dd, J = 6.0, 1.7 Hz, 1H), 5.25 (d, J = 1.5 Hz, 1H), 5.00 (d, J = 
11.0 Hz, 1H), 4.87 (d, J = 11.0 Hz, 1H), 4.85 (dd, J = 5.0, 1.9 Hz, 1H), 3.17 (qd, J = 7.4, 5.0 
Hz, 1H), and 1.09 (d, J = 7.4 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 172.7, 136.1, 135.8, 
133.8, 129.7, 128.9, 128.7, 91.6, 82.9, 78.1, 45.1, and 10.6; IR (film) 3089, 2970, 2970, 2934, 
2876, 1697, 1497, 1455, 1377, 1209, and 1053 cm-1; HR-ESIMS requires for C14H16NO3 












: TFE (1:1 v/v)
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(±)-(4S, 5R, 1S)-4-ethyl-8-oxo-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one 
(66c): 
 
 Prepared in 86% yield (0.157 mmol, 40.6 mg) from the reaction of 2-bromo-N- 
(phenylmethoxy)butanamide (0.183 mmol, 50.0 mg) with furan via general procedure B. Rf = 
0.3 (3:1 hexanes:ethyl acetate); Rf 0.50 (3:1, hexanes: ethyl acetate); 1H-NMR (500 MHz, 
CDCl3): δ 7.45 – 7.42 (m, 2H), 7.41 – 7.32 (m, 3H), 6.51 (dd, J = 6.0, 1 Hz, 1H), 6.38 (dd, J = 
6.0, 1.8 Hz, 1H), 5.25 (d, J = 1.2 Hz, 1H), 4.99 (d, J = 11.0 Hz, 1H), 4.95 (dd, J = 5.1, 1.8 Hz, 
1H), 4.87 (d, J = 11.0 Hz, 1H), 2.99 (dt, J = 10.1, 5.1 Hz, 1H), 2.01 (dqd, J = 15.4, 7.5 5.3, 
7.5, 15.4 Hz, 1H), 1.24 – 1.14 (m, 1H), and 1.03 (t, J = 7.5 Hz, 3H). 13C-NMR (126 MHz, 
CDCl3): δ 172.1, 135.8, 133.6, 129.7, 128.8, 128.6, 91.4, 91.4, 81.3, 78.0, 51.8, 19.5, and 
12.3; IR (film) 3250 (br), 3032, 2966, 2929, 2877, 1696 (st), 1497, 1455, 1371, 1209, 1104, 
1055, and 1033 cm-1; HR-ESIMS requires for C15H17NO3 (M+Na)+ 282.1101, found 
282.1083. 
 
(±)-(4S, 5R, 1S) 4-(2,2-dimethylethyl)-8-oxo-2-(phenylmethoxy)-2- azabicyclo[3.2.1]oct-
6-en-3-one (66d): 
 
 Prepared in 54% yield (52.7 mg, 0.18 mmol) from the reaction of 2-bromo-2,2-
dimethyl-N- (phenylmethoxy)propanamide (103.5 mg, 0.34 mmol) with furan via general 
procedure B. Rf = 0.49 (3:1 hexanes:ethyl acetate); 1H-NMR (500 MHz, CDCl3): δ 7.43 (m, 







: TFE (1:1 v/v)












: TFE (1:1 v/v)
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(d, J = 1.3 Hz, 1H), 5.00 (dd, J = 4.8, 1.8 Hz, 1H), 4.98 (d, J = 11.0 Hz, 1H), 4.88 (d, J = 11.0 
Hz, 1H), 3.04 (d, J = 4.8 Hz, 1H), and 1.10 (s, 9H); 13C-NMR (126 MHz, CDCl3): δ 141.6, 
136.0, 134.5, 134.0, 129.8, 128.8, 128.6, 91.6, 81.5, 78.0, 60.5, 32.3, and 29.8; IR (film): 
3210, 3090, 3064, 3032, 2958, 2871, 1672 (st), 1497, 1480, 1455, 1365(s), 1231, 1211, 1162, 
1054, and 1038 cm-1; HR-ESIMS requires for C17H21NO3 (M+Na)+ 312.1455, found 
312.1446. 
 
(±)-(4S, 5R, 1S)-4-chloro-8-oxo-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one 
(endo-66f) and (±)-(4R, 5R, 1S)-4-chloro-8-oxo-2-(phenylmethoxy)-2- 
azabicyclo[3.2.1]oct-6-en-3-one (exo-66f): 
 
 Prepared in 73% yield (0.31 mmol, 72 mg) from the reaction of 2,2-dichloro-N- 
(phenylmethoxy)acetamide (0.43 mmol, 100.2 mg) with furan via general procedure B. Rf = 
0.50 (3:1 hexanes:ethyl acetate) 1H NMR (400MHz, CDCl3) δ 7.51 – 7.30 (m, 3H), 6.54 (dd, 
J = 6.0, 1.1 Hz, 1H), 6.51 (dd, J = 6.0, 1.7 Hz, 1H), 5.27 (d, J = 1.1 Hz, 1H), 5.09 (dd, J = 5.1, 
1.6 Hz, 1H), 5.00 (d, J = 11.0 Hz, 1H), 4.89 (d, J = 11.0 Hz, 1H), and 4.76 (d, J = 5.2 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 165.9, 136.8, 135.3, 133.1, 129.8, 129.2, 128.2, 92.1, 
82.1, 78.3, and 56.9; IR (film): 3032, 2950, 2922, 2852, 1712 (st), 1455, 1369, 1213, 1189, 
1059, and 1023 cm-1. HR-ESIMS requires for C13H12ClNO3 (M+Na)+ 288.0398, found 
288.0391. exo-diastereoisomer: Rf = 0.3 (3:1 hexanes:ethyl acetate); 1H NMR (400MHz, 
CDCl3): δ 7.48 – 7.35 (m, 2H), 6.68 (d, J = 5.9 Hz, 1H), 6.34 (dd, J = 6.0, 1.1 Hz, 1H), 5.28 
(s, 1H), 5.02 (d, J = 10.9 Hz, 1H), 4.98 (s, 1H), 4.92 (d, J = 10.9 Hz, 1H), and 4.09 (s, 1H); 







: TFE (1:1 v/v)
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78.4, and 56.1; IR (neat): 3067, 3034, 2946, 2885, 1694, and 1046 cm-1; HR-ESIMS requires 
for C13H12ClNO3 (M+Na)+ 288.0398, found 288.0399. 
 
(±)-(4S, 5R, 1S)-4-(4-chlorophenyl)-8-oxo-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6- 
en-3-one (66g): 
 
 Prepared in 53% yield (0.16 mmol, 54.4 mg) from the reaction of 2-choro-2-(4- 
chlorophenyl)-N-(phenylmethoxy)acetamide (0.31 mmol, 95.5 mg) with furan via general 
procedure B. Rf = 0.48 (3:1 hexanes:ethyl acetate); 1H-NMR (500 MHz, CDCl3): δ 7.50 – 
7.44 (m, 2H), 7.44 – 7.34 (m, 3H), 7.28 (ABd, J = 8.5 Hz, 2H), 7.05 (ABd, J = 8.5 Hz, 2H), 
6.55 (dd, J = 6.0, 1.1 Hz, 1H), 6.19 (dd, J = 6.0, 1.7 Hz, 1H), 5.36 (d, J = 1.3 Hz, 1H), 5.05 
(d, J = 11.0 Hz, 1H), 4.96 (d, J = 11.0 Hz, 1H), 4.94 (dd, J = 5.3, 1.8 Hz, 1H), and 4.38 (d, J = 
5.3 Hz, 1H); 13C-NMR (126 MHz, CDCl3): δ 169.7, 136.0, 136.0, 135.6, 133.8, 133.8, 132.0, 
131.1, 129.83, 129.1, 128.8, 128.7, 91.8, 91.8, 83.1, 83.1, 78.3, and 56.5; IR (film): 3089, 
3064, 3031, 2924, 1688 (st), 1492, 1454, 1368, 1275, 1260, 1211, 1091, 1059, and 1017 cm-1; 














: TFE (1:1 v/v)












 Prepared in 78% yield (0.32 mmol, 85.2 mg) from the reaction of 2-bromo-2-methyl 
N- (phenylmethoxy)propanamide (0.42 mmol, 115.0 mg) with furan via general procedure B. 
Rf = 0.40 (3:1 hexanes:ethyl acetate); 1H-NMR (500 MHz, CDCl3): δ 7.46 – 7.28 (m, 5H), 
6.56 (dd, J = 5.9, 1 Hz, 1H), 6.43 (dd, J = 5.9, 1.9 Hz, 1H), 5.21 (d, J = 1.1 Hz, 1H), 4.97 (d, J 
= 10.9 Hz, 1H), 4.87 (d, J = 10.9 Hz, 1H), 4.46 (d, J = 1.8 Hz, 1H), 1.49 (s, 3H), and 1.05 (s, 
3H); 13C-NMR (126 MHz, CDCl3): δ 175.7, 135.7, 135.5, 134.6, 129.8, 128.9, 128.6, 91.5, 
87.4, 78.0, 49.3, 27.1, and 19.9; IR (film): 3055 (br), 1692 (st), 1470, 1385, 1362, 1265, 1217, 






 Prepared in 65% yield (0.22 mmol, 65.9 mg) from the reaction of 2-bromo-N- 
(phenylmethoxy)cyclohexane carboxamide (0.34 mmol, 107.2 mg) with furan via general 
procedure B. Rf = 0.62 (3:1 hexanes:ethyl acetate); 1H-NMR (500 MHz, CDCl3): δ 7.48 – 
7.29 (m, 5H), 6.54 (d, J = 5.8 Hz, 1H), 6.43 (dd, J = 6.0, 1.7 Hz, 1H), 5.18 (d, J = 1.1Hz, 1H), 
4.96 (d, J = 10.9 Hz, 1H), 4.93 (d, J = 1.4 Hz, 1H), 4.86 (d, J = 10.9 Hz, 1H), 2.06 (d, J = 







: HFIP (1:1 v/v)











OBn Et3N (2.0 equiv.)
: HFIP (1:1 v/v)
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and 1.47 – 1.19 (m, 6H); 13C-NMR (101 MHz, CDCl3): δ 175.7, 135.8, 135.5, 134.5, 129.8, 
128.8, 128.6, 91.2, 82.9, 77.9, 53.3, 33.7, 28.9, 25.5, 21.7, and 21.5; IR (film): 3063, 3031, 
2927, 2858, 1690, 1496, 1454, 1367, 1210, 1187, 1076, and 1064 cm-1. HR-ESIMS requires 
for C18H21NO3 (M+Na)+, 322.1414, found 322.1424. 
 
(±)-(4S, 5R, 1S)-4-ethyl-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one (endo-66j) 
and (±)-(4R, 5R, 1S) 4-ethyl- -2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3- one 
(exo-66j): 
 
 Prepared in 85% yield (0.32 mmol, 82.3 mg) from the reaction of 2-bromo-N- 
(phenylmethoxy)butanamide (0.37 mmol, 100.4 mg) with cyclopentadiene via general 
procedure B (characterized as a mixture 2.5:1 exo:endo). Endo diastereoisomer: Rf = 0.54 
(3:1 hexanes:ethyl acetate); 1H-NMR (500 MHz, CDCl3): δ 7.53 – 7.28 (m, 5H), 6.30 (dd, J = 
5.5, 2.0 Hz, 1H), 6.12 (dd, J = 5.4, 2.7 Hz, 1H), 4.95 (d, J =10.8 Hz, 1H), 4.88 (d, J = 10.8 
Hz, 1H), 3.90 (d, J = 6.1 Hz, 1H), 2.93 (app q, J = 4.2 Hz, 1H), 2.59 (dt, J = 10.4, 4.1 Hz, 
1H), 2.09 (dt, J = 12.1, 7.8 Hz, 1H), 1.99 (dd, J = 11.0, 5.3 Hz, 1H), 1.85 (d, J = 10.8 Hz, 1H), 
1.37 – 1.16 (m, 2H), and 1.01 (t, J = 7.5 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 171.6, 
137.2, 137.0, 136.0, 129.8, 129.7, 128.7, 128.5, 77.19, 64.5, 51.5, 42.4, 40.8, 21.6, and 12.3; 
IR (film): 3063, 3031, 2961, 2874, 1668 (st), 1455, and 1368 cm-1; HR-ESIMS requires for 
C16H19NO2 (M+Na)+ 280.1308, found 280.1296. Exo diastereoisomer: Rf = 0.41 (3:1 
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3): δ 7.5 – 7.3 (m, 5H), 6.30 (dd, J = 5.5, 
2.5 Hz, 1H), 6.17 (dd, J = 5.5, 2.9 Hz, 1H), 4.93 (d, J = 10.7 Hz, 1H), 4.86 (d, J = 10.7 Hz, 
1H), 3.86 (br s, 1H), 2.73 (app t, J = 4.2 Hz, 1H), 2.20 (dd, J = 10.1, 5.3 Hz, 1H), 2.12-2.16 







: TFE (1:1 v/v)
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1.59 (m, 1H), 1.31-1.18 (m, 1H), and 1.05 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
174.5, 138.3, 136.4, 136.0, 129.9, 128.8, 128.5, 77.0, 64.4, 51.5, 42.2, 38.8, 34.3, 30.5, 25.7, 
21.6, and 21.3. IR (film): 3063, 3031, 2961, 2874, 1679, 1496, 1455, 1370 cm-1; HR-ESIMS 
requires for C16H19NO2 (M+Na)+ 280.1308, found 280.1303. 
 
(±)-(4S, 5R, 1S)-4-chloro-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one (endo-
66k) and 
(±)-(4R, 5R, 1S)-4-chloro-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one (exo-
66k): 
 
 Prepared in 64 % yield (0.28 mmol, 73.8 mg) from the reaction of 2-bromo-N- 
(phenylmethoxy)butanamide (0.43 mmol, 100.8 mg) with cyclopentadiene via general 
procedure B. Rf = 0.53 (3:1 hexanes:ethyl acetate); 1H-NMR (500 MHz, CDCl3): δ 7.46 – 
7.34 (m, 3H), 6.32 (dd, J = 5.7, 2.2 Hz, 1H), 6.31 – 6.28 (m, 1H), 4.98 (d, J = 10.9 Hz, 1H), 
4.92 (d, J = 10.9 Hz, 1H), 4.71 (d, J = 4.4 Hz, 1H), 2.06 (dt, J = 11.6, 4.8 Hz, 1H), and 1.90 
(d, J = 11.5 Hz, 1H); 13C-NMR (126 MHz, CDCl3): δ 164.7, 138.0, 136.5, 135.5, 129.9, 
129.0, 128.6, 77.4, 65.0, 61.0, 46.8, and 41.7; IR (film): 3066, 3033, 2926, 2853, 1679, 1455, 












: TFE (1:1 v/v)
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(±)-(1ʼR, 5ʼS)-spiro[cyclohexane-1,2' -4ʼ-(phenylmethoxy)-4ʼ- azabicyclo[3.2.1]oct[6]en]-
3'-one (66l): 
 
 Prepared in 81 % yield (0.26 mmol, 72.9 mg) from the reaction of 2-bromo-N- 
(phenylmethoxy)butanamide (0.32 mmol, 100.4 mg) with cyclopentadiene via general 
procedure B. Rf = 0.6 (3:1 hexanes:ethyl acetate); 1H-NMR (400 MHz, CDCl3): 7.42 (d, J = 
7.5 Hz, 2H), 7.40 – 7.29 (m, 3H), 6.25 (dd, J = 5.6, 2.0 Hz, 1H), 6.16 (dd, J = 5.6, 2.9 Hz 
1H), 4.92 (d, J = 10.4 Hz, 2H), 4.88 (d, J = 10.3 Hz, 2H), 3.84 (dd, J = 4.2, 3.5 Hz, 1H), 2.98 
(dd, J = 4.1, 3.1 Hz, 1H), 1.98 (d, J = 11.2 Hz, 1H), 1.94 (dt, J = 16.6, 12.6 Hz, 1H) 1.88-1.84 
(m, 1H), 1.83 (dt, J = 10.6, 4.5 Hz, 1H), 1.75 (dq, J = 13.4, 3.6 Hz, 1H), 1.70- 1.60 (m, 3H), 
1.55-1.42 (m, 2H), and 1.42-1.31 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 174.5, 138.6, 
136.4, 136.0, 130.0, 128.7, 128.5, 77.0, 64.4, 51.5, 42.3, 38.8, 34.3, 30.5, 25.7, 21.6, and 21.3; 
IR (film): 3062, 3030, 2925, 2858, 1662 (st), 1454, and 1371 cm-1; HR-ESIMS requires for 




 Produced as a byproduct in 56% yield from the reaction of 2-bromo-2-methyl-N- 
(phenylmethoxy) propanamide with TEA in furan and trifluoroethanol. Rf = 0.26 (3:1 
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) δ 8.88 (s, 1H), 7.56 – 7.31 (m, 5H), 4.94 
(s, 2H), 3.68 (q, J = 8.3 Hz, 2H), 1.43 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 170.8, 134.9, 




OBn Et3N (2.0 equiv.)
: HFIP (1:1 v/v)
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(neat): 3218 (br), 3036; 2942, 2886, 1663 (st), 1430, 1455, 1485, 1386, 1369, 1307, 1285, 
1217, 1181, 1145, 1029, and 1010 cm-1; HR-ESIMS requires for C13H17F3NO3 (M+H)+ 
292.1155, found 292.1160. 
 
2-methyl-N-(phenylmethoxy)-2-propenamide: Elimination product from the reaction 
attempted cycloaddition of 62 with LiClO4/Et3N in diethyl ether. 
 
 Produced in 61% yield from the reaction of 2-bromo-2-methyl-N- (phenylmethoxy) 
propanamide with LiClO4/Et3N in furan and diethyl ether. Rf = 0.4 (3:1 hexanes:ethyl 
acetate); 1H NMR (400 MHz, CDCl3) δ 8.19 (br s, 1H), 7.49 – 7.29 (m, 5H), 5.55 (pent, J = 1 
Hz, 1H), 5.32 (dq, J = 1.6, 1.0 Hz, 1H), 4.96 (s, 2H), and 1.92 (dd, J = 1.6, 1.2 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 167.2, 138.0, 135.4, 129.5, 129.0, 128.8, 120.4, 78.3, and 18.6; IR 
(film): 3199 (br), 3064, 3032, 2954, 2878, 1658, 1620, 1496, 1453, 1372, 1322, 1209, and 
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Chapter 3: Target Directed Studies Of Aza-[4+3] Cycloaddition Scaffolds 
 
3.1 Introduction 
 The family of protein kinase C (PKC) enzymes catalyzes the transfer of the γ-phosphate 
from adenosine triphosphate (ATP) to serine or threonine residues on their respective substrate 
proteins.1-7 Phosphorylation that is mediated by PKC had been found to be pivitol in a number of 
cellular processes, including but not limited to gene expression and cell proliferation. Unregulated 
PKC activation has been discovered to play a part in a variety of clinical disease states, with the 
most prominent being carcinogenesis.8 Thus, extensive efforts have been made over the last 
several years to identify selective and potent inhibitors of PKC. Balanol 70 is a secondary 
metabolite of the fungus Verticillium balanoides, and was first isolated and characterized in 1993 
by Kulanthaivel and co-workers.9 Balanol was found to be a powerful inhibitor of PKC at low 
nanomolar concentrations, and its total synthesis has been reported by several research groups.10-
13 Given the seven-membered nitrogen ring at the core of its structure, we were curious to explore 
the possibility of utilizing our cycloaddition methodology (described in Chapter 2) toward a new 
approach to synthesizing balanol in an overall shorter and more concise route (Scheme 3.1.1). 
The first portion of this chapter outlines our progress in applying an aza-[4+3] cycloaddition 
substrate to the synthesis of balanol. 
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Scheme 3.1.1. Proposal to synthesize balanol 70 starting from a simple pre-functionalized α-haloamide. 
	  
 Iminosugars are analogues of monosaccharides where the endocyclic oxygen is replaced 
with a nitrogen atom, a substitution that prevents the metabolism of these compounds.14 
Polyhydroxylated piperidines, or six-membered ring-size iminosugars, have received the most 
attention to detail, owing to their ability to mimic their analogous pyranoses in interactions with 
carbohydrate-processing enzymes. Deoxynojirimycin 71 (DNJ) (Figure 3.1.1), an analogue of 
glucose, is the archetypal iminosugar and occurs naturally in mulberry plants, Streptomyces, and 
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body’s ability to breakdown carbohydrates into glucose, and has more recently been shown to 
reduce plasma lipids as well as inhibit free radical generation.16 Miglustat 73 (marketed under the 
trade name Zavesca) is an inhibitor of glucosylceramide synthase, and is used to treat adults with 
mild to moderate Type I Gaucher disease.17 Due to their similarity, iminosugars share many 
chemical features with mono- and disaccharides. With respect to spatial aspects, they occupy an 
area of chemical space similar to that of carbohydrates, but different from that of other small 
heterocyclic molecules typically explored in screening libraries.18 The attraction of iminosugars 
however extends beyond being simply different. As small polar molecules they possess the ability 
for efficient uptake by the body,19 while at the same time they remaining adequately distinct from 
carbohydrates to avoid processing by carbohydrate-modifying enzymes, thus giving them 
chemical and biological stability. This “dual nature” of properties sets apart iminosugars as a 
special class in the on-going search for new drug molecules. Continuing developments in the 
depths of understanding of glycobiology are constantly identifying new targets to which 
iminosugars can appropriately be applied in the search for drug candidates.18 Since the 
commercialization of the first iminosugar-based drug (GlysetTM) in 1996, the rate at which new 
discoveries in the field of sugar mimetics with nitrogen replacement of the endocyclic oxygen has 
been steadily on the rise.20 Several structures either have been, or are currently involved in 
clinical trials for the treatment of cancers,21 diabetes,22 viral infections,23 and rare genetic 
diseases.24,25  
 Our goal in the contribution to this rapidly growing field of research was to demonstrate 
the utility of our new reaction methodology (described in Chapter 2) to provide a general means 
to access iminosugar scaffolds. More specifically, we wanted to establish a versatile synthetic 
strategy that allowed for the option to access a variety of derivatives from our general aza-[4+3] 
cycloaddition scheme. Herein, the latter part of this chapter describes synthetic efforts devoted to 
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the construction of seven-membered iminosugar analogues from commercially available starting 
materials and a common intermediate in high yields and diastereoselectivity. 
3.2 Towards a Concise and Stereoselective Synthesis of Balanol 
 Synthetic studies toward the total synthesis of balanol began with α-chlorocycloadduct 74 
(from Chapter 2) (Scheme 3.2.1), thinking that the halogen functionality could provide a 
necessary handle for functional group manipulation at the 3-position of the azepane ring. 
Reduction of 74 using lithium aluminum hydride and aluminum trichloride proceeded cleanly to 
give azepine 75 in good yield. The next step of our synthesis would involve displacement of 
chloride by a nitrogen-centered nucleophile. Reaction of 75 with sodium azide in dimethyl 
sulfoxide (DMSO) at 90 °C was found to effectively install a nitrogen functionality. A one-pot 
reductive acylation sequence was carried out, using first palladium-catalyzed hydrogenation 
followed by acylation of the resulting free amine with p-methoxybenzoyl chloride. However upon 
purification, instead of the expected seven-membered azepane, piperidine 78 was recovered as the 
sole product, presumably to have arisen from ring contraction during the azide displacement step. 
Although we observed an unwanted ring size, we were able to demonstrate proof of concept 
toward realizing the core structure of balanol by esterifying the alcohol of 78 with benzoic 
anhydride, catalyzed by 4-dimethylaminopyridine (DMAP) to give 79 in good yield. 
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Scheme 3.2.1. Synthetic efforts directed toward balanol starting from cycloadduct 74. 
	  
 Given the exceptional electron rich character on the nitrogen atom due to the electron-
donating benzyloxy group, we proposed a plausible mechanism for the observed ring contraction 
in which intramolecular nucleophilic attack by nitrogen would give aziridinium ion 80 (Scheme 
3.2.2). Subsequent nucleophilic attack by azide to relieve the three-membered ring strain would 
ultimately give rise to piperidine 79. Attempts to directly displace chloride from the starting 
cycloadduct 74 including microwave and the previously described conditions all resulted in 
decomposition of the substrate. In light of ring contraction being an inevitable result of our 
current methodology, current work on this project is being focused on the development of new 
cycloaddition conditions that avoid the use of halogens. We are investigating conditions whereby 
an aza-oxyallylic cation intermediate 82 is generated by direct oxidation of α-nitrogen substituted 
amides 81, giving a cycloadduct such as 83. Reduction would provide pre-functionalized azepine 
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Scheme 3.2.2. Proposed ring contraction mechanism and current work to circumvent problem. 
	  
3.3 Synthesis of 7-Membered Iminosugar Analogues: A General Strategy for the Rapid 
Construction of Polyhydroxylated Azepane Derivatives 
 Compared to naturally occurring five- and six-membered iminosugar homologues, 
polyhydroxylated azepanes or azepane iminosugars have garnered less attention and thus been 
less investigated. The first azepane iminosugars were first synthesized in 1967 by Paulsen,26 with 
more interest in this field being acquired thirty years later when Wong studied their bioactivities 
and found comparable outcomes with their five- and six-membered relatives.27-32 Over the past 
several years, new azepane iminosugar family members have surfaced including seven-membered 
DNJ homologues,28 and 1-N-iminosugars,29 both of which showed promising inhibitory 
properties. Additionally, acetylamino group substituted azepanes have been shown to be potent 
inhibitors of N-acetyl-β-hexosaminidases.30 Azepanes in bicyclic form, known as 
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activity has been reported yet.31 Several other higher homologues of calystegine have also shown 
promising inhibitory properties.32 Despite all of the promising biological leads and increased 
interest in these types of compounds, currently no general synthetic strategies exist that allow for 
convenient structural modifications. We considered the possibility of utilizing aza-[4+3] 
cycloaddition reactions and the privileged scaffolds they afford, as well as the rich functionality 
produced from a single synthetic step, as potential building blocks for azepane iminosugars. 
Given the versatility of our method and the ability to readily tune the substituent groups at the 3-
position (Scheme 3.3.1), we sought to consider if seven-membered iminosugars could be 
accessed diastereoselectively and in only a few short synthetic steps. 
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 To explore the viability of our proposal, dimethyl cycloadduct 63 (Scheme 3.3.2) was 
chosen as a model substrate. Alkene dihydroxylation of 63 catalyzed by osmium tetroxide 
proceeded in high yield, giving syn-diol 85 as a single diastereoisomer. Protection of the diol as 
its acetal using 2,2-dimethoxypropane and catalyzed by camphor sulfonic acid gave cleanly 86 in 
excellent yield.33 Selective reductive N-O bond cleavage was accomplished by the action of 
Mo(CO)6 in refluxing acetonitrile and water to provide amide 87 in high yield.34 For the next 
step, it was found that refluxing of 87 in excess lithium aluminum hydride (LAH) not only 
provided reduction of the carbonyl, but also ring opening of the hemiaminal ether had occurred to 
give the desired azepane 88 in excellent yield and install the first hydroxyl group. The structure 
and relative stereochemistry of 88 was unambiguously assigned by single crystal X-ray 
diffraction (Figure 3.3.1). Finally, stirring of 88 in trifluoroacetic acid and water was found to 
cleanly deprotect the diols to give the desired polyhydroxylated azepane 89 in good overall yield 
starting from cycloadduct 63. 
 
	  
Figure 3.3.1.	  Thermal ellipsoid plot of azepane 88 at 50% probability. Hydrogen atoms are represented as 
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Alternatively, it was found that we could eliminate the protection/deprotection steps and 
synthesize 89 more directly and efficiently simply by reordering the reaction sequence. Reductive 
cleavage of the N-O bond of 63 by Mo(CO)6 provided amide 90 with no sacrifice in yield 
(Scheme 3.3.3). Next, LAH mediated amide reduction and subsequent hemiaminal ether ring 
opening gave azepine 91. Catalytic dihydroxylation again by osmium tetroxide yielded 89 in 
excellent overall yield, completing the synthesis and providing access to the seven-membered 
iminosugar family of compounds in only five synthetic steps and excellent overall yield from 
commercially available starting materials. Although simple in form, the reaction sequence 
described provides access to seven-membered iminosugar scaffolds in only 5 short synthetic steps 
and relatively easy reactions. Additionally, the methodology provides for a large degree of 
variability at the C-terminus of a simple α-haloamide starting material. This type of methodology 
could easily be employed to assist in the construction of libraries of compounds to test for 
biological activity as well as structure activity relationship (SAR) studies. 
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Attention was turned towards the α-chloro-cycloadduct, thinking that the halogen 
functionality could provide the necessary handle for installing a fourth hydroxyl group on the 
ring. Initial studies began by subjecting either endo or exo α-chloro-cycloadduct 66 to N-O bond 
cleaving conditions, however this reaction proved ineffective and resulted in decomposition of 
the starting material (Scheme 3.3.4). Other reductive conditions including Zn/AcOH, SmI2, and a 
titanocene (III) chloride procedure reported by Miller and co-workers35 were all found to be 
incompatible with the substrate and could not affect the desired N-O bond cleavage. Under 
palladium catalyzed hydrogenation conditions, C-O bond reduction resulted in recovery of 
undesired hydroxamic acid 92 as the sole product. 
 
	  
Scheme 3.3.4. Screening of N-O reduction conditions of 66. 
	  
Since all of the above reagents involve one-electron reducing mechanisms and are usually 
not tolerant of halogens, efforts were focused on first displacing the chloride with oxygen-centred 
nucleophiles to install the desired functionality before moving on to N-O bond reduction. To our 
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proved to be unproductive and resulted in either decomposition or recovery of the starting 
material (Scheme 3.3.5). In an effort to circumvent these issues, we thought that re-ordering of 
the reaction scheme could provide a solution to the observed difficulties. At this point, studies 
were conducted on α-alkyl-substituted substrates as model systems in parallel with the α-chloro 
cycloadduct material for purposes of reaction exploration/optimization. Dihydroxylation of 
cycloadducts endo 66f and 66c by osmium tetroxide was found to proceed in good yield 
providing syn-diols 93 and 95 (Scheme 3.3.6). Subsequent protection of the alcohols using 2,2-
dimethoxypropane and catalyzed by camphor sulfonic acid as previously described gave acetals 
94 and 96 in excellent yield, setting the stage for reduction of the amide and ring opening of the 
hemiaminal ether.33 Treatment of 96 to LAH following the previously mentioned conditions 
however was found to be unproductive, which instead of the desired product, resulted in recovery 
of carbinol amine 97, albeit as a single diastereoisomer. The structure of 97 was confirmed as 
well as the relative stereochemical configuration unambiguously assigned by single crystal X-ray 
analysis (Figure 3.3.2). 
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Scheme 3.3.6. Synthesis of acetal-protected diols 94 and 96 starting from cycloadducts endo 66f and 66c. 
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Figure 3.3.2. Thermal ellipsoid plot of carbinol amine 97 at 50% probability. Hydrogen atoms are 
represented as spheres of arbitrary radius. Grey = carbon, red = oxygen, blue = nitrogen. 
	  
	   Aluminum hydride, or alane (generated in situ from lithium aluminum hydride and 
aluminum trichloride), has been shown to be an excellent overall reducing agent that reduces a 
wide variety of functional groups while leaving unaltered halogens, alkenes, and nitro groups.36 
Although evidence supporting single electron pathway mechanisms has been reported,37 
reductions by alane take place primarily by a two-electron mechanism.38,39 In this light, we 
proposed that alane would be a suitable reducing reagent that could chemoselectively reduce the 
amide while at the same time leaving the chloride unaffected. Indeed, upon subjection of acetal-
protected diol 94 to a solution of LAH and aluminum trichloride in THF, it was found that the 
amide was reduced to the desired amine as well as the aminal ether ring opened to give an 
alcohol, however the acetal had also been reduced to give isopropyl ether 98 as the final product 
(Scheme 3.3.6). After consulting the literature we discovered that reduction of acetals by alane to 
give the half protected diol is a known transformation.40 Other reducing agents such as borane, 
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borohydride all failed to give the desired reactivity as well and resulted in recovery of the starting 
material. 
	  
Scheme 3.3.7. Alane reduction of 94 to give isopropyl ether 98. 
	  
 Once again we thought that perhaps re-ordering of the reaction scheme could possibly 
circumvent the observed unwanted reactivity. Since alane has been shown to be tolerant of both 
halogens and double bonds, it was hypothesized that reduction of α-chloro cycloadduct endo 66f 
as the first step in our synthesis could be a viable option. Exposure of endo 66f to a slight excess 
of aluminum hydride under refluxing conditions was found to effectively provide azepine 75 
(previously synthesized in Section 3.2) in good yield and as a single diastereoisomer (Scheme 
3.3.8). Attempts to displace chloride with oxygen-centered nucleophiles under previously 
described conditions (Scheme 3.3.5) resulted in either decomposition or recovery of the starting 
material, with the exception of one case. We found that 3-chloroazepine 75 underwent facile ring 
contraction when reacted with silver acetate in DMF at 90 °C, giving tetrahydropyridine 100 in 
modest yield, albeit as a single diastereoisomer. Again, given the exceptional electron-rich 
character of the nitrogen atom, a plausible mechanism would involve the ring contraction going 
through an aziridinium ion intermediate such as 99 and ultimately collapsing to the six-membered 
ring similar to our observed ring contraction observation in Section 3.2. We saw this 
serendipitous result as an opportunity to extend our aza-[4+3] cycloaddition scaffolds to the 
synthesis of piperidine iminosugars. As previously stated, we were unable to reductively cleave 
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electron donating character on the nitrogen atom. Therefore, ring contraction turned out to be an 
inevitable result and we were unable to install a fourth oxygen functionality with our current 
methodology and retain the seven-membered ring, regardless of reaction conditions or re-ordering 
of the synthetic scheme. 
 
	  
Scheme 3.3.8. Alane reduction of cycloadduct endo 66f to give azepine 75 and subsequent silver acetate-




All reactions were carried out under an atmosphere of nitrogen in oven-dried glassware 
with magnetic stirring, unless otherwise specified. All reagents and solvents were purchased from 
Sigma-Aldrich Chemical Company and used without any further purification. TLC information 
was recorded on Silicycle glass 60 F254 plates and developed by staining with KMnO4 or ceric 
ammonium molybdate. Purification of reaction products was carried out by flash chromatography 
using Silicycle Siliaflash® P60 (230-400 mesh). 1H-NMR spectra were measured on Varian 400 
(400 MHz) or Varian 500 (500 MHz) spectrometers and are reported in ppm (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad; integration; coupling constant(s) in Hz 
using TMS as an internal standard (TMS at 0.00 ppm) in CDCl3, CD3CN, or CD3OD. 13C-NMR 
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internal standard (CDCl3 at 77.36 ppm), (CD3CN at 118.26 ppm) or (CD3OD at 49.86 ppm). 
Infrared (IR) spectra were recorded on a Nicolet 6700 FT-IR with a diamond ATR and data are 
reported as cm-1 (br = broad, st = strong). High-resolution mass spectra were obtained using an 
Agilent 6230 TOF LC/MS with an atmospheric pressure photo-ionization (APPI) or electrospray 
(ESI) source with purine and HP-0921 as internal calibrants. 
 
(±)-(4S, 5R, 1S)-4-chloro-8-oxo-2-(phenylmethoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one (66f 
endo, 74) 
 
 To a solution of 2,2-dichloro-N-(phenylmethoxy)acetamide (100.2 mg, 0.43 mmol) in 
CF3CH2OH (TFE) and furan [1:1 (v/v) 0.25 M] at 0 °C was added triethylamine (2 equiv.) 
dropwise. The solution was allowed to warm to room temperature and the reaction mixture was 
stirred for 72 hours. After removal of the volatiles under reduced pressure, the crude mixture was 
purified by flash column chromatography (3:1 hexanes:ethyl acetate) to afford 72 mg of 74 endo 
(0.31 mmol, 79% yield) (2:1 endo:exo) as a yellow oil. Rf = 0.50 (3:1 hexanes:ethyl acetate); 1H 
NMR (400 MHz, CDCl3) δ 7.51 – 7.30 (m, 3H), 6.54 (dd, J = 6.0, 1.1 Hz, 1H), 6.51 (dd, J = 6.0, 
1.7 Hz, 1H), 5.27 (d, J = 1.1 Hz, 1H), 5.09, (dd, J = 5.1, 1.6 Hz, 1H), 5.00 (d, J = 11.0 Hz, 1H), 
4.89 (d, J = 11.0 Hz, 1H), 5.09 (dd, J = 5.1, 1.6 Hz, 1H), 5.00 (d, J = 11.0 Hz, 1H), 4.89 (d, J = 
11.0 Hz, 1H), and 4.76 (d, J = 5.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 165.9, 136.8, 135.3, 
133.1, 129.8, 129.2, 128.2, 92.1, 82.1, 78.3, and 56.9; IR (film) 3032, 2950, 2922, 2852, 1712 (s), 
1455, 1369, 1213, 1189, 1059, 1023 cm-1. HR-ESIMS requires for C13H12ClNNaO3 (M+Na)+ 
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(±)-(3S, 4R)-N-phenylmethoxy-3-chloro-4-hydroxy-2,3,4,7-tetrahydro-1H-azepine (75) 
 
 To an oven dried 100 mL Schlenk flask equipped with a magnetic stir bar was added dry 
THF (19 mL) under an atmosphere of nitrogen. The flask was placed in an ice bath and aluminum 
chloride (7.57 mmol, 1.01 g) was added in portions over a period of 5 minutes. Upon complete 
dissolution of the aluminum chloride, a solution of lithium aluminum hydride in dry THF (11.4 
mmol, 5.7 mL) was added dropwise at that same temperature over a period of 15 minutes and the 
resulting solution was stirred at 0 °C for 20 minutes. The cycloadduct 74 (3.79 mmol, 1.01 g) was 
then added in THF (25 mL) dropwise over a period of 20 minutes and the reaction mixture was 
refluxed under nitrogen for 1.5 hours. The reaction flask was cooled to 0 °C and quenched with 
water followed by 10% NaOH. The aluminum salts were filtered off and the filtrate was dried 
over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by column 
chromatography (10% - 33% Hex:EtOAc) to afford 0.67 g of 75 as a white crystalline solid (2.64 
mmol, 70% yield). Rf = 0.54 (2:1 hexanes:ethyl acetate); M.P. 59.5 – 62.0 °C; 1H NMR (500 
MHz, CDCl3): δ 7.35 – 7.30 (m, 5H), 5.81 (dt, J = 11.9, 3.1 Hz, 1H), 5.67 (dt, J = 12.0, 6.0 Hz, 
1H), 4.69 (s, 2H), 4.36 (d, J = 8.2 Hz, 1H), 4.18 (td, J = 8.3, 4.7 Hz, 1H), 3.77 (dd, J = 14.1, 4.7 
Hz, 1H), 3.62 (dd, J = 15.9, 6.2 Hz, 1H), 3.44 – 3.39 (m, 1H), 3.22 (dd, J = 14.0, 8.0 Hz, 1H), and 
2.86 – 2.83 (m, 1H); 13C NMR (101 MHz, CDCl3): δ 137.20, 132.20, 128.71, 128.38, 128.03, 
126.27, 74.64, 73.34, 64.26, 61.87, and 57.41; IR (neat) 3556, 3105 (br), 3006, 2987, 2965, 1464, 
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(±)- (2S, 3R)-N-phenylmethoxy-2-azidomethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (76) 
 
 To a solution of 75 (4.94 mmol, 1.46 g) in DMSO (36 mL) was added sodium azide (28.8 
mmol, 1.88 g) all at once and the resulting solution was stirred at 90 °C until TLC analysis 
indicated complete consumption of the starting material (3 days). The reaction was quenched with 
water and the aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined organic 
extracts were washed with water, brine, and then dried over anhydrous sodium sulfate. After 
concentration under reduced pressure the crude residue was purified by column chromatography 
to afford 1.05 g of azide 76 (4.03 mmol, 82% yield) as a pale yellow oil. Rf = 0.4 (2:1 
hexanes:ethyl acetate); 1H NMR (400 MHz, CD3OD): δ 7.35 – 7.25 (m, 5H), 5.69 (t, J = 6.2 Hz, 
1H), 5.62 (ddd, J = 9.9, 4.0, 1.9 Hz, 1H), 4.80 (s, 1H), 4.74 (d, J = 1.7 Hz, 2H), 4.21 (d, J = 9.6 
Hz, 1H), 3.73 (d, J = 13.2 Hz, 1H), 3.65 – 3.57 (m, 2H), 3.31 (d, J = 15.3 Hz, 1H), and 2.72 (br s, 
1H); 13C NMR (101 MHz, CD3OD): δ 137.16, 128.82, 128.56, 128.01, 127.67, 123.94, 74.72, 
67.76, 65.05, 53.49, and 48.63; IR (neat) 3361 (br), 3087, 3063, 3031, 2919, 2872, 2822, 2094 
(st), 1493, 1451, 1363, 1280, 1260, 1207, 1080, 1018, 909, 868, 844, and 741 cm-1; HR-ESIMS 
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(±)- (2S, 3R)-N-phenylmethoxy-2-((4-methoxybenzene)amido)-3-hydroxypiperidine (78) 
 
 To a solution of 76 (2.0 mmol, 520 mg) in methanol (10 mL) was added palladium 
hydroxide on activated carbon (10 mol%, 5 mg) and the resulting black suspension was placed 
under an atmosphere of hydrogen (atmospheric pressure) and stirred at room temperature until 
TLC analysis indicated complete consumption of the starting material and appearance of a polar 
spot (4 hours). The reaction mixture was filtered over celite and the pad washed with methanol (3 
x 10 mL) and then concentrated under reduced pressure. The resulting residue was then taken up 
in dichloromethane (20 mL) and triethylamine (2.4 mmol, 0.3 mL) and cooled to 0 °C. 4-
methoxybenzoyl chloride was added dropwise and the reaction mixture was allowed to reach 
room temperature. When TLC analysis indicated complete consumption of the polar spot the 
solvent was removed under reduced pressure and the crude residue was purified by column 
chromatography (3:1 to 2:1 hexanes:ethyl acetate) to give 580 mg of 78 (1.6 mmol, 78% yield) as 
a yellow oil. Rf = 0.2 (1:1 hexanes:ethyl acetate); 1H NMR (400 MHz, CDCl3): δ 7.54 – 7.27 (m, 
6H), 6.88 – 6.76 (m, 2H), 5.46 (s, 1H), 5.01 – 4.96 (m, 1H), 4.69 (dd, J = 12.1, 4.2 Hz, 1H), 4.57 
(dd, J = 12.1, 4.1 Hz, 1H), 4.09 – 4.03 (m, 1H), 3.94 (ddt, J = 11.9, 7.5, 4.1 Hz, 1H), 3.79 (s, 3H), 
3.48 – 3.40 (m, 2H), 3.13 (br s, 1H), 2.44 – 2.26 (m, 2H), 1.98 (d, J = 4.8 Hz, 1H), 1.91 – 1.84 
(m, 1H), 1.70 (d, J = 9.2 Hz, 1H), 1.42 – 1.24 (m, 2H), and 1.20 (td, J = 7.1, 3.0 Hz, 1H); 13C 
NMR (101 MHz, CDCl3): δ 162.29, 138.22, 129.51, 129.04, 128.71, 128.31, 125.76, 122.62, 
113.44, 73.19, 66.80, 60.31, 55.37, 37.01, 31.10, 20.98, and 14.17; IR (neat) 3420, (br), 3343 
(br), 3028, 2939, 2860, 2833, 1631, 1605, 1534, 1496, 1457, 1443, 1298, 1251, 1177, 1098, 1030, 
912, 844, and 768 cm-1; HR-ESIMS requires for C21H27N2O4 (M+H)+ 371.1965, found 371.1964. 
N
HO
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(±)-(2S, 3R)-N-phenylmethoxy-2-((4-methoxybenzene)amido)-3-hydroxybenzoic acid 
piperidine (79) 
 
 To a solution of 78 (0.7 mmol, 250 mg) in pyridine was added benzoic anhydride (1.4 
mmol, 318 mg) and DMAP (20 mol%, 30 mg) and the resulting solution was stirred at room 
temperature overnight. Upon completion, the reaction was quenched with saturated sodium 
bicarbonate solution and extracted with ether (3 x 15 mL). The combined organic extracts were 
washed with water, brine, dried over anhydrous sodium sulfate, and concentrated under reduced 
pressure to give 273 mg of 79 (0.6 mmol, 82% yield) as a pale yellow oil that was used without 
further purification. Rf = 0.4 (2:1 hexanes:ethyl acetate); 1H NMR (400 MHz, CDCl3): δ 8.62 – 
8.59 (m, 1H), 8.06 – 8.01 (m, 3H), 7.55 – 7.51 (m, 3H), 7.44 – 7.39 (m, 3H), 7.30 – 7.25 (m, 5H), 
6.83 (d, J = 8.8 Hz, 2H), 4.72 (d, J = 7.5 Hz, 2H), 3.82 (s, 3H), 3.50 (d, J = 11.7 Hz, 1H), 2.63 (s, 
1H), 2.23 (d, 11.3 Hz, 1H), 1.79 – 1.70 (m, 2H), and 1.50 – 1.40 (m, 1H); 13C NMR (101 MHz, 
CDCl3): δ 166.58, 161.86, 149.78, 135.92, 133.05, 132.85, 129.72, 129.53, 128.68, 128.55, 
128.38, 128.31, 123.69, 113.48, 106.48, 55.33, 39.14, 38.13, and 29.65; IR (neat) 3063, 3031, 
3007, 2945, 2860, 2836, 1717 (st), 1658, 1605, 1531, 1493, 1452, 1313, 1295, 1251, 1177, 1107, 
1065, 1027, 989, 936, 912, 841, and 762 cm-1; HR-ESIMS requires for C28H30N2O5 (M+H)+ 
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(±)-(6R, 7R, 5R, 1S)-4,4-dimethyl-6,7-dihydroxy-8-oxo-2-(phenylmethoxy)-2-
azabicyclo[3.2.1]oct-3-one (85) 
 
 To a solution of 63 (3.86 mmol, 1.00g) in acetonitrile, water, and acetone (23 mL total, 
1:1:1 v/v) at room temperature was added NMO (7.72 mmol, 0.8 mL, 50 wt% in H2O) followed 
by an OsO4 solution (5.02 mL of 1 wt% in H2O). The reaction mixture was stirred overnight at 
that same temperature followed by filtering of the solution over a pad of celite. The pad was 
washed with ethyl acetate (3 x 15 mL) and the solvent removed under reduced pressure. The 
crude product was recrystallized from DCM:hexanes to give the pure diol 975 mg of 85 as light 
green crystals (3.32 mmol, 86% yield). Rf = 0.2 (1:1 hexanes:ethyl acetate); M.P. = 116.4 – 117.9 
°C; 1H NMR (500 MHz, CDCl3): δ 7.45 – 7.34 (m, 5H), 4.96 (d, J = 10.6 Hz, 1H), 4.84 (d, J = 
10.7 Hz, 1H), 4.82 (d, J = 1.0 Hz, 1H), 4.36 (dd, J = 5.2, 1.0 Hz, 1H), 4.22 (q, J = 6.2 Hz, 2H), 
3.48 (s, 2H), 2.72 (dt, J = 9.4, 5.4 Hz, 1H), 1.27 (s, 3H), and 1.19 (s, 3H); 13C NMR (126 MHz, 
CDCl3): δ 169.19, 134.60, 129.67, 129.11, 128.66, 93.94, 85.53, 77.58, 74.02, 69.75, 47.49, 
18.70, and 12.26; IR (neat) 3272 (br), 3031, 2992, 2969, 2928, 2869, 1690, 1658 (st), 1454, 1401, 
1384, 1357, 1333, 1242, 1216, 1107, 1095, 1051, 1036 (st), 1009, 989, 933, 824, 765, 741, and 
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(±)-(6R, 7R, 5R, 1S)-4,4-dimethyl-6,7-dimethyldioxolan-8-oxo-2-(phenylmethoxy)-2-
azabicyclo[3.2.1]oct-3-one (86) 
 
 To a solution of 85 (8.3 mmol, 2.4 g) in dichloromethane (35.0 mL) and 2,2-
dimethoxypropane (12.5 mmol, 1.5 mL) was added camphor-10-sulfonic acid (2 mol%, 39 mg) 
and the resulting solution was stirred at room temperature for 3 hours. The reaction mixture was 
quenched with saturated sodium bicarbonate and the aqueous layer was extracted with 
dichloromethane (3 x 25 mL). The combined organic layers were washed with brine, dried over 
anhydrous sodium sulfate, and concentrated under reduced pressure. The crude residue was 
purified by column chromatography (3:1 hexanes:ethyl acetate) to afford 1.86 g of 86 as a white 
crystalline solid (5.6 mmol, 96% yield). Rf = 0.5 (3:1 hexanes:ethyl acetate); M.P. = 101.3 °C; 1H 
NMR (500 MHz, CDCl3): δ 7.43 – 7.35 (m, 5H), 4.97 (d, J = 10.7 Hz, 1H), 4.87 (d, J = 10.7 Hz, 
1H), 4.79 (s, 1H), 4.74 (d, J = 5.6 Hz, 1H), 4.69 (d, J = 5.6 Hz, 1H), 3.98 (s, 1H), 1.44 (s, 3H), 
1.41 (s, 3H), 1.27 (s, 3H), and 1.19 (s, 3H); 13C NMR (121 MHz, CDCl3): δ 172.67, 134.81, 
129.82, 129.09, 128.64, 112.82, 92.22, 89.23, 82.41, 79.05, 43.87, 27.37, 25.96, 24.86, and 19.54; 
IR (neat) 3034, 2984, 2931, 2869, 1672 (st), 1490, 1472, 1457, 1395, 1378, 1254, 1230, 1207, 
1163, 1065 (st), 1045, 1009, 962, 892, 818, and 744 cm-1; HR-ESIMS requires for C18H23NO5 
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(±)-(6R, 7R, 5R, 1S)-4,4-dimethyl-6,7-dimethyldioxolan-8-oxo-2-azabicyclo[3.2.1]oct-3-one 
(87) 
 
 To a stirred solution of 86 (3.6 mmol, 1.2 g) degassed under nitrogen in ACN:H2O (35.0 
mL, 9:1 v/v) was added Mo(CO)6 (4.32 mmol, 1.14 g) all at once and the resulting solution was 
degassed again. The reaction mixture was refluxed vigorously overnight followed by filtering 
through a pad of celite. The pad was washed with 3 x 20 mL portions of ethyl acetate and the 
filtrate was concentrated under reduced pressure. The crude residue was purified by column 
chromatography (1:1 hexanes:ethyl acetate) to afford 668 mg of the pure amide 87 as a white 
solid (2.94 mmol, 82% yield). Rf = 0.1 (1:1 hexanes:ethyl acetate); M.P. = 194.8 °C; 1H NMR 
(500 MHz, CDCl3): δ 6.87 (br s, 1H), 5.04 (d, J = 3.3 Hz, 1H), 4.87 (d, J = 5.6 Hz, 1H), 4.65 (d, J 
= 5.6 Hz, 1H), 4.04 (s, 1H), 1.48 (s, 3H), 1.40 (s, 3H), 1.32 (s, 3H), and 1.19 (s, 3H); 13C NMR 
(121 MHz, CDCl3) δ 174.70, 112.87, 88.67, 85.83, 85.51, 79.12, 42.27, 27.51, 26.10, 25.04, and 
19.86; IR (neat) 3181 (br), 2989, 2975, 2945, 2877, 1672 (st), 1634, 1484, 1469, 1451, 1366, 
1263, 1224, 1207, 1189, 1166, 1092, 1059 (st), 1042, 1015, 971, 933, 871, 836, 818, and 785 cm-
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(±)-(6R, 7R, 5R, 1S)-4,4-dimethyl-6,7-dimethyldioxolan-2,3,4,7-tetrahydro-1H-azepine (88) 
 
 To a stirred solution of 87 (0.44 mmol, 100 mg) in dry THF (5 mL) at 0 °C was added a 
solution of LAH (1.76 mmol, 0.88 mL) in dry THF dropwise. Upon addition the ice bath was 
removed and the reaction mixture was refluxed overnight. Upon completion the reaction mixture 
was quenched with water and sodium hydroxide at 0 °C followed by filtration of the inorganic 
salts. The filtrate was dried over anhydrous magnesium sulfate, filtered, and concentrated under 
reduced pressure. The crude residue was purified by column chromatography 
(EtOAc:MeOH:Et3N 2% MeOH, 1% Et3N) to afford 78.4 mg of the pure azepane 88 as an 
opaque solid (0.36 mmol, 83% yield). X-ray quality crystals were grown by slow evaporation of a 
dichloromethane/hexanes solution of 88. Rf = 0.3 (EtOAc:MeOH:Et3N 2% MeOH, 1% Et3N); 
M.P. = 126.9 °C; 1H NMR (500 MHz, CDCl3): δ 4.36 (dd, J = 7.8, 2.9 Hz, 1H), 4.30 (ddd, J = 
10.5, 7.8, 5.5 Hz, 1H), 3.64 (d, J = 2.7 Hz, 1H), 3.10 (d, J = 10.0 Hz, 1H), 3.01 (dd, J = 12.8, 10.5 
Hz, 1H), 2.34 (d, J = 13.0 Hz, 1H), 1.49 (s, 3H), 1.36 (s, 3H), 1.01 (s, 3H), and 0.98 (s, 3H); 13C 
NMR (121 MHz, CDCl3): δ 107.96, 78.07, 77.52, 56.11, 49.85, 37.47, 27.43, 26.61, 23.66, and 
22.23; IR (neat) 3087 (br), 2984, 2954, 2916, 2866, 2845, 1466, 1451, 1378, 1354, 1266, 1213, 
1168, 1145, 1104, 1060 (st), 1033, 1009, 978, 877, 827, and 809 cm-1; HR-ESIMS requires for 
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(±)-(4R, 5R, 6R)-4,5,6-trihydroxy-3,3-dimethylazepane (89) 
 
 To a solution of trifluoroacetic acid (10 mL) and water (5 mL) was added 88 (0.23 mmol, 
50 mg) and the resulting solution was stirred at room temperature for 3 hours. After removal of 
the volatiles under reduced pressure, the crude residue was ran through a short plug of silica gel 
(EtOAc:MeOH:Et3N 20% MeOH, 1% Et3N, eluent) and concentrated to give 35 mg of 89 as a 
colourless oil (0.2 mmol, 87% yield). Rf = 0.3 (EtOAc:MeOH:Et3N 20% MeOH, 1% Et3N); 1H 
NMR (400 MHz, CD3OD): δ 4.15 – 4.07 (m, 1H), 4.00 (t, J = 2.2 Hz, 1H), 3.51 (d, J = 2.0 Hz, 
1H), 3.28 (dtd, J = 3.4, 2.0, 1.2 Hz, 1H), 3.25 (d, J = 4.6 Hz, 1H), 3.16 (d, J = 0.7 Hz, 1H), 2.87 
(d, J = 13.8 Hz, 1H), 1.12 (s, 3H), and 1.07 (s, 3H); 13C NMR (101 MHz, CD3OD): δ 78.92, 
74.95, 68.86, 53.33, 46.39, 36.50, 25.12, and 23.20; IR (neat) 3352 (br), 3090, 2975, 2913, 2880, 
1666, 1472, 1425, 1198, 1177, 1089, 1062, 1012, 936, 836, 800, and 718 cm-1; HR-ESIMS 
requires for C8H17NO3 (M+H)+ 176.1281, found 176.1282. 
 
(±)-(1R, 5S)-4,4-dimethyl-8-oxo-2-azabicyclo[3.2.1]oct-6-en-3-one (90) 
 
 To a stirred solution of 63 (3.02 mmol, 783.5 mg) degassed under nitrogen in ACN:H2O 
(20.1 mL, 9:1 v/v) was added Mo(CO)6 (3.62 mmol, 957 mg) all at once and the resulting 
solution was degassed again. The reaction mixture was refluxed vigorously overnight followed by 
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the filtrate was concentrated under reduced pressure. The crude residue was purified by column 
chromatography (1:1 hexanes:ethyl acetate) to afford 420 mg of the pure amide 90 as a white 
solid (2.74 mmol, 91% yield). Rf = 0.1 (1:1 hexanes:ethyl acetate); M.P. = 130.5 – 133.5 °C; 1H 
NMR (500 MHz, CDCl3): δ 7.65 (s, 1H), 6.55 (dd, J = 6.0, 1.4 Hz, 1H), 6.40 (dd, J = 5.9, 1.9 Hz, 
1H), 5.44 (dd, J = 3.0, 1.4 Hz, 1H), 4.50 (d, J = 1.9 Hz, 1H), 1.46 (s, 3H), and 1.04 (s, 3H); 13C 
NMR (101 MHz, CDCl3): δ 176.17, 136.80, 132.08, 86.26, 84.65, 47.21, 27.29, and 19.79; IR 
(neat) 3163 (br), 3053, 2998, 2961, 2933, 2903, 2872, 1647 (st), 1473, 1460, 1393, 1356, 1326, 
1262, 1246, 1179, 1048, 944, 892, 852, and 742 cm-1; HR-ESIMS requires for C8H11NO2 




 To a solution of 90 (0.71 mmol, 100 mg) in dry THF (3 mL) at 0 °C was added a solution 
of LAH (2.84 mmol, 1.42 mL) in dry THF dropwise. The ice bath was removed and the reaction 
mixture was refluxed overnight under a nitrogen atmosphere. Upon completion, the reaction was 
quenched with water and 10% NaOH. The inorganic salts were filtered and the filtrate was dried 
over anhydrous sodium sulfate followed by concentration under reduced pressure. The crude 
residue was purified by flash chromatography (EtOAc:MeOH:Et3N 10% MeOH, 1% Et3N) to 
afford 82 mg of azepine 91 as a light brown oil (0.6 mmol, 82% yield). (Rf = 0.3 (ethyl acetate, 
10 % methanol, 1% triethylamine); 1H NMR (400 MHz, CDCl3): δ 5.99 – 5.92 (m, 1H), 5.65 
(dtd, J = 11.5, 3.9, 0.8 Hz, 1H), 3.74 (d, J = 6.3 Hz, 1H), 3.59 – 3.52 (m, 1H), 3.42 (s, 2H), 3.36 – 
3.28 (m, 1H), 2.91 (dd, J = 13.6, 1.0 Hz, 1H), 2.58 (d, J = 13.6 Hz, 1H), 1.09 (s, 3H), and 0.84 (s, 
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25.16; IR (neat) 3308 (br), 3022, 2948, 2901, 2866, 1646, 1622, 1454, 1407, 1384, 1360, 1307, 
1278, 1216, 1121, 1042 (st), 1021, 956, and 871 cm-1; HR-ESIMS requires for C8H15NO (M+H)+ 
142.1226, found 142.1224. 
 
(±)-(4R, 5R, 6R)-4,5,6-trihydroxy-3,3-dimethylazepane (89) 
 
 Osmium tetroxide (0.5 mL of a 1 wt% solution in water) and NMO (0.71 mmol, 0.1 mL) 
were added to a stirred solution of 91 (0.35 mmol, 50 mg) in acetonitrile, water, and acetone (2.1 
mL, 1:1:1 v/v) and the resulting reaction mixture was stirred under nitrogen overnight. The 
reaction mixture was filtered over celite and the pad washed with methanol (3 x 10 mL) followed 
by concentration under reduced pressure. The residue was passed through a plug of silica gel 
(EtOAc:MeOH:Et3N 20% MeOH, 1% Et3N, eluent) followed by concentration to give 49.5 mg of 
89 as a colourless oil (0.28 mmol, 81% yield). Rf = 0.3 (EtOAc:MeOH:Et3N 20% MeOH, 1% 
Et3N); 1H NMR (400 MHz, CD3OD): δ 4.15 – 4.07 (m, 1H), 4.00 (t, J = 2.2 Hz, 1H), 3.51 (d, J = 
2.0 Hz, 1H), 3.28 (dtd, J = 3.4, 2.0, 1.2 Hz, 1H), 3.25 (d, J = 4.6 Hz, 1H), 3.16 (d, J = 0.7 Hz, 
1H), 2.87 (d, J = 13.8 Hz, 1H), 1.12 (s, 3H), and 1.07 (s, 3H); 13C NMR (101 MHz, CD3OD): δ 
78.92, 74.95, 68.86, 53.33, 46.39, 36.50, 25.12, and 23.20; IR (neat) 3352 (br), 3090, 2975, 2913, 
2880, 1666, 1472, 1425, 1198, 1177, 1089, 1062, 1012, 936, 836, 800, and 718 cm-1; HR-ESIMS 
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(±)-(4R, 5R, 1S)-4-chloro-8-oxo-2-(hydroxy)-2-azabicyclo[3.2.1]oct-3-one (92) 
 
 To a solution of 66f (4.22 mmol, 1.12 g) in ethyl acetate (21.1 mL) was added palladium 
on activated carbon (10% by mass, 0.11 g) and the resulting suspension was evacuated under 
vacuum and hydrogenated at atmospheric pressure for 30 minutes. The reaction mixture was 
filtered over a pad of celite and the pad washed with 3 x 10 mL portions of ethyl acetate to give 
675 mg of hydroxamic acid 92 (3.8 mmol, 90% yield) as an orange solid that was used without 
any further purification. Rf = 0.1 (1:1 hexanes:ethyl acetate); M.P. = Decom. 1H NMR (500 MHz, 
CDCl3): δ 9.74 (br s, 1H), 6.10 (s, 1H), 5.41 (d, J = 4.1 Hz, 1H), 4.77 (d, J = 2.7 Hz, 2H), 2.55 
(ddd, J = 12.4, 9.4, 2.7 Hz, 1H), 2.33 – 2.24 (m, 1H), 2.15 (dddd, J = 13.2, 11.1, 6.2, 2.7 Hz, 1H), 
and 2.05 (tdd, J = 11.7, 6.7, 4.0 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ 162.66, 91.25, 78.77, 
64.11, 56.28, 32.13, and 22.19; IR (neat) 3072 (br), 3031, 2998, 2951, 2842, 1646 (st), 1501, 
1460, 1437, 1354, 1289, 1245, 1204, 1142, 1068, 1042, 947, 921, 838, 782, 724, and 656 cm-1; 
HR-ESIMS requires for C6H8ClNO3 (M+Na)+ 200.0085, found 200.0087. 
 
(±)-(4S, 6R, 7R, 5R, 1S) 4-chloro-6,7-dihydroxy-8-oxo-2-(phenylmethoxy)-2-
azabicyclo[3.2.1]oct-3-one (93) 
 
 To a solution of 66f endo (1.0 mmol, 275.3 mg) in acetonitrile, water, and acetone (6 mL 
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followed by an OsO4 solution (1.3 mL of 1 wt% in H2O). The reaction mixture was stirred 
overnight at that same temperature followed by filtering of the solution over a pad of celite. The 
pad was washed with ethyl acetate (3 x 10 mL) and the solvent removed under reduced pressure. 
The crude product was recrystallized from dichloromethane:hexanes to give 255 mg of the pure 
diol 93 as a colourless oil (0.85 mmol, 85% yield). Rf = 0.3 (1:1 hexanes:ethyl acetate); 1H NMR 
(500 MHz, CDCl3): δ 7.38 (tdd, J = 7.0, 3.3, 1.4 Hz, 5H), 4.98 (dd, J = 10.6, 1.2 Hz, 1H), 4.90 – 
4.85 (m, 1H), 4.59 (dd, J = 5.4, 1.3 Hz, 1H), 4.55 (t, J = 6.1 Hz, 1H), 4.47 (dd, J = 5.4, 1.2 Hz, 
1H), 4.24 (td, J = 6.0, 1.4 Hz, 1H), 4.10 (qd, J = 7.2, 1.5 Hz, 1H), and 3.72 (ddd, J = 15.5, 10.1, 
5.7 Hz, 1H); 13C NMR (121 MHz, CDCl3): δ 161.88, 133.65, 129.97, 129.50, 128.80, 93.72, 
87.90, 73.17, 71.20, and 55.10; IR (neat) 3408 (br), 3378, 3057, 3001, 2981, 2954, 2922, 1702 
(st), 1440, 1369, 1339, 1295, 1233, 1210, 1101, 1001, 945, 906, 838, 753, 715, and 659 cm-1; 
HR-ESIMS requires for C13H14ClNO5 (M+Na)+ 322.0453, found 322.0452. 
 
(±)-(4S, 6R, 7R, 5R, 1S) 4-chloro-6,7-dimethyldioxolan-8-oxo-2-(phenylmethoxy)-2-
azabicyclo[3.2.1]oct-3-one (94) 
 
 To a solution of 93 (2.12 mmol, 740 mg) in dichloromethane (10.0 mL) and 2,2-
dimethoxypropane (4.24 mmol, 0.4 mL) was added camphor-10-sulfonic acid (2 mol%, 10 mg) 
and the resulting solution was stirred at room temperature for 3 hours. The reaction mixture was 
quenched with saturated sodium bicarbonate and the aqueous layer was extracted with 
dichloromethane (3 x 10 mL). The combined organic layers were washed with brine, dried over 
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purified by column chromatography (3:1 hexanes:ethyl acetate) to afford 670 mg of 94 as a white 
crystalline solid (0.82 mmol, 95% yield). Rf = 0.5 (3:1 hexanes:ethyl acetate); M.P. = 112.3 – 
114.1 °C; 1H NMR (500 MHz, CDCl3): δ 7.45 – 7..37 (m, 5H), 5.03 (d, J = 10.8 Hz, 1H), 4.96 (d, 
J = 5.7 Hz, 1H), 4.92 (d, J = 10.8 Hz, 1H), 4.90 (t, J = 0.5 Hz, 1H), 4.70 (d, J = 5.7 Hz, 1H), 4.65 
(d, J = 5.6 Hz, 1H), 4.58 (dd, J = 5.6, 0.6 Hz, 1H), 1.45 (d, J = 0.9 Hz, 3H), 1.29 (d, J = 0.9 Hz, 
3H); 13C NMR (101 MHz, CDCl3): δ 163.15, 134.45, 130.37, 129.39, 128.08, 113.31, 93.38, 
83.21, 81.75, 79.34, 53.83, 52.60, 26.25, and 25.44; IR (neat) 3031, 2987, 2945, 2895, 1699 (st), 
1496, 1463, 1454, 1381, 1333, 1278, 1242, 1204, 1157, 1092 (st), 1071, 1048, 1012, 986, 965, 
945, 909, 862, 853, 812, and 700 cm-1; HR-ESIMS requires for C16H18ClNO5 (M+H)+ 340.0946, 
found 340.0949. 
 
(±)-(4S, 6R, 7R, 5R, 1S) 4-ethyl-6,7-dihydroxy-8-oxo-2-(phenylmethoxy)-2-
azabicyclo[3.2.1]oct-3-one (95) 
 
 To a solution of 66c (3.86 mmol, 1.00g) in acetonitrile, water, and acetone (23 mL total, 
1:1:1 v/v) at room temperature was added NMO (7.72 mmol, 0.8 mL, 50 wt% in H2O) followed 
by an OsO4 solution (5.02 mL of 1 wt% in H2O). The reaction mixture was stirred overnight at 
that same temperature followed by filtering of the solution over a pad of celite. The pad was 
washed with ethyl acetate (3 x 15 mL) and the solvent removed under reduced pressure. The 
crude product was recrystallized from DCM:hexanes to give 975 mg of the pure diol 95 as light 
green crystals (3.32 mmol, 86% yield). Rf = 0.2 (1:1 hexanes:ethyl acetate); M.P. = 116.4 – 117.9 
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10.7 Hz, 1H), 4.82 (d, J = 1.0 Hz, 1H), 4.36 (dd, J = 5.2, 1.0 Hz, 1H), 4.22 (q, J = 6.2 Hz, 2H), 
3.48 (s, 2H), 2.72 (dt, J = 9.4, 5.4 Hz, 1H), 2.06 (dqd, J = 15.3, 7.7, 5.4 Hz, 1H), 1.37 – 1.25 (m, 
1H), and 1.04 (t, 3H); 13C NMR (126 MHz, CDCl3): δ 169.19, 134.60, 129.67, 129.11, 128.66, 
93.94, 85.53, 77.58, 74.02, 69.75, 47.49, 18.70, and 12.26; IR (neat) 3272 (br), 3031, 2992, 2969, 
2928, 2869, 1690, 1658 (st), 1454, 1401, 1384, 1357, 1333, 1242, 1216, 1107, 1095, 1051, 1036 
(st), 1009, 989, 933, 824, 765, 741, and 700 cm-1; HR-ESIMS requires for C15H19NO5 (M+Na)+ 
316.1155, found 316.1160. 
 
(±)-(4S, 6R, 7R, 5R, 1S) 4-ethyl-6,7-dimethyldioxolan-8-oxo-2-(phenylmethoxy)-2-
azabicyclo[3.2.1]oct-3-one (96) 
 
 To a solution of 95 (0.871 mmol, 255.4 mg) in dichloromethane (2.0 mL) and 2,2-
dimethoxypropane (1.31 mmol, 0.16 mL) was added camphor-10-sulfonic acid (2 mol%, 4 mg) 
and the resulting solution was stirred at room temperature for 3 hours. The reaction mixture was 
quenched with saturated sodium bicarbonate and the aqueous layer was extracted with 
dichloromethane (3 x 5 mL). The combined organic layers were washed with brine, dried over 
anhydrous sodium sulfate, and concentrated under reduced pressure. The crude residue was 
purified by column chromatography (3:1 hexanes:ethyl acetate) to afford 275 mg of 96 as a white 
crystalline solid (0.82 mmol, 95% yield). Rf = 0.5 (3:1 hexanes:ethyl acetate); M.P. = 111.3 – 
114.1 °C; 1H NMR (500 MHz, CDCl3): δ 7.49 – 7.33 (m, 5H), 5.00 (dd, J = 10.6, 0.6 Hz, 1H), 
4.87 (d, J = 5.6 Hz, 1H), 4.85 (s, 1H), 4.71 (d, J = 5.7 Hz, 1H), 4.63 (d, J = 5.7 Hz, 1H), 4.45 (d, J 
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15.1, 7.1, 2.1 Hz, 1H), 1.27 (s, 3H), and 1.07 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3): δ 
169.43, 134.91, 129.60, 128.97, 128.62, 112.76, 92.05, 82.96, 78.56, 47.02, 25.87, 24.72, 18.70, 
and 12.30; IR (neat) 2995, 2981, 2966, 2936, 2872, 1687 (st), 1460, 1448, 1378, 1348, 1333, 
1269, 1233, 1207, 1157, 1080 (st), 1051, 1018, 986, 974, 900, 862, 812, 750, and 691 cm-1; HR-
ESIMS requires for C18H23NO5 (M+H)+ 334.1649, found 334.1659. 
 
(±)-(4S, 3R, 6R, 7R, 5R, 1S) 4-ethyl-3-hydroxy-6,7-dimethyldioxolan-8-oxo-2-
(phenylmethoxy)-2-azabicyclo[3.2.1]octane (97) 
 
 To a solution of LAH (3.0 mmol, 114 mg) in dry THF under a nitrogen atmosphere at 0 
°C was added 96 dropwise over a period of 10 minutes. The reaction mixture was then refluxed 
overnight followed by cooling to 0 °C. The reaction was quenched with water and 10% sodium 
hydroxide, filtered, and dried over anhydrous Na2SO4. The solvent was removed under reduced 
pressure and the crude residue was recrystallized from hexanes to give 97 as a white solid (1.2 
mmol, 402 mg, 80% yield). X-ray quality crystals were grown by slow evaporation of a 
dichloromethane/hexanes solution of 93. Rf = 0.4 (2:1 hexanes:ethyl acetate); M.P. = 64.6 – 66.4 
°C; 1H NMR (400 MHz, CDCl3): δ 7.40 – 7.30 (m, 5H), 4.86 (s, 1H), 4.81 (s, 2H), 4.51 (d, J = 
5.7 Hz, 1H), 4.25 (d, J = 3.7 Hz, 1H), 3.73 (dd, J = 9.4, 7.6 Hz, 1H), 1.80 – 1.70 (m, 2H), 1.48 (s, 
3H), 1.32 (s, 3H), and 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3): δ 136.85, 129.02, 
128.54, 128.34, 111.78, 82.19, 81.57, 78.42, 75.56, 42.22, 25.95, 24.65, 20.46, 19.76, 11.93, and 
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980, 815, 765, and 729 cm-1; HR-ESIMS requires for C18H25NO5 (M+H)+ 336.1805, found 
336.2492. 
 
(±)-(3S, 4R, 5R, 6R)-N-phenylmethoxy-3-chloro-4-hydroxy-5-isopropyloxy-6-hydroxy-
azepane (98) 
 
 To an oven dried 100 mL Schlenk flask equipped with a magnetic stir bar was added dry 
THF (25 mL) under an atmosphere of nitrogen. The flask was placed in an ice bath and aluminum 
chloride (5.3 mmol, 704 mg) was added in portions over a period of 10 minutes. Upon complete 
dissolution of the aluminum chloride, a solution of lithium aluminum hydride in dry THF (7.9 
mmol, 4.0 mL) was added dropwise at that same temperature over a period of 15 minutes and the 
resulting solution was stirred at 0 °C for 20 minutes. The acetal-protected diol 90 (2.6 mmol, 895 
mg) was then added in THF (10 mL) dropwise over a period of 20 minutes and the reaction 
mixture was refluxed under nitrogen for 1.5 hours. The reaction flask was cooled to 0 °C and 
quenched with water followed by 10% NaOH. The aluminum salts were filtered off and the 
filtrate was dried over Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by column chromatography (3:1 – 2:1 Hex:EtOAc) to afford 94 as a white crystalline 
solid (2.2 mmol, 730 mg, 84% yield). Rf = 0.2 (2:1 hexanes:ethyl acetate); M.P. 70.4 – 75.8 °C; 
1H NMR (500 MHz, CDCl3): δ 7.39 – 7.29 (m, 5H), 4.69 (d, J = 2.8 Hz, 2H), 4.15 (ddd, J = 7.2, 
5.3, 4.2 Hz, 1H), 4.08 – 4.05 (m, 1H), 3.89 (td, J = 6.8, 2.1 Hz, 1H), 3.64 (ddd, J = 8.0, 5.9, 2.2 
Hz, 1H), 3.61 (d, J = 5.5 Hz, 1H), 3.60 – 3.57 (m, 1H), 3.39 (dd, J = 15.1, 5.9 Hz, 1H), 3.19 (dd, 
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9.8, 6.1 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ 137.22, 128.99, 128.35, 128.04, 77.54, 75.10, 
74.61, 73.13, 71.07, 63.09, 61.58, 59.63, 22.69, and 22.27; IR (neat) 3305 (br), 3087, 3060, 2972, 
2925, 2889, 2845, 1496, 1454, 1366, 1322, 1269, 1222, 1157, 1121, 1080, 1018 (st), 968, 921, 
862, 735, and 694 cm-1; HR-ESIMS requires for C16H24ClNO4 (M+Na)+ 352.1286, found 
352.1256. 
 
(±)-(2S, 3R)-N-phenylmethoxy-2-acetoxymethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (100) 
 
 To a stirred solution of 75 (1.0 mmol, 250 mg,) in DMF (12 mL) was added AgOAc (2.0 
mmol, 334 mg,) all at once and the resulting suspension was heated in a sealed flask at 90 °C for 
72 hours. The crude reaction mixture was filtered through a pad of celite and the pad was washed 
with ethyl acetate (2 x 15 mL) followed by methanol (15 mL). The filtrate was concentrated 
under reduced pressure at 65 °C to remove DMF and the crude residue was purified by column 
chromatography (33% to 50% hexanes:ethyl acetate) to afford 224 mg of 100 as a pale yellow oil 
(0.81 mmol, 60% yield). Rf = 0.33 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CD3OD): δ 
7.34 – 7.24 (m, 5H), 5.74 – 5.66 (m, 2H), 4.83 (s, 1H), 4.70 (d, J = 10.7 Hz, 1H), 4.65 (d, J = 10.6 
Hz, 1H), 4.48 (d, J = 12.7 Hz, 1H), 4.40 (dd, J = 11.5, 5.0 Hz, 1H), 4.24 (dd, J = 8.3, 3.6 Hz, 1H), 
3.66 (d, J = 15.8 Hz, 1H), 3.39 – 3.32 (m, 1H), 2.81 (s, 1H), and 2.05 (s, 3H); 13C NMR (101 
MHz, CD3OD): δ 171.54, 137.13, 128.78, 128.60, 127.90, 127.60, 123.97, 74.88, 66.99, 64.61, 
60.89, 53.67, and 19.49; IR (neat) 3405 (br), 3034, 2917, 2860, 1736, 1451, 1363, 1236, 1024, 
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Chapter 4: New Building Blocks for Iminosugars: A Concise Synthesis of Polyhydroxylated 
N-Alkoxypiperidines through an Aza-[4+3] Cycloaddition 
 
4.1 Introduction 
 Recently, iminosugars functionalized through a hydroxylamine N-O bond have been an 
attractive synthetic target due to the fact that the barrier to inversion at the nitrogen atom of 
trialkylhydroxylamines is higher than simple amines.1 However, at approximately 15 kcal/mol 
this barrier is not sufficient to prevent rapid inversion at room temperature.1 Ideally with this low 
barrier to inversion, it is anticipated that any iminosugar derivative possessing a hydroxylamine 
motif could sample the full extent of conformational space available at room temperature and 
adapt in order to effectively bind to enzymes specific for either axial or equatorially linked 
substrates.2 Therefore, we saw this void as a motive for developing a general and concise 
synthesis of N-alkoxy iminosugar analogs that had the potential for incorporating a wide variety 
of alkyl chains and functional groups at the N-O terminus. 
 
	  
Scheme 4.1.1. Facile ring contraction observed from Chapter 3. 
	  
 We recently found that α-chloroazepane 75 (Scheme 4.1.1) underwent facile ring 
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electron rich character of the nitrogen atom, a plausible mechanism would involve the ring 
contraction going through an aziridinium ion intermediate such as 99 and ultimately collapsing to 
the six-membered ring. It was this discovery that led us to believe that simple functional group 
manipulations could provide access to the iminosugar class of compounds in a way that was not 
only stereoselective and concise, but that also was scalable. Moreover, we envisioned that the 
stereochemical flexibility our methodology afforded would enable a diversity-oriented approach 
for the synthesis of a library of compounds for biological screening as well as structure activity 
relationship (SAR) studies. With the goal of developing new C-N bond forming reactions with 
broad applications in target directed syntheses, we envisioned an α-chlorocycloadduct formed 
from the cycloaddition of an aza-oxyallylic cation as a general means to easily and 
stereoselectively construct the cyclic core of polyhydroxylated N-alkoxypiperidines (Scheme 
4.1.2). Additionally, we thought that the rich functionality our method afforded could provide the 
necessary handles needed for functional group manipulations in order to elaborate these cores to 
the desired targets. We also envisioned that our synthesis could provide easy access to 
stereoisomers that are traditionally difficult to synthesize with current methodology. This chapter 
focuses on our report of a general strategy for the preparation of polyhydroxylated N-
alkoxypiperidines that is concise, scalable, diastereoselective, and highly versatile to allow for the 
construction of a library of derivatives for both biological activity and SAR studies. 
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4.2 A Concise and Diastereoselective Synthesis of Polyhydroxylated N-Alkoxypiperidines 
through an Aza-[4+3] Cycloaddition 
 Initial studies commenced with synthesizing dichloroamides 101 (Synthesized in Chapter 
2) and 104 from dichloroacetyl chloride and either O-benzylhydroxylamine or methoxy amine 
hydrochloride (Scheme 4.2.1). Cycloaddition of the amide substrates provided α-
chlorocycloadducts 102 and 103 (previously reported in Chapter 2), as well as 105 and 106 in 
good overall yield with a diastereoisomeric ratio of 2:1 endo:exo.3,4 It is worth mentioning that 
although the diastereoselectivity of these reactions was rather poor, our goal was to develop a 
methodology that could access a variety of stereoisomers, thus both diastereoisomers were 
considered useful and elaborated to the desired targets. Slow addition of the corresponding 
cycloadducts to a solution of aluminum hydride at 0 °C followed by refluxing for 90 minutes 
gave cleanly 3-chloroazepine products 107-108 and 111-112 in good yield and as single 
diastereoisomers (Scheme 4.2.2). The exceptionally high crystalline quality of azepine 108 
allowed for its analysis by single crystal X-ray diffraction, thus confirming its structure as well as 
Scheme 4.2.1. Synthesis of cycloadducts 102, 103, 105, and 106 from a  
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the relative trans stereochemical configuration of the 3-chloride and 4-hydroxyl group (Figure 
4.2.1). Silver acetate mediated ring contraction provided tetrahydropyridine products 109-110 and 
113-114 in fair yield and as single diastereoisomers. 
 
 
Scheme 4.2.2. Synthesis of 3-chloroazepines 107-108 and 111-112; subsequent ring contraction to give 
tetrahydropyridines 109-110 and 113-114. 
 
	  
Figure 4.2.1. Thermal ellipsoid plot of azepine 108 at 50% probability. Hydrogen atoms are represented as 
spheres of arbitrary radius. Gray = carbon, red = oxygen, blue = nitrogen, green = chlorine. 
	  
 To the best of our knowledge, this reaction represents the first example of an 
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position with a leaving group. A similar azepine ring contraction example was reported in the 
literature by Davies and co-workers, albeit their substrate was not pre-functionalized with an 
appended leaving group.5 In this respect, we have developed a new methodology for the rapid and 
stereoselective construction of tetrahydropyridine cores in only a few short synthetic steps from 
commercially available starting materials. Additionally, the resulting skeletons are richly 
functionalized and could be envisioned as versatile building blocks for the construction of other 
iminosugar derivatives or piperidine natural products of interest. Acetate hydrolysis using 
potassium carbonate in methanol6 produced diols 115-116 and 119-120 (Scheme 4.2.3) in high 
yields, with 119 being of particular interest due to its high crystallinity and potential for X-ray 
analysis. Indeed, slow evaporation of benzene from 119 afforded crystals of suitable quality for 
X-ray diffraction studies (Figure 4.2.2). 
 
	  
Scheme 4.2.3. Acetate hydrolysis products 115-116 and 119-120; Osmium tetroxide-mediated olefin 
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Figure 4.2.2. Thermal ellipsoid plot of tetrahydropyridine 119 at 50% probability. Hydrogen atoms are 
represented as spheres of arbitrary radius. Gray = carbon, red = oxygen, blue = nitrogen. 
	  
We found the observed stereochemistry of diol 119 intriguing, and led us to consider the 
following mechanistic hypothesis. The resulting stereochemistry suggests a double inversion-type 
mechanism, whereby a Lewis acid catalyzed abstraction of chloride by silver would lead to 
backside nucleophilic attack by ring nitrogen to form the aziridinium ion intermediate 123 
(Scheme 4.2.4). Subsequent nucleophilic attack by acetate onto the aziridinium ion 123 would 
provide tetrahydropyridine 113. With the desired diols in hand, the last step to complete the 
syntheses would involve utilization of the alkene to install the remaining alcohol groups. 
Dihydroxylation of the alkene using catalytic osmium tetroxide was	   found to be a simple and 
high-yielding method for installing the remaining hydroxyl groups. Exposure of the substrates 




















Scheme 4.2.4. Mechanistic proposal of aziridinium ion-mediated ring contraction of 111 to 113. 
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provided the final polyhydroxylated products 117-118 and 121-122 in	  good yields and as single 
diastereoisomers (Scheme 4.2.3). Upon analysis of 121 by single crystal X-ray diffraction, the 
oxidation was determined to occur selectively from the opposite face of the allylic carbinol group 
resulting in a trans-configuration relative to the C-3 alcohol group in all cases (Figure 4.2.3). 
These scaffolds represent 4 novel iminosugar derivatives with unique stereochemical 




Figure 4.2.3. Thermal ellipsoid plot of polyhydroxylated piperidine 121. Hydrogen atoms are represented 
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4.3 Experimental 
All reactions were carried out under an atmosphere of nitrogen in oven-dried glassware 
with magnetic stirring, unless otherwise specified. All reagents and solvents were purchased from 
Sigma-Aldrich Chemical Company and used without any further purification. TLC information 
was recorded on Silicycle glass 60 F254 plates and developed by staining with KMnO4 or ceric 
ammonium molybdate. Purification of reaction products was carried out by flash chromatography 
using Silicycle Siliaflash® P60 (230-400 mesh). 1H-NMR spectra were measured on Varian 400 
(400 MHz) or Varian 500 (500 MHz) spectrometers and are reported in ppm (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad; integration; coupling constant(s) in Hz 
using TMS as an internal standard (TMS at 0.00 ppm) in CDCl3, CD3CN, or CD3OD. 13C-NMR 
spectra were recorded on V400 or V500 spectrometers and reported in ppm using solvent as an 
internal standard (CDCl3 at 77.36 ppm), (CD3CN at 118.26 ppm) or (CD3OD at 49.86 ppm). 
Infrared (IR) spectra were recorded on a Nicolet 6700 FT-IR with a diamond ATR and data are 
reported as cm-1 (br = broad, st = strong). High-resolution mass spectra were obtained using an 
Agilent 6230 TOF LC/MS with an atmospheric pressure photo-ionization (APPI) or electrospray 
(ESI) source with purine and HP-0921 as internal calibrants. Single crystal X-ray diffraction was 
performed at 100 K on a Bruker SMART Apex II CCD instrument using graphite-
monochromated Mo Kα radiation. The crystals were covered in Paratone oil and mounted on glass 
fibers. Lorentz and polarization effects were corrected using SAINTSI and absorption corrections 
were applied using SADABS.S2 The structures were solved using direct methods using OLEX2.S3 
References 
S1 SAINT: Program for data reduction, Version 7.68A; Bruker AXS: Madison, WI, 2009. 
S2 G. M. Sheldrick. Acta Crystallogr., Sect. A.: Found. Crystallogr. 2008, 64, 112.  
S3 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard,  and H. Puschmann, J. Appl. 
Cryst. 2009, 42, 339. 
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(±)-2,2-dichloro-N-(methoxy)acetamide (104): 
 
 To a suspension of methoxyamine hydrochloride (27.1 mmol, 2.26 g) and triethylamine 
(54.2 mmol, 5.48) in CH2Cl2 (0.25 M) at 0 °C was added dropwise 2,2-dichloroacetyl chloride 
(27.1 mmol, 4.0 g,) dropwise. The reaction mixture was then warmed to room temperature and 
stirred until TLC analysis (3:1 hexanes:ethyl acetate) indicated complete consumption of the 
starting material (1 hour). The solvent was then removed under reduced pressure and the crude 
product was purified via flash column chromatography (2:1 hexanes:ethyl acetate) to provide 3.5 
g of the pure haloamide 104 as a white crystalline solid (3.5 g, 22.2 mmol, 82% yield). Rf = 0.3 
(2:1 hexanes: ethyl acetate); M.P. = 40.5 – 42.8 °C; 1H NMR (500 MHz, CDCl3) δ 11.38 (br s, 
1H), 6.28 (s, 1H), and 3.90 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 162.51, 64.17, and 63.95; IR 
(neat) 3172 (br), 2998, 2940, 1674 (st), 1500, 1439, 1335, 1210, 1057, and 974 cm-1; HR-ESIMS 
requires for C3H5ClNO2 (M+H)+ 158.9798, found 158.9784. 
 
(±)-(4S, 5R, 1S)-4-chloro-8-oxo-2-(methoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one (endo) and 
(±)-(4R, 5R, 1S)-4-chloro-8-oxo-2-(methoxy)-2-azabicyclo[3.2.1]oct-6-en-3-one (exo) (105, 
106): 
 
 To a solution of 2,2-dichloro-N-(phenylmethoxy)acetamide (22.2 mmol, 3.5 g) in 



































	   90 
The solution was allowed to warm to room temperature and the reaction mixture was stirred for 
24 hours. After removal of the volatiles under reduced pressure, the crude mixture was purified 
by flash column chromatography (3:1 hexanes:ethyl acetate) to afford 3.4 g (17.9 mmol, 80 % 
yield) of the pure cycloadduct endo isomer as a yellow solid and the exo isomer as a yellow oil 
(2:1 endo:exo). Endo-diastereoisomer: Rf = 0.4 (2:1 hexanes:ethyl acetate); M.P. = 87.8 °C; 1H 
NMR (500 MHz, CDCl3): δ 6.81 (dd, J = 6.0, 1.3 Hz, 1H), 6.60 (dd, J = 6.0, 1.8 Hz, 1H), 5.63 (d, 
J = 1.4 Hz, 1H), 5.18 (dd, J = 5.1, 1.9 Hz, 1H), 4.80 (d, J = 5.1 Hz, 1H), 3.82 (s, 3H); 13C NMR 
(101 MHz, CDCl3): δ 165.53, 136.79, 133.22, 90.80, 82.05, 63.56, and 56.67; IR (neat) 3101, 
3015, 3091, 2990, 2942, 1679 (st), 1442, 1394, 1325, 1242, 1062, 1030, 926, and 834 cm-1; HR-
ESIMS requires for C7H8ClNO3 (M+Na)+ 212.0085, found 212.0083. Exo-diastereoisomer: Rf = 
0.3 (2:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3): δ 6.87 (dd, J = 6.1, 1.4 Hz, 1H), 
6.50 (dd, J = 5.9, 2.0 Hz, 1H), 5.70 (d, J = 1.5 Hz, 1H), 5.08 (d, J = 2.1 Hz, 1H), 4.16 (d, J = 1.0 
Hz, 1H), and 3.84 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 165.16, 137.88, 131.70, 89.90, 84.06, 
63.41, and 55.69; IR (neat) 3094, 2987, 2939, 2901, 1692 (st), 1439, 1363, 1274, 1236, 1157, 
1046 (st), 986, 903, and 834 cm-1; HR-ESIMS requires for C7H8ClNO3 (M+Na)+ 212.0085, found 
212.0087. 
 
(±)-(3S, 4R)-N-phenylmethoxy-3-chloro-4-hydroxy-2,3,4,7-tetrahydro-1H-azepine (107) 
 
 To an oven dried 100 mL Schlenk flask equipped with a magnetic stir bar was added dry 
THF (19 mL) under an atmosphere of nitrogen. The flask was placed in an ice bath and aluminum 
chloride (7.57 mmol, 1.01 g) was added in portions over a period of 5 minutes. Upon complete 
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mmol, 5.7 mL) was added dropwise at that same temperature over a period of 15 minutes and the 
resulting solution was stirred at 0 °C for 20 minutes. The cycloadduct 102 (3.79 mmol, 1.01 g) 
was then added in THF (25 mL) dropwise over a period of 20 minutes and the reaction mixture 
was refluxed under nitrogen for 1.5 hours. The reaction flask was cooled to 0 °C and quenched 
with water followed by 10% NaOH. The aluminum salts were filtered off and the filtrate was 
dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by 
column chromatography (10% - 33% Hex:EtOAc) to afford 0.67 g of 107 as a white crystalline 
solid (2.64 mmol, 70% yield). Rf = 0.54 (2:1 hexanes:ethyl acetate); M.P. 59.5 – 62.0 °C; 1H 
NMR (500 MHz, CDCl3): δ 7.35 – 7.30 (m, 5H), 5.81 (dt, J = 11.9, 3.1 Hz, 1H), 5.67 (dt, J = 
12.0, 6.0 Hz, 1H), 4.69 (s, 2H), 4.36 (d, J = 8.2 Hz, 1H), 4.18 (td, J = 8.3, 4.7 Hz, 1H), 3.77 (dd, J 
= 14.1, 4.7 Hz, 1H), 3.62 (dd, J = 15.9, 6.2 Hz, 1H), 3.44 – 3.39 (m, 1H), 3.22 (dd, J = 14.0, 8.0 
Hz, 1H), and 2.86 – 2.83 (m, 1H); 13C NMR (101 MHz, CDCl3): δ 137.20, 132.20, 128.71, 
128.38, 128.03, 126.27, 74.64, 73.34, 64.26, 61.87, and 57.41; IR (neat) 3556, 3105 (br), 3006, 
2987, 2965, 1464, 1376, 1055 (s), and 1037 cm-1; HR-ESIMS requires for C13H17ClNO2 (M+H)+ 
254.0948, found 254.0950. 
 
(±)-(3S, 4R)-N-methoxy-3-chloro-4-hydroxy-2,3,4,7-tetrahydro-1H-azepine (108) 
 
 To an oven dried 100 mL Schlenk flask equipped with a magnetic stir bar was added dry 
THF (19 mL) under an atmosphere of nitrogen. The flask was placed in an ice bath and aluminum 
chloride (12.1 mmol, 1.61 g) was added in portions over a period of 5 minutes. Upon complete 
dissolution of the aluminum chloride, a solution of lithium aluminum hydride in dry THF (18.1 
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resulting solution was stirred at 0 °C for 20 minutes. The cycloadduct 105 (6.03 mmol, 1.14 g) 
was then added in THF (40 mL) dropwise over a period of 20 minutes and the reaction mixture 
was refluxed under nitrogen for 1.5 hours. The reaction flask was cooled to 0 °C and quenched 
with water followed by 10% NaOH. The aluminum salts were filtered off and the filtrate was 
dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by 
column chromatography (25% - 33% Hex:EtOAc) to afford 0.75 g of 108 as a white crystalline 
solid (4.22 mmol, 70% yield). X-ray quality crystals were grown by slow evaporation of a 
dichloromethane/hexanes solution of 108. Rf = 0.55 (1:1 hexanes:ethyl acetate); M.P. = 63.9 – 
65.4 °C; 1H NMR (500 MHz, CDCl3): δ 5.84 (dt, J = 11.9, 2.9 Hz, 1H), 5.75 – 5.70 (m, 1H), 4.39 
(d, J = 7.2 Hz, 1H), 4.19 (td, J = 8.6, 4.5 Hz, 1H), 3.82 (ddd, J = 13.9, 4.5, 1.5 Hz, 1H), 3.68 
(ddd, J = 15.9, 6.5, 1.2 Hz, 1H), 3.53 (s, 3H), 3.42 (d, J = 16.2 Hz, 1H), 3.19 (dd, J = 13.8, 8.4 
Hz, 1H), and 2.86 (br s, 1H); 13C NMR (101 MHz, CDCl3): δ 132.97, 125.91, 73.42, 63.72, 62.07, 
59.68, and 56.50; IR (neat) 3326 (br), 3031, 2949, 2810, 1458, 1385, 1350, 1283, 1198, 1062, 
1024 (st), 897, and 774 cm-1; HR-ESIMS requires for C7H12ClNO2 (M+H)+ 178.0629, found 
178.0627. 
 
(±)-(2S, 3R)-N-phenylmethoxy-2-acetoxymethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (109) 
 
 To a stirred solution of 107 (1.0 mmol, 250 mg,) in DMF (12 mL) was added AgOAc 
(2.0 mmol, 334 mg,) all at once and the resulting suspension was heated in a sealed flask at 90 °C 
for 72 hours. The crude reaction mixture was filtered through a pad of celite and the pad was 
washed with ethyl acetate (2 x 15 mL) followed by methanol (15 mL). The filtrate was 
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by column chromatography (33% to 50% hexanes:ethyl acetate) to afford 224 mg of 109 as a pale 
yellow oil (0.81 mmol, 60% yield). Rf = 0.33 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, 
CD3OD): δ 7.34 – 7.24 (m, 5H), 5.74 – 5.66 (m, 2H), 4.83 (s, 1H), 4.70 (d, J = 10.7 Hz, 1H), 4.65 
(d, J = 10.6 Hz, 1H), 4.48 (d, J = 12.7 Hz, 1H), 4.40 (dd, J = 11.5, 5.0 Hz, 1H), 4.24 (dd, J = 8.3, 
3.6 Hz, 1H), 3.66 (d, J = 15.8 Hz, 1H), 3.39 – 3.32 (m, 1H), 2.81 (s, 1H), and 2.05 (s, 3H); 13C 
NMR (101 MHz, CD3OD): δ 171.54, 137.13, 128.78, 128.60, 127.90, 127.60, 123.97, 74.88, 
66.99, 64.61, 60.89, 53.67, and 19.49; IR (neat) 3405 (br), 3034, 2917, 2860, 1736, 1451, 1363, 
1236, 1024, and 698 cm-1; HR-ESIMS requires for C15H19NO4 (M+H)+ 278.1387, found 
278.1384. 
 
(±)-(2S, 3R)-N-methoxy-2-acetoxymethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (110) 
 
 To a stirred solution of 108 (1.1 mmol, 200 mg,) in DMF (15 mL) was added AgOAc 
(2.2 mmol, 367 mg,) all at once and the resulting suspension was heated in a sealed flask at 90 °C 
for 72 hours. The crude reaction mixture was filtered through a pad of celite and the pad was 
washed with ethyl acetate (2 x 15 mL) followed by methanol (15 mL). The filtrate was 
concentrated under reduced pressure at 65 °C to remove DMF and the crude residue was purified 
by column chromatography (33% to 50% hexanes:ethyl acetate) to afford 143 mg of 110 as a pale 
yellow oil (0.71 mmol, 64% yield). Rf = 0.23 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, 
CDCl3): δ 5.81 – 5.77 (m, 1H), 5.73 (dddd, J = 10.1, 3.8, 2.3, 1.3 Hz, 1H), 4.55 (dd, J = 11.7, 4.3 
Hz, 1H), 4.35 (dd, J = 11.7, 4.2 Hz, 1H), 4.23 (d, J = 7.6 Hz, 1H), 3.70 – 3.64 (m, 1H), 3.57 (s, 
3H), 3.43 – 3.38 (m, 1H), 2.97 – 2.93 (m, 1H), 2.56 (d, J = 11.3 Hz, 1H), and 2.12 (s, 3H); 13C 
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19.65; IR (neat) 3444 (br), 2937, 2891, 2845, 2811, 1729 (st), 1454, 1439, 1372, 1228 (st), 1029, 
965, and 901 cm-1; HR-ESIMS requires for C9H15NO4 (M+Na)+ 224.0893, found 224.0890. 
 
(±)-(3R, 4R)-N-phenylmethoxy-3-chloro-4-hydroxy-2,3,4,7-tetrahydro-1H-azepine (111) 
 
 To an oven dried 250 mL Schlenk flask equipped with a magnetic stir bar was added dry 
THF (55 mL) under an atmosphere of nitrogen. The flask was placed in an ice bath and aluminum 
chloride (21.8 mmol, 2.91 g) was added in portions over a period of 5 minutes. Upon complete 
dissolution of the aluminum chloride, a solution of lithium aluminum hydride in dry THF (32.7 
mmol, 16.4 mL) was added dropwise at that same temperature over a period of 15 minutes and 
the resulting solution was stirred at 0 °C for 20 minutes. The cycloadduct 103 (10.9 mmol, 2.89 
g) was then added in THF (72 mL) dropwise over a period of 20 minutes and the reaction mixture 
was refluxed under nitrogen for 1.5 hours. The reaction flask was cooled to 0 °C and quenched 
with water followed by 10% NaOH. The aluminum salts were filtered off and the filtrate was 
dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by 
column chromatography (10% - 33% Hex:EtOAc) to afford 1.96 g of 111 as a colorless oil (1.96 
g, 7.72 mmol, 71% yield). Rf = 0.36 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3): δ 
7.35 – 7.31 (m, 5H), 5.86 (dd, J = 11.7, 6.2 Hz, 1H), 5.72 (dt, J = 11.6, 4.7 Hz, 1H), 4.69 (s, 2H), 
4.45 (td, J = 8.0, 1.3 Hz, 1H), 4.32 (ddd, J = 8.0, 6.0, 2.2 Hz, 1H), 3.70 (dd, J = 16.5, 5.0 Hz, 1H), 
3.59 (dd, J = 13.8, 7.8 Hz, 1H), 3.55 – 3.49 (m, 2H), 2.91 (d, J = 8.9 Hz, 1H); 13C NMR (101 
MHz, CDCl3): δ 137.01, 131.06, 129.20, 128.77, 128.46, 128.17, 74.74, 71.45, 62.00, 60.19, and 
57.05; IR (neat) 3498 (br), 3150, 2976, 2865, 2852, 1489, 1424, 1176, and 1054 cm-1; HR-ESIMS 
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(±)-(3R, 4R)-N-methoxy-3-chloro-4-hydroxy-2,3,4,7-tetrahydro-1H-azepine (112) 
 
 To an oven dried 100 mL Schlenk flask equipped with a magnetic stir bar was added dry 
THF (19 mL) under an atmosphere of nitrogen. The flask was placed in an ice bath and aluminum 
chloride (7.48 mmol, 0.997 g) was added in portions over a period of 5 minutes. Upon complete 
dissolution of the aluminum chloride, a solution of lithium aluminum hydride in dry THF (11.2 
mmol, 5.6 mL) was added dropwise at that same temperature over a period of 15 minutes and the 
resulting solution was stirred at 0 °C for 20 minutes. The cycloadduct 106 (3.74 mmol, 1.01 g) 
was then added in THF (25 mL) dropwise over a period of 20 minutes and the reaction mixture 
was refluxed under nitrogen for 1.5 hours. The reaction flask was cooled to 0 °C and quenched 
with water followed by 10% NaOH. The aluminum salts were filtered off and the filtrate was 
dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by 
column chromatography (10% - 33% Hex:EtOAc) to afford 0.46 g of 112 as a colorless oil (2.59 
mmol, 69% yield). Rf =  (2:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3): δ 5.94 – 5.89 
(m, 1H), 5.78 (dt, J = 11.4, 4.8 Hz, 1H), 4.49, (ddd, J = 8.7, 6.6, 2.4 Hz, 1H), 4.41 – 4.35 (m, 1H), 
3.75 (dd, J = 16.3, 5.0 Hz, 1H), 3.66 – 3.60 (m, 1H), 3.58 – 3.55 (m, 1H), and 3.55 (s, 3H); 13C 
NMR (101 MHz, CDCl3): δ 131.40, 129.12, 71.47, 61.17, 60.21, 59.75, and 55.96; IR (neat) 3405 
(br), 2971, 2939, 2860, 2825, 1458, 1435, 1369, 1312, 1052 (st), 1033, 1017, 926, and 745 cm-1; 
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(±)-(2R, 3R)-N-phenylmethoxy-2-acetoxymethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (113) 
 
 To a stirred solution of 111 (0.9 mmol, 229 mg,) in DMF (11 mL) was added AgOAc 
(1.81 mmol, 302 mg,) all at once and the resulting suspension was heated in a sealed flask at 90 
°C for 72 hours. The crude reaction mixture was filtered through a pad of celite and the pad was 
washed with ethyl acetate (2 x 10 mL) followed by methanol (10 mL). The filtrate was 
concentrated under reduced pressure at 65 °C to remove DMF and the crude residue was purified 
by column chromatography (20% to 33% hexanes:ethyl acetate) to afford 174 mg of 113 as a pale 
yellow oil (0.63 mmol, 69% yield). Rf = 0.36 (2:1 hexanes:ethyl acetate); 1H NMR (500 MHz, 
CD3OD): δ 7.37 – 7.25 (m, 5H), 5.88 – 5.81 (m, 1H), 5.74 (dd, J = 10.0, 4.9 Hz, 1H), 4.81 (d, J = 
1.8 Hz, 1H), 4.73 – 4.69 (m, 1H), 4.65 (dd, J = 11.0, 1.6 Hz, 1H), 4.56 (dd, J = 10.8, 5.5 Hz, 1H), 
4.32 (ddd, J = 11.2, 7.3, 1.7 Hz, 1H), 4.12 (d, J = 4.1 Hz, 1H), 3.74 (dd, J = 16.6, 4.5 Hz, 1H), 
3.28 – 3.22 (m, 1H), 3.04 (s, 1H), and 2.00 (d, J = 1.7 Hz, 3H); 13C NMR (101 MHz, CD3OD): δ 
171.42, 137.22, 128.67, 127.95, 127.66, 126.71, 125.74, 75.32, 64.99, 62.20, 58.72, 54.23, and 
19.56; IR (neat) 3467 (br), 3028, 2922, 2860, 2816, 1728 (st), 1454, 1366, 1236, 1086, 1039, and 
735 cm-1; HR-ESIMS requires for C15H19NO4 (M+H)+ 278.1387, found 278.1388. 
 
(±)-(2R, 3R)-N-methoxy-2-acetoxymethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (114) 
 
 To a stirred solution of 112 (1.4 mmol, 252 mg,) in DMF (13 mL) was added AgOAc 
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for 72 hours. The crude reaction mixture was filtered through a pad of celite and the pad was 
washed with ethyl acetate (2 x 15 mL) followed by methanol (15 mL). The filtrate was 
concentrated under reduced pressure at 65 °C to remove DMF and the crude residue was purified 
by column chromatography (33% to 50% hexanes:ethyl acetate) to afford 186 mg of 114 as a pale 
yellow oil (0.92 mmol, 186 mg, 65% yield). Rf = 0.23 (1:1 hexanes:ethyl acetate); 1H NMR (400 
MHz, CD3OD): δ 5.89 – 5.83 (m, 1H), 5.79 (ddd, J = 10.0, 4.5, 1.9 Hz, 1H), 4.55 (dd, J = 10.9, 
5.7 Hz, 1H), 4.34 (dd, J = 10.9, 7.5 Hz, 1H), 4.11 (d, J = 7.2 Hz, 1H), 3.82 (dd, J = 16.6, 4.6 Hz, 
1H), 3.52 (s, 3H), 3.26 – 3.20 (m, 1H), 3.02 (t, J = 5.8 Hz, 1H), and 2.07 (s, 3H); 13C NMR (101 
MHz, CD3OD): δ 171.37, 126.71, 125.56, 64.55, 61.95, 59.72, 58.65, 53.46, and 19.49; IR (neat) 
3443, 3003, 2967, 2939, 2920, 2860, 2844, 1727 (st), 1454, 1369, 1236, 1052 (st), 1012, and 748 





 To a solution of 109 (2.24 mmol, 620 mg) in methanol (45 mL) was added potassium 
carbonate (46.6 mmol, 6.44 g) all at once and the resulting suspension was stirred for 16 hours at 
room temperature. After concentration under reduced pressure, the crude residue was taken up in 
45 mL of water and extracted with CHCl3:i-PrOH (3:1 v:v, 3 x 25 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, and concentrated to afford the crude diol. 
The crude product was then ran through a short plug of silica gel (eluent 1:1 hexanes:ethyl 
acetate) to give 440 mg of the pure diol 115 as a colorless oil (1.87 mmol, 83% yield). Rf = 0.14 
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2H), 4.76 (s, 2H), 4.24 (d, J = 8.2 Hz, 1H), 3.94 (dd, J = 10.94, 2.55 Hz, 1H), 3.85 (dd, J = 11.1, 
5.2 Hz, 1H), 3.66 – 3.59 (m, 1H), 3.37 – 3.30 (m, 1H), and 2.65 (s, 1H); 13C NMR (101 MHz, 
CD3OD): δ 137.35, 128.79, 128.51, 127.87, 127.53, 123.95, 74.83, 69.62, 65.12, 58.89, and 
53.49; IR (neat) 3364, 3063, 3028, 2930, 2879, 2825, 1496, 1451, 1366, 1264, 1242, 1030, 1002, 
913, and 736 cm-1; HR-ESIMS requires for C13H17NO3 (M+Na)+ 258.1101, found 258.1097. 
 
(±)-(2S, 3R)-N-methoxy-2-hydroxymethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (116) 
 
 To a solution of 110 (1.36 mmol, 273 mg) in methanol (27 mL) was added potassium 
carbonate (28.3 mmol, 3.9 g) all at once and the resulting suspension was stirred for 16 hours at 
room temperature. After concentration under reduced pressure, the crude residue was taken up in 
10 mL of water and extracted with CHCl3:i-PrOH (3:1 v:v, 3 x 15 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, and concentrated to afford 190 mg of diol 
116 as a white solid that was used without further purification (1.19 mmol, 88% yield). Rf = 0.4 
(5% DCM:MeOH); M.P. = 121.2 – 123.4 °C; 1H NMR (400 MHz, CD3OD): δ 5.85 – 5.79 (m, 
1H), 5.74 (dd, J = 9.7, 4.2 Hz, 1H), 4.15 (s, 1H), 3.96 (ddd, J = 10.9, 5.6, 1.0 Hz, 1H), 3.88 (ddd, 
J = 10.9, 6.7, 1.0 Hz, 1H), 3.77 (ddd, J = 16.5, 4.5, 1.2 Hz, 1H), 3.51 (s, 3H), 3.18 (d, J = 16.6 
Hz, 1H), and 2.78 (s, 1H); 13C NMR (101 MHz, CD3OD): δ 127.01, 125.51, 67.74, 65.12, 59.82, 
59.63, and 53.75; IR (neat) 3352 (br), 3245 (br), 2921, 2851, 2808, 1457, 1384, 1265, 1243, 
1225, 1121, 1026, 947, 895, 870, and 846 cm-1; HR-ESIMS requires for C7H13NO3 (M+Na)+ 
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(±)-(2S, 3R, 4S, 5S)-N-phenylmethoxy-2-hydroxymethyl-3,4,5-trihydroxypiperidine (117) 
 
 To a solution of 115 (1.83 mmol, 430 mg) in acetonitrile, acetone, and deionized water 
(11 mL, 1:1:1 v/v) was added NMO (3.66 mmol, 0.4 mL) followed by 2.4 mL of a 1 wt. % 
solution of osmium tetroxide in deionized water and the resulting solution was stirred overnight at 
room temperature. The reaction mixture was then filtered through a pad of celite and the pad 
washed with methanol (3 x 15 mL). After concentration under reduced pressure, the crude residue 
was purified by column chromatography (5% - 10% DCM:MeOH) to afford 431 mg of the pure 
piperidine 117 as an off white solid (1.6 mmol, 88% yield). Rf = 0.3 (10% DCM:MeOH); M.P. = 
98.6 – 100.8 °C; 1H NMR (400 MHz, CD3OD): δ 7.38 – 7.22 (m, 5H), 4.73 (d, J = 1.0 Hz, 1H), 
4.00 (ddd, J = 11.2, 2.8, 1.0 Hz, 1H), 3.91 – 3.88 (m, 1H), 3.79 (td, J = 9.7, 1.0 Hz, 1H), 3.54 
(ddd, J = 11.4, 3.5, 1.0 Hz, 1H), 3.35 (ddd, J = 9.6, 3.6, 1.0 Hz, 1H), 3.29 (dq, J = 3.0, 1.5 Hz, 
1H), 2.67 (dd, J = 11.6, 1.8 Hz, 1H), and 2.34 (d, J = 9.7 Hz, 1H); 13C NMR (101 MHz, CD3OD): 
δ 136.94, 128.54, 127.93, 127.61, 74.77, 74.61, 70.91, 68.18, 67.40, 58.50, and 58.25; IR (neat) 
3225 (br), 3031, 2978, 2951, 2919, 2842, 1460, 1451, 1437, 1366, 1319, 1210, 1101, 1062, 1042, 
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(±)-(2S, 3R, 4S, 5S)-N-methoxy-2-hydroxymethyl-3,4,5-trihydroxypiperidine (118) 
 
 To a solution of 116 (0.69 mmol, 109 mg) in acetonitrile, acetone, and deionized water 
(4.05 mL, 1:1:1 v/v) was added NMO (1.37 mmol, 0.2 mL) followed by 0.9 mL of a 1 wt. % 
solution of osmium tetroxide in deionized water and the resulting solution was stirred overnight at 
room temperature. The reaction mixture was then filtered through a pad of celite and the pad 
washed with methanol (3 x 10 mL). After concentration under reduced pressure, the crude residue 
was purified by column chromatography (5% - 20% DCM:MeOH) to afford 122 mg of the pure 
piperidine 118 as a colorless gum (0.6 mmol, 92%). Rf = 0.5 (20% DCM:MeOH); 1H NMR (400 
MHz, CD3OD): δ 3.99 (ddd, J = 7.0, 3.7, 1.8 Hz, 1H), 3.73 (td, J = 7.6, 3.2 Hz, 1H), 3.66 (ddd, J 
= 5.9, 1.8, 0.5 Hz, 1H), 3.47 (s, 3H), 3.33 (s, 1H), 3.23 – 3.16 (m, 1H), 3.11 (dd, J = 3.2, 0.9 Hz, 
1H), 3.09 – 3.07 (m, 1H), and 3.06 – 3.03 (m, 1H); 13C NMR (101 MHz, CD3OD): δ 76.42, 
75.11, 70.78, 67.43, 59.86, 58.99, and 58.00; IR (film) 3346 (br), 2952, 2921, 2903, 2851, 2072, 
1463, 1375, 1225, 1118, 1087, 1057, 1042, 971, 898, and 818 cm-1; HR-ESIMS requires for 





 To a solution of 114 (0.958 mmol, 266 mg) in methanol (19 mL) was added potassium 
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room temperature. After concentration under reduced pressure, the crude residue was taken up in 
25 mL of water and extracted with CHCl3:i-PrOH (3:1 v:v, 3 x 15 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, and concentrated to afford 224 mg of diol 
119 as an off-white solid that was used without further purification (0.95 mmol, 99% yield). X-
ray quality crystals were grown by slow evaporation of a benzene solution of 119. Rf = 0.15 (1:1 
hexanes:ethyl acetate); M.P. = 89.5 – 91.8 °C; 1H NMR (500 MHz, CD3OD): δ 7.41 – 7.25 (m, 
5H), 5.87 – 5.81 (m, 1H), 5.73 (ddd, J = 9.9, 4.8, 1.9 Hz, 1H), 4.84 (s, 2H), 4.71 (q, J = 10.9 Hz, 
2H), 4.20 (br s, 1H), 4.01 (dd, J = 10.9, 5.3 Hz, 1H), 3.92 (dd, J = 10.9, 7.0 Hz, 1H), 3.73 (dd, J = 
16.8, 4.6 Hz, 1H), 3.24 (d, J = 16.8 Hz, 1H), and 2.85 (br s, 1H); 13C NMR (101 MHz, CD3OD): 
δ 137.31, 128.63, 127.95, 127.64, 127.00, 125.71, 75.32, 67.82, 65.48, 59.83, and 54.55; IR 
(neat) 3322 (br), 3034, 2872, 2813, 1454, 1401, 1369, 1124, 1089, 1045, 998, and 953 cm-1; HR-
ESIMS requires for C13H17NO3 (M+H)+ 236.1281, found 236.1283. 
 
(±)-(2R, 3R)-N-methoxy-2-hydroxymethyl-3-hydroxy-1,2,3,6-tetrahydropyridine (120) 
 
 To a solution of 114 (0.82 mmol, 165 mg) in methanol (16 mL) was added potassium 
carbonate (17.1 mmol, 2.36 g) all at once and the resulting suspension was stirred for 16 hours at 
room temperature. After concentration under reduced pressure, the crude residue was taken up in 
10 mL of water and extracted with CHCl3:i-PrOH (3:1 v:v, 3 x 15 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, and concentrated to afford 117 mg of diol 
120 as an off-white solid that was used without further purification (0.73 mmol, 89% yield). Rf = 
0.3 (5% DCM:MeOH); M.P. = 67.4 – 70.1 °C; 1H NMR (400 MHz, CD3OD): δ 5.85 – 5.79 (m, 
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J = 10.9, 6.7, 1.0 Hz, 1H), 3.77 (ddd, J = 16.5, 4.5, 1.2 Hz, 1H), 3.51 (s, 3H), 3.18 (d, J = 16.6 
Hz, 1H), and 2.78 (s, 1H); 13C NMR (101 MHz, CD3OD): δ 127.01, 125.51, 67.74, 65.12, 59.82, 
59.63, and 53.75; IR (neat) 3303, 2980, 2930, 2885, 2816, 1470, 1451, 1388, 1337, 1299, 1223, 
1125, 1078, 1049, 1008, 986, 935, and 751 cm-1; HR-ESIMS requires for C7H13NO3 (M+Na)+ 
182.0788, found 182.0788. 
 
(±)-(2R, 3R, 4S, 5S)-N-phenylmethoxy-2-hydroxymethyl-3,4,5-trihydroxypiperidine (121) 
 
 To a solution of 119 (0.992 mmol, 233.3 mg) in acetonitrile, acetone, and deionized 
water (6 mL, 1:1:1 v/v) was added NMO (1.98 mmol, 0.21 mL) followed by 1.3 mL of a 1 wt. % 
solution of osmium tetroxide in deionized water and the resulting solution was stirred overnight at 
room temperature. The reaction mixture was then filtered through a pad of celite and the pad 
washed with methanol (3 x 10 mL). After concentration under reduced pressure, the crude residue 
was purified by column chromatography (5% - 10% DCM:MeOH) to afford 220 mg of the pure 
piperidine 121 as a white solid (0.82 mmol, 82% yield). X-ray quality crystals were grown by 
vapor diffusion of pentane into an ethanol solution of 121. Rf = 0.2 (10% DCM:MeOH); M.P. = 
130.7 – 133.5 °C; 1H NMR (400 MHz, CD3OD): δ 7.40 – 7.21 (m, 5H), 4.83 (s, 2H), 4.70 (d, J = 
10.7 Hz, 1H), 4.63 (d, J = 10.6 Hz, 1H), 3.97 (d, J = 8.9 Hz, 1H), 3.95 – 3.92 (m, 1H), 3.89 (d, J 
= 10.8 Hz, 1H), 3.76 (s, 1H), 3.23 (ddd, J = 9.6, 4.6, 1.0 Hz, 1H), 2.84 (s, 1H), and 2.76 (d, J = 
10.4 Hz, 1H); 13C NMR (101 MHz, CD3OD): δ 137.17, 128.56, 127.94, 127.60, 74.87, 70.61, 
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1451, 1437, 1366, 1319, 1210, 1101, 1062, 1042, 974, 909, and 856 cm-1; HR-ESIMS requires 
for C13H19NO5 (M+H)+ 270.1336, found 270.1337. 
 
(±)-(2R, 3R, 4S, 5S)-N-methoxy-2-hydroxymethyl-3,4,5-trihydroxypiperidine (122) 
 
 To a solution of 120 (0.63 mmol, 100 mg) in acetonitrile, acetone, and deionized water 
(3.75 mL, 1:1:1 v/v) was added NMO (1.26 mmol, 0.13 mL) followed by 0.8 mL of a 1 wt. % 
solution of osmium tetroxide in deionized water and the resulting solution was stirred overnight at 
room temperature. The reaction mixture was then filtered through a pad of celite and the pad 
washed with methanol (3 x 10 mL). After concentration under reduced pressure, the crude residue 
was purified by column chromatography (5% - 20% DCM:MeOH) to afford 97.3 mg of the pure 
piperidine 122 as an off white gum (0.5 mmol, 80%). Rf = 0.4 (20% DCM:MeOH); 1H NMR 
(500 MHz, CD3OD): δ 4.03 – 3.93 (m, 2H), 3.89 (dt, J = 12.1, 6.0 Hz, 2H), 3.80 – 3.72 (m, 1H), 
3.48 (s, 3H), 3.23 (dd, J = 9.7, 4.6 Hz, 1H), 2.77 (s, 1H), and 2.69 (s, 1H); 13C NMR (500 MHz, 
CD3OD): δ 70.42, 70.18, 65.37, 64.36, 59.68, 59.15, and 55.04; IR (neat) 3297, (br), 2961, 2940, 
2918, 2891, 2845, 1454, 1369, 1228, 1103, 1072, 1051, 1039, 1014, 974, and 950 cm-1; HR-
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Chapter 5: Alternative Methods of Generating Aza-Oxyallylic Cations 
 
5.1 Introduction 
 As discussed in Chapter 2, one of the limitations encountered in our methodology was the 
inability to incorporate heteroatoms at the α-carbon of the α-haloamide starting materials. This 
disadvantage turned out to be quite significant, as the only way to incorporate oxygen or nitrogen 
into a cycloadduct was by nucleophilic displacement of a chloride atom and always resulted in 
ring contraction to a six-membered tetrahydropyridine core. Recently, our group has reported the 
oxidative 1,4-diamination of dienes using simple urea derivatives 124 to construct diaza-seven-
membered heterocycles 126 (Scheme 5.1.1).1 This reaction hinges on formation of a diaza-
oxyallylic cation intermediate 125 in situ through a series of deprotonation and oxidation events 
of a dibenzyloxyurea derivative respectively. Given that hypervalent iodide reagents have been 
shown to be effective oxidants for the generation of N-acylnitrenium ions from O-alkyl 
hydroxamates,2,3 it was our vision to explore the possibility of generating an aza-oxyallylic cation 
by deprotonation followed by oxidation of an O-alkyl hydroxamate functionalized at the α-
position with either oxygen or nitrogen. 
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5.2 Toward an Oxidative Generation of Aza-Oxyallylic Cations 
 In order to explore the feasibility of our hypothesis, two substrates were synthesized, 2-
methoxy-N-(phenylmethoxy)acetamide 128 and 2-(N-phthalyl)-N-(phenylmethoxy)acetamide 130 
from the corresponding commercially available acid chlorides 127 and 129 respectively (Scheme 
5.2.1). Given that (diacetoxyiodo)benzene (DIB) was found to be the optimal oxidant for the 1,4-
diamination cases, we initially set out to screen bases using 2,2,3,3-tetrafluoro-1-propanol as the 
solvent.4 First studied was α-methoxy hydroxamate 128 and was dissolved in the solvent and 
diene followed by addition of the oxidant and base at 0 °C. Various bases were evaluated in their 
ability to affect the desired reactivity including triethylamine, 2,6-lutidine, cesium carbonate, 
sodium carbonate, diisopropylamine, potassium t-butoxide, and CHF2CF2CH2ONa, with the 
results being tabulated in Table 5.2.1 below. Amine bases such as triethylamine, 
diisopropylamine, and 2,6-lutidine gave undesired reactivity and resulted in either no reaction or 
solvolysis of the intermediate (entries 1-3). Sodium carbonate and cesium carbonate were both 
found to be ineffective, providing almost a quantitative recovery of the starting material (entries 4 
and 5). We were optimistic about the sodium salt of 2,2,3,3-tetrafluor-1-propanol being able to 
give at least a small amount of the desired cycloadduct given the success of the oxidative 1,4-





























DCM, 0 °C to R.T.
HCl
Scheme 5.2.1. Synthesis of α-heteroatom-substituted amide starting materials. 
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the intermediate (entry 5). Interestingly, potassium t-butoxide appeared to have given the desired 
product in a trace amount as observed by crude 1H NMR (entry 6), however attempts to optimize 
the reaction to provide enough of the pure cycloadduct for characterization including slow 
addition of the substrate to the reaction mixture, changing the order of addition of reagents, and 
lowering of the temperature were all unproductive. Using potassium t-butoxide as the base and 
switching to the more bulkier hexafluoroisopropanol solvent was thought to be helpful, however 




Entry Solvent Base % Yield 
1 CHF2CF2CH2OH Et3N solvolysis 
2 CHF2CF2CH2OH (i-pr)2NH solvolysis 
3 CHF2CF2CH2OH 2,6-lutidine N.R. 
4 CHF2CF2CH2OH Na2CO3 N.R. 
5 CHF2CF2CH2OH Cs2CO3 N.R. 
6 CHF2CF2CH2OH CHF2CF2CH2ONa solvolysis 
7 CHF2CF2CH2OH t-BuOK tracea 
8 HFIP t-BuOK N.R. 

















Table 5.2.1. Solvent and Base Effects in the Oxidative Generation
of Alpha-Methoxy Substituted Aza-Oxyallylic Cations
128
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 Next studied was α-N-phthalyl hydroxamate 130 in a similar fashion, with 
hexafluoroisopropanol being chosen as the solvent in an effort to minimize competitive solvolysis 
products. Once again, triethylamine, diisopropylamine, and 2,6-lutidine gave no reaction and 
resulted in recovery of the starting material (entries 1-3, Table 5.2.2). Sodium carbonate and 
cesium carbonate were observed to be incompatible bases, giving decomposition of the reactant 
(entries 4 and 5). The sodium salt of 2,2,3,3-tetrafluor-1-propanol and potassium t-butoxide both 
appeared to have provided the desired cycloadduct 132, albeit once again in trace amounts as 
detected by crude 1H NMR analysis (entries 6 and 7). Optimization attempts to provide enough 
product for unambiguous characterization including temperature changes, order of reagent 
addition changes, and different solvents were all unfruitful. Initially, it appears that more 
promising results could be obtained with the α-N-phthalyl substrate. One hypothesis could be that 
the acidity of the α-protons is higher due to the electron withdrawing phthalimide group. 
However, an equally viable argument could be made that the resulting aza-oxyallylic cation 
intermediate is now being destabilized and not allowing for formation of the desired cycloadduct. 
Nonetheless, it appears that this project could have viable merit and continued work on this 
methodology could be worthwhile, especially in the context of target directed synthesis. 
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Entry Solvent Base % Yield 
1 HFIP Et3N N.R. 
2 HFIP (i-pr)2NH N.R. 
3 HFIP 2,6-lutidine N.R. 
4 HFIP Na2CO3 decomposition 
5 HFIP Cs2CO3 decomposition 
6 HFIP CHF2CF2CH2ONa tracea 
7 HFIP t-BuOK tracea 
8 CHF2CF2CH2OH CHF2CF2CH2ONa solvolysis 
9 CHF2CF2CH2OH t-BuOK solvolysis 





(0.25 M) 0 °C
:
Table 5.2.2. Solvent and Base Effects in the Oxidative Generation
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5.3 Experimental: 
All reactions were carried out under an atmosphere of nitrogen in oven-dried glassware 
with magnetic stirring, unless otherwise specified. All reagents and solvents were purchased from 
Sigma-Aldrich Chemical Company and used without any further purification. TLC information 
was recorded on Silicycle glass 60 F254 plates and developed by staining with KMnO4 or ceric 
ammonium molybdate. Purification of reaction products was carried out by flash chromatography 
using Silicycle Siliaflash® P60 (230-400 mesh). 1H-NMR spectra were measured on Varian 400 
(400 MHz) or Varian 500 (500 MHz) spectrometers and are reported in ppm (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad; integration; coupling constant(s) in Hz 
using TMS as an internal standard (TMS at 0.00 ppm) in CDCl3, CD3CN, or CD3OD. 13C-NMR 
spectra were recorded on V400 or V500 spectrometers and reported in ppm using solvent as an 
internal standard (CDCl3 at 77.36 ppm), (CD3CN at 118.26 ppm) or (CD3OD at 49.86 ppm). 
Infrared (IR) spectra were recorded on a Nicolet 6700 FT-IR with a diamond ATR and data are 
reported as cm-1 (br = broad, st = strong). High-resolution mass spectra were obtained using an 
Agilent 6230 TOF LC/MS with an atmospheric pressure photo-ionization (APPI) or electrospray 




 To a stirred suspension of O-benzylhydroxylamine hydrochloride (46.1 mmol, 7.35 g) in 
dichloromethane (184 mL, 0.25 M) and triethylamine (92.2 mmol, 12.9 mL) in an ice bath at 0 °C 
was added methoxyacetyl chloride (46.1 mmol, 4.2 mL) dropwise, followed by removal of the ice 
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removed under reduced pressure and the crude solid was purified by column chromatography (3:1 
to 2:1 hexanes:ethyl acetate) to afford 8.84 g of amide 124 as a white crystalline solid (45.3 
mmol, 94% yield). Rf = 0.3 (1:1 hexanes:ethyl acetate); M.P. = 41.4 – 42.8 °C; 1H NMR (500 
MHz, CDCl3): δ 8.83 (br s, 1H), 7.45 – 7.33 (m, 5H), 4.95 (s, 2H), 3.95 (s, 2H), and 3.33 (s, 3H); 
13C NMR (101 MHz, CDCl3): δ 166.67, 135.08, 129.13, 128.72, 128.54, 78.34, 71.44, and 59.34 
IR (neat) 3193 (br), 3060, 3031, 2995, 2945, 2919, 2875, 2830, 1661 (st), 1496, 1478, 1451, 
1360, 1269, 1230, 1198, 1110 (st), 1065, 1003, 986, 953, 909, 841, and 744 cm-1; HR-ESIMS 




 To a stirred suspension of O-benzylhydroxylamine hydrochloride (4.1 mmol, 650 mg) in 
dichloromethane (16 mL, 0.25 M) and triethylamine (8.2 mmol, 1.1 mL) in an ice bath at 0 °C 
was added phthalylglycyl chloride (4.1 mmol, 910.1 mg) in small portions, followed by removal 
of the ice bath and warming of the reaction mixture to room temperature for 1 hour. The solvent 
was removed under reduced pressure and the crude solid was purified by column chromatography 
(2:1 hexanes:ethyl acetate) to afford 602 mg of amide 130 as a white crystalline solid (1.9 mmol, 
50% yield). Rf = 0.2 (2:1 hexanes:ethyl acetate); M.P. = 167.0 – 168.1 °C; 1H NMR (500 MHz, 
CD3OD): δ 7.93 – 7.76 (m, 3H), 7.47 – 7.30 (m, 4H), 4.84 (s, 1H), 4.23 (s, 1H), and 3.29 (dd, J = 
2.9, 1.6 Hz, 2H); 13C (121 MHz, CD3OD): δ 167.66, 166.69, 135.32, 134.14, 132.01, 129.13, 
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1682 (st), 1684 (st), 1613, 1493, 1463, 1451, 1413, 1389, 1360, 1319, 1248, 1233, 1192, 1113, 
1086, 1045, 1012, 971, 947, 897, 756, and 738 cm-1; HR-ESIMS requires for C17H14N2O4  
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Chapter 6: Conclusions and Future Work 
 
6.1 Conclusions and Future Work 
 Historically, the aza-oxyallylic cation intermediate was proposed in order to rationalize 
the selectivity behind the nucleophilic ring opening of α-lactams. Despite proposals of the aza-
oxyallylic cation’s involvement in a variety of processes, experimental and theoretical evidence 
had largely ruled out its existence. A key solvolysis experiment by Kikugawa coupled with our 
own theoretical investigations led us to believe that placement of an electron donating alkoxy 
group on the nitrogen atom could provide a necessary stabilization to the intermediate.1-3 Inspired 
by the large comprehensive body of work on [4+3] cycloadditions of oxyallylic cations, we 
demonstrated that α-halo hydroxamates react with cyclic dienes under basic conditions in 
fluorinated solvents, providing the first experimental evidence of an aza-oxyallylic cation. Most 
of the substrates in the aza-[4+3] cycloaddition demonstrated a selectivity for the endo 
diastereoisomer (≥19:1 endo:exo). The exception was α-chloro cycloadduct 66f, with the 
diastereoisomeric ratio being high at 40% conversion ((≥19:1 endo:exo); but equilibrated to a 2:1 
endo:exo ratio upon reaction completion. When the purified endo-adduct was re-subjected to the 
reaction conditions the product was observed to have isomerized to a 1:1 mixture of 
diastereoisomers. In light of this result, we believe that there is some sort of kinetic preference for 
the endo-cycloadduct, however additional investigations aimed at better understanding the exact 
nature of this selectivity could prove worthwhile. Our initial report focused on demonstrating the 
viability of our method toward constructing seven-membered heterocycles, with little exploration 
of the actual reaction mechanism. Another project that could stem from this work would include 
comprehensive mechanistic studies, specifically directed at determining if the reaction was more 
of a stepwise process or concerted. 
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 Recently, our methodology has found application in the field of polymer chemistry by 
Fishman and Kiessling, who utilized our heterocyclic scaffold 133 as a starting point to 
synthesize a new class of degradable polymers.4 Ring opening metathesis polymerization 
(ROMP) using Grubbs’ catalyst 134 was found to readily occur on monomer 133 in THF at room 
temperature. It was demonstrated that several poly-oxazinones 135 were stable over pH values 
from 4.6 to 9.1; however decomposition to β-hydroxy amide 136 and enal 137 readily occurred 
upon subjection to pH 2.5 or highly basic conditions. The flexibility of our method allows for the 
incorporation of a wide variety of side chains both at the C- and N-terminus, permitting extensive 
derivatization in this new class of degradable polymer. In a special case, Kiessling showed that an 
azide functional group is tolerant to the aza-[4+3] cycloaddition and could be used as a linker to 
glycosides via a click reaction with a propargylated sugar. Subsequent polymerization of this 
glycosidic monomer demonstrated that biomolecules could be incorporated into the degradable 
backbone, which could allow applications in a number of biomedical applications. Additional 
projects in this field could include applying our method toward the construction of a library of 
polymers for biological testing and application exploration. 
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Scheme 6.1.1. [3.2.1]-Aza-bicyclononenes as new monomers for the synthesis of a new class of 
biodegradable ROMP polymers. 
	  
 A six-membered piperidine analogue of balanol was synthesized in good yield and high 
diastereoselectivity, and although the desired target was not realized, we nonetheless 
demonstrated the feasibility of our approach if the ring contraction problem can be solved. Our 
method has the advantages of being diastereoselective and stems from commercially available 
starting materials, as well as the reactions being relatively simple and scalable for large amounts 
of material. On the other hand, it might be worthwhile to study the effect of shrinking the 
nitrogen-containing ring size and determine how this affects the biological activity. A seven-
membered iminosugar derivative was achieved in only five short synthetic steps from 
commercially available starting materials and through an aza-[4+3] cycloaddition reaction. The 
reactions are high yielding, diastereoselective, and have the capability of incorporating a wide 
variety of side chains at the three-position. Further extensions of this project could involve 
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 A concise approach to the stereoselective synthesis of polyhydroxylated N-
alkoxypiperidines from common seven-membered azacyclic cores was developed. The strategy 
hinged on the rich functionality that is provided through aza-[4+3] cycloaddition reactions of 
putative aza-oxyallylic cation intermediates with furan. A chemoselective double reduction using 
alane provided the prefunctionalized azepines. Silver acetate promoted ring contraction and 
subsequent acetate hydrolysis with potassium carbonate provided a novel method for the 
construction of tetrahydropyridine cores in good yield and high diastereoselectivity. Finally, 
stereoselective catalytic dihydroxylation mediated by osmium tetroxide gave the final 
polyhydroxylated products in high yields. This method represents a versatile approach to 
tetrahydropyridine cores and iminosugar derivatives that is only five steps from furan and 1,1-
dichloroacetyl chloride. Other directions from this work are being focused on better 
understanding the ring contraction mechanism and elaborating the tetrahydropyridine scaffolds to 
other piperidine natural products of interest to our group. 
 Since our initial report, this new class of heterocycloaddition reactions has been applied 
to the selective 1,4-diamination of alkenes and the synthesis of polyheterocyclic scaffolds via an 
intramolecular aza-[4+3] cycloaddition.5-7 The advances described in this dissertation provide 
tremendous potential for organic synthesis and method development. The high degree of 
selectivity contained in the aza-[4+3] cycloaddition and the bold array of functionality provided 
in the resulting adducts presents adequate opportunities in target-directed synthesis, and has 
already found application toward the development of a new ROMP degradable polymer. Moving 
forward, it is expected that the development of new approaches to generating aza-oxyallylic 
cation intermediates will be realized, leading to heteroatomic analogs that delivers selective 1,4-
difunctionalization of dienes. Along with these new methods of generation, the ambivalent 
reactivity of this versatile intermediate can be taken advantage of in non-cycloaddition reactions. 
An increased understanding of the mechanistic pathway of these reactions will pave the way for 
	   118 
enantioselective reactions of aza-oxyallylic cations and enable researchers to take full advantage 
of their use in organic synthesis. 
	   119 
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A.1 1H and 13C NMR Spectra 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Elimination product from the reaction of attempted 
cycloaddition of 62 with LiClO4/Et3N in diethyl ether











Elimination product from the reaction of attempted 
cycloaddition of 62 with LiClO4/Et3N in diethyl ether






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.2 Computational Data 
	   244 
Full Citation for reference 18: 
 
Gaussian 03, Revision C.02, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, 
M. A.; Cheeseman, J. R.; Montgomery, Jr., J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, 
J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; 
Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; 
Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; 
Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. 
E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, 
K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; 
Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; 
Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; 
Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; 
Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, 
M. W.; Gonzalez, C.; and Pople, J. A.; Gaussian, Inc., Wallingford CT, 2004. 
 
Example input file for geometry minimization: 
 
%nproc = 2 % 
 
chk = I81a.chk  
 
%mem = 2GB 
 
#n opt b3lyp/6-31G* scrf = (cpcm, solvent = methanol) 
 
 azaoxyallylcation dimethyl N-methoxy in methanol 
 
0 1 
C  -4.88003 0.59080 0.09215 
C  -3.42999 0.96634 0.11274 
C  -2.28202 0.01468 0.22341 
C  -3.10581 2.42744 0.09334 
O  -2.70002 -1.12595 -0.03955 
N  -1.10635 0.49900 0.52164 
O  -0.13333 -0.51633 0.61433 
	   245 
C  0.67457 -0.47389 -0.55096 
H  -5.07804 -0.44975 0.36244 
H  -5.29605 0.76899 -0.90482 
H  -5.43537 1.20852 0.80640 
H  -3.97375 3.02041 -0.21341 
H  -2.30051 2.64427 -0.61578 
H  -2.80286 2.76539 1.08923 
H  1.47902 -1.20579 -0.43945 
H  1.11964 0.51840 -0.67446 
H  0.08740 -0.73446 -1.43680 
 
RADII = UAKS 
 
 




Total energy: HF = -365.203694 
 
# of imaginary frequencies = 0 
 
C  1.242187 -1.447664  -1.090548 
C  0.858851 -0.470754 0.003783 
H  2.315419 -1.667339 -1.041859 
H  1.015903 -1.038748 -2.079348 
H  0.700982 -2.394891 -0.971560 
C  1.087579 -0.957327 1.425543 
H  0.514621 -1.872492 1.620938 
H  0.804667 -0.205336 2.169912 
H  2.148084 -1.192820 1.570807 
C  0.783499 1.005041 -0.201236 
N  -0.384732 0.368569 -0.276281 
C  -1.694176 0.509807 0.363537 
C  -2.718991 -0.453803 -0.228050 
H  -2.005195 1.550266 0.215570 
H  -1.592786 0.347895 1.446185 
H  -2.845839 -0.278068 -1.301261 
H  -3.688364 -0.317402 0.263722 
H  -2.409312 -1.494875 -0.084282 



















Total energy: HF = -401.0423649 
 
# of imaginary frequencies = 0 
 
O  1.588434 0.329171 0.309267 
N  0.445852 0.200193 -0.517917 
C  -0.607054 1.037141 -0.260671 
C  2.595168 -0.586460 -0.137260 
O  -0.864133 2.205941 -0.085492 
C  -0.912870 -0.384018 0.004522 
C  -1.036489 -0.732292 1.476619 
C  -1.554857 -1.338884 -0.976441 
H  3.447981 -0.411489 0.523435 
H  2.875855 -0.383357 -1.176313 
H  2.257351 -1.624665 -0.038985 
H  -2.089747 -0.697991 1.776208 
H  -0.472381 -0.042091 2.110054 
H  -0.666626 -1.749140 1.652835 
H  -2.640724 -1.349860 -0.824034 
H  -1.178294 -2.356619 -0.820480 


































Total energy: HF = -401.0345846 
 
# of imaginary frequencies = 0 
 
C  -2.695911 -0.504180 0.120765 
C  -1.441931 0.273460 -0.002908 
C  -0.224850 -0.509983 -0.066285 
C  -1.535903 1.756588 -0.049620 
O  -0.209439 -1.762496 -0.055405 
N  0.848891 0.339251 -0.073002 
O  1.977297 -0.400046 -0.008639 
C  3.141014 0.437317 0.094486 
H  -2.530096 -1.392175 0.739067 
H  -2.954505 -0.893465 -0.881216 
H  -3.538843 0.093511 0.480436 
H  -2.278890 2.053797 -0.813006 
H  -0.578469 2.242337 -0.235723 
H  -1.953416 2.113319 0.914036 
H  3.988283 -0.249867 0.131122 
H  3.095480 1.036168 1.010481 

































Total energy: HF = -401.0342371 
 
# of imaginary frequencies = 0 
 
O  1.571947 0.256103 0.366448 
N  0.448985 0.183909 -0.497929 
C  -0.595219 1.047510 -0.248904 
C  2.619482 -0.549870 -0.169263 
O  -0.854227 2.211207 -0.093927 
C  -0.914921 -0.378039 0.000856 
C  -1.053430 -0.739194 1.469026 
C  -1.568331 -1.314718 -0.991597 
H  3.454023 -0.428395 0.526268 
H  2.911357 -0.205648 -1.167563 
H  2.329200 -1.607184 -0.215983 
H  -2.106250 -0.686728 1.767145 
H  -0.478524 -0.065020 2.109070 
H  -0.702310 -1.763623 1.642181 
H  -2.655789 -1.312537 -0.850608 
H  -1.209128 -2.341162 -0.847177 


































Total energy: HF = -401.0189598 
 
# of imaginary frequencies = 0 
 
O  -1.977646 -0.395145 0.021437 
N  -0.843699 0.323074 -0.068762 
C  0.232680 -0.538518 -0.134537 
C  -3.111604 0.470252 0.147429 
O  0.238440 -1.775361 -0.195934 
C  1.425374 0.274638 0.016439 
C  2.672801 -0.485669 0.270198 
C  1.508138 1.752423 -0.136451 
H  -3.979989 -0.190058 0.172030 
H  -3.167494 1.147768 -0.710315 
H  -3.046420 1.049363 1.074245 
H  2.999455 -0.940704 -0.679718 
H  2.464878 -1.339770 0.924677 
H  3.486458 0.134881 0.655664 
H  2.175132 1.991500 -0.980887 
H  1.986477 2.198362 0.748253 





























Example input file for the relaxed potential energy surface scan: 
 
%nproc = 2 
 
%mem = 4 GB 
 
#N b3lyp/6-31G* opt = modredundant guess = always scrf = (cpcm, solvent = methanol) 
 
a relaxed PES scan 
 
0  1 
O  1.588434 0.329171 0.309267 
N  0.445852 0.200193 -0.517917 
C  -0.607054 1.037141 -0.260671 
C  2.595168 -0.586460 -0.137260 
O  -0.864133 2.205941 -0.085492 
C  -0.912870 -0.384018 0.004522 
C  -1.036489 -0.732292 1.476619 
C  -1.554857 -1.338884 -0.976441 
H  3.447981 -0.411489 0.523435 
H  2.875855 -0.383357 -1.176313 
H  2.257351 -1.624665 -0.038985 
H  -2.089747 -0.697991 1.776208 
H  -0.472381 -0.042091 2.110054 
H  -0.666626 -1.749140 1.652835 
H  -2.640724 -1.349860 -0.824034 
H  -1.178294 -2.356619 -0.820480 
H  -1.352168 -1.039947 -2.008116 
	  
26 + = 0.1 S 100.1 
 
Relaxed PES scan for 57 in methanol 
 


















Relaxed PES scan for 58 in methanol 
 
















Relaxed PES scan for 59 in the gas phase 
 



















A.3 X-Ray Crystallography Data 




Figure A.3.1.	  Thermal ellipsoid plot of azepane 88 at 50% probability. Hydrogen atoms are 
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Table A.3.1.  Crystal data and structure refinement for 88. 
 
Identification code  kb005_0m 
Empirical formula  C11H20NO3 
Formula weight  214.28 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 5.9830(4) Å α = 90°. 
 b = 11.0773(7) Å β = 98.9630(10)°. 
 c = 17.8208(11) Å γ = 90°. 
Volume 1166.66(13) Å3 
Z 4 
Density (calculated) 1.220 Mg/m3 
Absorption coefficient 0.088 mm-1 
F(000) 468 
Crystal size 0.27 x 0.14 x 0.02 mm3 
Theta range for data collection 2.17 to 29.14°. 
Index ranges -8<=h<=8, -15<=k<=15, -24<=l<=24 
Reflections collected 21780 
Independent reflections 3136 [R(int) = 0.0627] 
Completeness to theta = 29.14° 99.9 %  
Absorption correction sadabs 
Max. and min. transmission 0.9979 and 0.9771 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3136 / 0 / 139 
Goodness-of-fit on F2 0.903 
Final R indices [I>2sigma(I)] R1 = 0.0557, wR2 = 0.1427 
R indices (all data) R1 = 0.0853, wR2 = 0.1638 
Largest diff. peak and hole 0.688 and -0.726 e.Å-3 
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Table A.3.2.   Bond lengths [Å] and angles [°] for  88. 
_____________________________________________________  
O(2)-C(7)  1.434(2) 
O(2)-C(3)  1.437(2) 
O(3)-C(4)  1.420(2) 
O(3)-H(3A)  0.8400 
O(1)-C(7)  1.424(2) 
O(1)-C(2)  1.430(2) 
N(1)-C(6)  1.460(2) 
N(1)-C(1)  1.465(2) 
N(1)-H(1A)  0.8800 
C(5)-C(10)  1.530(3) 
C(5)-C(11)  1.532(3) 
C(5)-C(6)  1.545(2) 
C(5)-C(4)  1.547(2) 
C(4)-C(3)  1.526(3) 
C(4)-H(4A)  1.0000 
C(1)-C(2)  1.522(3) 
C(1)-H(1B)  0.9900 
C(1)-H(1C)  0.9900 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(11)-H(11C)  0.9800 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.504(3) 
C(7)-C(9)  1.516(3) 
C(3)-C(2)  1.552(2) 
C(3)-H(3B)  1.0000 
C(9)-H(9A)  0.9800 
C(9)-H(9B)  0.9800 
C(9)-H(9C)  0.9800 
C(8)-H(8A)  0.9800 
C(8)-H(8B)  0.9800 
C(8)-H(8C)  0.9800 
C(2)-H(2A)  1.0000 
C(10)-H(10A)  0.9800 
C(10)-H(10B)  0.9800 




























































C(7)-C(8)-H(8C)                   109.5 
















Symmetry transformations used to generate equivalent atoms:  
  
#1 -x+1,-y+1,-z    #2 -x+1,-y+1,-z+1       
 
 Table A.3.3.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 88. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(3A) 4889 1760 2061 26 
H(1A) 2610 -2132 2957 22 
H(4A) 2905 2246 2961 18 
H(1B) 2584 -1747 1700 22 
H(1C) 4276 -650 1939 22 
H(11A) 5425 769 4579 31 
H(11B) 4486 2041 4240 31 
H(11C) 6525 1394 3913 31 
H(6A) 5933 -489 3220 21 
H(6B) 4736 -1068 3872 21 
H(3B) -390 1137 2489 19 
H(9A) -3096 906 1133 35 
H(9B) -2900 879 248 35 
H(9C) -3079 2143 670 35 
H(8A) 2817 1981 466 36 
H(8B) 645 2833 270 36 
H(8C) 753 1577 -166 36 
H(2A) -544 -553 1831 20 
H(10A) 1524 68 4349 30 
H(10B) 175 -78 3505 30 
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Symmetry transformations used to generate equivalent atoms:  
  
 #1 -x+1,-y+1,-z    #2 -x+1,-y+1,-z+1       




Figure A.3.2. Thermal ellipsoid plot of diol 95 at 50% probability. Hydrogen atoms are 
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Table A.3.5.  Crystal data and structure refinement for 95. 
Identification code  twin5 
Empirical formula  C2.50 H3.17 N0.17 O0.83 
Formula weight  48.89 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.064(3) Å a= 76.711(5)°. 
 b = 11.442(3) Å b= 85.166(5)°. 
 c = 14.671(4) Å g = 76.139(5)°. 
Volume 1437.0(7) Å3 
Z 24 
Density (calculated) 1.356 Mg/m3 
Absorption coefficient 0.102 mm-1 
F(000) 624 
Crystal size 0.55 x 0.16 x 0.07 mm3 
Theta range for data collection 1.43 to 25.00°. 
Index ranges -10<=h<=10, -13<=k<=13, 0<=l<=17 
Reflections collected 5147 
Independent reflections 5149 [R(int) = 0.069] 
Completeness to theta = 25.00° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9934 and 0.9464 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5149 / 0 / 383 
Goodness-of-fit on F2 1.017 
Final R indices [I>2sigma(I)] R1 = 0.0617, wR2 = 0.1300 
R indices (all data) R1 = 0.1000, wR2 = 0.1434 
Largest diff. peak and hole 0.565 and -0.420 e.Å-3 
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Table A.3.6.   Bond lengths [Å] and angles [°] for  95. 
_____________________________________________________  
N(1)-C(1)  1.363(4) 
N(1)-O(5)  1.402(3) 
N(1)-C(6)  1.473(4) 
O(1)-C(1)  1.219(4) 
O(2)-C(6)  1.409(4) 
O(2)-C(3)  1.448(4) 
O(3)-C(4)  1.418(3) 
O(3)-H(3A)  0.8400 
O(4)-C(5)  1.421(3) 
O(4)-H(4A)  0.8400 
O(5)-C(9)  1.451(4) 
C(1)-C(2)  1.520(4) 
C(2)-C(3)  1.533(4) 
C(2)-C(7)  1.540(4) 
C(2)-H(2A)  1.0000 
C(3)-C(4)  1.538(4) 
C(3)-H(3B)  1.0000 
C(4)-C(5)  1.559(4) 
C(4)-H(4B)  1.0000 
C(5)-C(6)  1.530(4) 
C(5)-H(5A)  1.0000 
C(6)-H(6A)  1.0000 
C(7)-C(8)  1.512(5) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-H(8A)  0.9800 
C(8)-H(8B)  0.9800 
C(8)-H(8C)  0.9800 
C(9)-C(10)  1.490(5) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.372(5) 
C(10)-C(15)  1.374(5) 
C(11)-C(12)  1.345(7) 
C(11)-H(11A)  0.9500 
C(12)-C(13)  1.314(8) 
C(12)-H(12A)  0.9500 
C(13)-C(14)  1.435(8) 
C(13)-H(13A)  0.9500 
C(14)-C(15)  1.423(6) 
C(14)-H(14A)  0.9500 
C(15)-H(15A)  0.9500 
N(2)-C(16)  1.348(4) 
N(2)-O(10)  1.409(3) 
N(2)-C(21)  1.468(4) 
O(6)-C(16)  1.231(3) 
O(7)-C(21)  1.404(3) 
O(7)-C(18)  1.448(3) 
O(8)-C(19)  1.424(3) 
O(8)-H(8D)  0.8400 
O(9)-C(20)  1.421(3) 
O(9)-H(9C)  0.8400 
O(10)-C(24)  1.462(4) 
C(16)-C(17)  1.530(4) 
C(17)-C(22)  1.529(4) 
C(17)-C(18)  1.528(4) 
C(17)-H(17A)  1.0000 
C(18)-C(19)  1.540(4) 
C(18)-H(18A)  1.0000 
C(19)-C(20)  1.551(4) 
C(19)-H(19A)  1.0000 
C(20)-C(21)  1.523(4) 
C(20)-H(20A)  1.0000 
C(21)-H(21A)  1.0000 
C(22)-C(23)  1.521(4) 
C(22)-H(22A)  0.9900 
C(22)-H(22B)  0.9900 
C(23)-H(23A)  0.9800 
C(23)-H(23B)  0.9800 
C(23)-H(23C)  0.9800 
C(24)-C(25)  1.497(4) 
C(24)-H(24A)  0.9900 
C(24)-H(24B)  0.9900 
C(25)-C(30)  1.384(4) 
C(25)-C(26)  1.388(5) 
C(26)-C(27)  1.387(5) 
C(26)-H(26A)  0.9500 
C(27)-C(28)  1.390(5) 
C(27)-H(27A)  0.9500 
C(28)-C(29)  1.372(5) 
C(28)-H(28A)  0.9500 
C(29)-C(30)  1.391(5) 
C(29)-H(29A)  0.9500 
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Table A.3.8.  Hydrogen bonds for 95  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(3)-H(3A)...O(9)#1 0.84 2.02 2.829(3) 160.2 
 O(4)-H(4A)...O(6)#2 0.84 1.97 2.771(3) 160.4 
 O(8)-H(8D)...O(4)#1 0.84 1.91 2.739(3) 169.1 
 O(9)-H(9C)...O(8)#3 0.84 1.88 2.706(3) 169.0 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+2,-z+1    #2 -x,-y+2,-z+1    #3 -x+1,-y+2,-z+2       
   	  
 




Figure A.3.3 Thermal ellipsoid plot of 97 at 50% probability. Hydrogen atoms are represented as 
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Table A.3.9.  Crystal data and structure refinement for 97. 
 
Identification code  kb003 
Empirical formula  C36H50N2O10 
Formula weight  670.78 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.5811(3) Å α = 95.6920(10)°. 
 b = 10.6861(4) Å β = 103.3680(10)°. 
 c = 17.8639(6) Å γ = 115.7510(10)°. 
Volume 1723.45(10) Å3 
Z 2 
Density (calculated) 1.293 Mg/m3 
Absorption coefficient 0.094 mm-1 
F(000) 720 
Crystal size 0.26 x 0.16 x 0.10 mm3 
Theta range for data collection 2.17 to 29.13°. 
Index ranges -14<=h<=14, -14<=k<=14, -24<=l<=24 
Reflections collected 39853 
Independent reflections 9290 [R(int) = 0.0347] 
Completeness to theta = 29.13° 99.9 %  
Absorption correction SADABS 
Max. and min. transmission 0.9905 and 0.9764 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9290 / 0 / 439 
Goodness-of-fit on F2 1.016 
Final R indices [I>2sigma(I)] R1 = 0.0411, wR2 = 0.1019 
R indices (all data) R1 = 0.0594, wR2 = 0.1128 
Largest diff. peak and hole 0.369 and -0.225 e.Å-3 
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 Table A.3.10.   Bond lengths [Å] and angles [°] for 97. 
_____________________________________________________  
O(1)-C(9)  1.4225(13) 
O(1)-C(3)  1.4562(13) 
N(1)-O(5)  1.4511(12) 
N(1)-C(9)  1.4697(14) 
N(1)-C(1)  1.4717(14) 
C(1)-O(4)  1.4092(13) 
C(1)-C(2)  1.5367(15) 
C(1)-H(1A)  0.9800 
O(2)-C(4)  1.4243(13) 
O(2)-C(5)  1.4343(13) 
C(2)-C(3)  1.5259(15) 
C(2)-C(10)  1.5345(15) 
C(2)-H(2A)  0.9800 
O(3)-C(8)  1.4210(13) 
O(3)-C(5)  1.4331(13) 
C(3)-C(4)  1.5286(15) 
C(3)-H(3A)  0.9800 
O(4)-H(4A)  0.8200 
C(4)-C(8)  1.5468(15) 
C(4)-H(4B)  0.9800 
O(5)-C(12)  1.4424(14) 
C(5)-C(7)  1.5087(16) 
C(5)-C(6)  1.5155(17) 
C(6)-H(6A)  0.9600 
C(6)-H(6B)  0.9600 
C(6)-H(6C)  0.9600 
C(7)-H(7A)  0.9600 
C(7)-H(7B)  0.9600 
C(7)-H(7C)  0.9600 
C(8)-C(9)  1.5311(15) 
C(8)-H(8A)  0.9800 
C(9)-H(9A)  0.9800 
C(10)-C(11)  1.5238(17) 
C(10)-H(10A)  0.9700 
C(10)-H(10B)  0.9700 
C(11)-H(11A)  0.9600 
C(11)-H(11B)  0.9600 
C(11)-H(11C)  0.9600 
C(12)-C(13)  1.5058(16) 
C(12)-H(12A)  0.9700 
C(12)-H(12B)  0.9700 
C(13)-C(14)  1.3896(17) 
C(13)-C(18)  1.3919(17) 
C(14)-C(15)  1.3849(18) 
C(14)-H(14A)  0.9300 
C(15)-C(16)  1.383(2) 
C(15)-H(15A)  0.9300 
C(16)-C(17)  1.3824(19) 
C(16)-H(16A)  0.9300 
C(17)-C(18)  1.3949(17) 
C(17)-H(17A)  0.9300 
C(18)-H(18A)  0.9300 
N(2)-O(10)  1.4512(12) 
N(2)-C(27)  1.4702(15) 
N(2)-C(19)  1.4719(15) 
O(6)-C(27)  1.4225(13) 
O(6)-C(21)  1.4568(13) 
O(7)-C(22)  1.4263(13) 
O(7)-C(23)  1.4345(13) 
O(8)-C(26)  1.4220(14) 
O(8)-C(23)  1.4312(14) 
O(9)-C(19)  1.4079(14) 
O(9)-H(9B)  0.8200 
O(10)-C(30)  1.4382(14) 
C(19)-C(20)  1.5379(16) 
C(19)-H(19A)  0.9800 
C(20)-C(21)  1.5300(16) 
C(20)-C(28)  1.5355(15) 
C(20)-H(20A)  0.9800 
C(21)-C(22)  1.5261(16) 
C(21)-H(21A)  0.9800 
C(22)-C(26)  1.5488(15) 
C(22)-H(22A)  0.9800 
C(23)-C(24)  1.5075(17) 
C(23)-C(25)  1.5123(17) 
C(24)-H(24A)  0.9600 
C(24)-H(24B)  0.9600 
C(24)-H(24C)  0.9600 
C(25)-H(25A)  0.9600 
C(25)-H(25B)  0.9600 
C(25)-H(25C)  0.9600 
C(26)-C(27)  1.5289(16) 
C(26)-H(26A)  0.9800 
C(27)-H(27A)  0.9800 
C(28)-C(29)  1.5231(17) 
C(28)-H(28A)  0.9700 
C(28)-H(28B)  0.9700 
C(29)-H(29A)  0.9600 
C(29)-H(29B)  0.9600 
C(29)-H(29C)  0.9600 
C(30)-C(31)  1.5000(17) 
C(30)-H(30A)  0.9700 
C(30)-H(30B)  0.9700 
C(31)-C(36)  1.3911(17) 
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C(31)-C(32)  1.3930(17) 
C(32)-C(33)  1.3911(18) 
C(32)-H(32A)  0.9300 
C(33)-C(34)  1.387(2) 
C(33)-H(33A)  0.9300 
C(34)-C(35)  1.3836(19) 
C(34)-H(34A)  0.9300 
C(35)-C(36)  1.3835(19) 
C(35)-H(35A)  0.9300 

































































































































































































































































































































Symmetry transformations used to generate equivalent atoms:  




Table A.3.12.  Hydrogen bonds for 97  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(4)-H(4A)...O(1)#1 0.82 2.16 2.9708(12) 172.1 
 O(9)-H(9B)...O(6)#2 0.82 2.16 2.9815(12) 179.6 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+1,-z    #2 -x+1,-y+1,-z+1       
 







Figure A.3.4. Thermal ellipsoid plot of azepine 108 at 50% probability. Hydrogen atoms are 










Table A.3.13.  Crystal data and structure refinement for 108. 
CCDC no. 1028235 
Identification code  klb008_0m 
Empirical formula  C7 H7 Cl N O2 
Formula weight  172.59 
Temperature  100.15 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 24.849(3) Å α = 90°. 
 b = 4.7231(5) Å β = 103.467(2)°. 
 c = 14.8643(17) Å γ = 90°. 
Volume 1696.6(3) Å3 
Z 8 
Density (calculated) 1.351 Mg/m3 
Absorption coefficient 0.400 mm-1 
F(000) 712 
Crystal size 0.159 x 0.063 x 0.057 mm3 
Theta range for data collection 1.685 to 26.426°. 
Index ranges -30<=h<=30, -5<=k<=5, -18<=l<=18 
Reflections collected 12847 
Independent reflections 1736 [R(int) = 0.0616] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7454 and 0.6525 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1736 / 6 / 106 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0562, wR2 = 0.1727 
R indices (all data) R1 = 0.0797, wR2 = 0.1969 
Extinction coefficient n/a 




Table A.3.14. Bond lengths [Å] and angles [°] for 108. 
_____________________________________________________  
C(1)-C(2)  1.522(4) 
C(1)-N(1)  1.471(4) 
C(2)-C(3)  1.523(4) 
C(2)-Cl(1)  1.812(3) 
C(3)-C(4)  1.505(5) 
C(3)-O(1)  1.423(3) 
C(4)-C(5)  1.315(5) 
C(5)-C(6)  1.498(5) 
C(6)-N(1)  1.484(5) 
C(7)-O(2)  1.426(4) 
C(7)-O(2A)  1.598(13) 
N(1)-O(2)  1.423(4) 
























































Figure A.3.5. Thermal ellipsoid plot of tetrahydropyridine 119 at 50% probability. Hydrogen 









Table A.3.16.  Crystal data and structure refinement for 119. 
CCDC no. 1028236 
Identification code  klb009_0m 
Empirical formula  C26 H34 N2 O6 
Formula weight  470.55 
Temperature  99.65 K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.9549(4) Å α = 106.4607(7)°. 
 b = 11.3328(5) Å β = 101.6175(7)°. 
 c = 11.8818(5) Å γ = 100.1738(7)°. 
Volume 1219.60(9) Å3 
Z 2 
Density (calculated) 1.281 Mg/m3 
Absorption coefficient 0.091 mm-1 
F(000) 504 
Crystal size 0.161 x 0.126 x 0.072 mm3 
Theta range for data collection 1.854 to 26.413°. 
Index ranges -12<=h<=12, -14<=k<=14, -14<=l<=14 
Reflections collected 23662 
Independent reflections 5015 [R(int) = 0.0515] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7454 and 0.7196 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5015 / 0 / 317 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0367, wR2 = 0.0677 
R indices (all data) R1 = 0.0618, wR2 = 0.0727 
Extinction coefficient n/a 




 Table A.3.17.   Bond lengths [Å] and angles [°] for 119. 
_____________________________________________________  
C(14)-C(15)  1.4928(18) 
C(14)-N(2)  1.4654(16) 
C(15)-C(16)  1.3203(18) 
C(16)-C(17)  1.4974(17) 
C(17)-C(18)  1.5323(17) 
C(17)-O(4)  1.4369(15) 
C(18)-C(19)  1.5120(17) 
C(18)-N(2)  1.4757(15) 
C(19)-O(5)  1.4286(14) 
C(20)-C(21)  1.4999(17) 
C(20)-O(6)  1.4366(14) 
C(21)-C(22)  1.3855(18) 
C(21)-C(26)  1.3837(18) 
C(22)-C(23)  1.3860(19) 
C(23)-C(24)  1.374(2) 
C(24)-C(25)  1.379(2) 
C(25)-C(26)  1.3821(18) 
N(2)-O(6)  1.4588(12) 
C(1)-C(2)  1.4917(19) 
C(1)-N(1)  1.4653(16) 
C(2)-C(3)  1.3216(19) 
C(3)-C(4)  1.4948(19) 
C(4)-C(5)  1.5294(18) 
C(4)-O(1)  1.4366(15) 
C(5)-C(6)  1.5135(18) 
C(5)-N(1)  1.4702(15) 
C(6)-O(2)  1.4267(15) 
C(7)-C(8)  1.5016(18) 
C(7)-O(3)  1.4305(15) 
C(8)-C(9)  1.3918(18) 
C(8)-C(13)  1.3875(17) 
C(9)-C(10)  1.3824(18) 
C(10)-C(11)  1.3852(18) 
C(11)-C(12)  1.3807(19) 
C(12)-C(13)  1.3851(18) 






















































































































Table A.3.19.  Hydrogen bonds for 119 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(1)-H(1)...O(5)#1 0.84 1.97 2.7226(13) 148.4 
 O(2)-H(2A)...O(1)#2 0.84 1.87 2.6837(13) 164.4 
 O(4)-H(4)...O(2)#3 0.837(16) 1.950(16) 2.7199(14) 152.4(15) 
 O(5)-H(5)...O(4)#4 0.832(16) 1.896(17) 2.7070(14) 164.5(17) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y+1,-z+1    #2 -x+1,-y+1,-z+2    #3 -x+1,-y+1,-z+1       








Figure A.3.6. Thermal ellipsoid plot of polyhydroxylated piperidine 121. Hydrogen atoms are 










Table A.3.20.  Crystal data and structure refinement for 121. 
CCDC no. 1028237 
Identification code  klb010_0m 
Empirical formula  C26 H38 N2 O10 
Formula weight  538.58 
Temperature  99.65 K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.3906(3) Å α = 112.4571(11)°. 
 b = 15.9299(9) Å β = 97.7331(11)°. 
 c = 17.3564(10) Å γ = 99.3952(11)°. 
Volume 1326.85(13) Å3 
Z 2 
Density (calculated) 1.348 Mg/m3 
Absorption coefficient 0.104 mm-1 
F(000) 576 
Crystal size 0.401 x 0.191 x 0.176 mm3 
Theta range for data collection 1.300 to 30.593°. 
Index ranges -7<=h<=7, -22<=k<=22, -24<=l<=24 
Reflections collected 33786 
Independent reflections 8134 [R(int) = 0.0579] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7461 and 0.6922 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8134 / 0 / 376 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0467, wR2 = 0.1191 
R indices (all data) R1 = 0.0775, wR2 = 0.1352 
Extinction coefficient n/a 




Table A.3.21.   Bond lengths [Å] and angles [°] for 121. 
_____________________________________________________  
C(1)-C(2)  1.5303(18) 
C(1)-N(1)  1.4736(17) 
C(2)-C(3)  1.5126(18) 
C(2)-O(1)  1.4354(15) 
C(3)-C(4)  1.5209(18) 
C(3)-O(2)  1.4243(15) 
C(4)-C(5)  1.5323(18) 
C(4)-O(3)  1.4182(15) 
C(5)-C(6)  1.5310(18) 
C(5)-N(1)  1.4813(16) 
C(6)-O(4)  1.4253(16) 
C(7)-C(8)  1.526(3) 
C(7)-C(8A)  1.489(3) 
C(7)-O(5)  1.4350(16) 
C(8)-C(9)  1.3900 
C(8)-C(13)  1.3900 
C(9)-C(10)  1.3900 
C(10)-C(11)  1.3900 
C(11)-C(12)  1.3900 
C(12)-C(13)  1.3900 
C(8A)-C(13A)  1.3900 
C(8A)-C(9A)  1.3900 
C(13A)-C(12A)  1.3900 
C(12A)-C(11A)  1.3900 
C(11A)-C(10A)  1.3900 
C(10A)-C(9A)  1.3900 
N(1)-O(5)  1.4575(13) 
C(14)-C(15)  1.5243(18) 
C(14)-N(2)  1.4716(17) 
C(15)-C(16)  1.5200(18) 
C(15)-O(6)  1.4251(15) 
C(16)-C(17)  1.5251(18) 
C(16)-O(7)  1.4257(16) 
C(17)-C(18)  1.5293(18) 
C(17)-O(8)  1.4270(16) 
C(18)-C(19)  1.5335(18) 
C(18)-N(2)  1.4695(16) 
C(19)-O(9)  1.4297(16) 
C(20)-C(21)  1.5095(17) 
C(20)-O(10)  1.4324(18) 
C(21)-C(22)  1.3900 
C(21)-C(26)  1.3900 
C(22)-C(23)  1.3900 
C(23)-C(24)  1.3900 
C(24)-C(25)  1.3900 
C(25)-C(26)  1.3900 







































































































































































Table A.3.23.  Hydrogen bonds for 121 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(2)-H(2A)...O(8)#1 0.84 1.83 2.6499(13) 163.8 
 O(3)-H(3A)...O(4)#2 0.84 1.87 2.7132(13) 176.5 
 O(6)-H(6)...O(7)#3 0.84 2.06 2.8814(13) 165.8 
 O(7)-H(7)...O(1) 0.84 1.94 2.7666(13) 170.2 
 O(8)-H(8)...O(9)#3 0.84 2.01 2.7652(14) 148.7 
 O(9)-H(9B)...O(1)#1 0.84 2.12 2.9047(14) 154.4 
 O(4)-H(4A)...N(1)#4 0.82(2) 2.16(2) 2.9729(14) 171.5(19) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y+1,-z    #2 -x,-y+2,-z+1    #3 x+1,y,z       
#4 x-1,y,z       
 
